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HFE-gene related Hereditary Hemochromatosis (HH) is characterized by an autosomal recessive
genetic mutation, which predisposes to an excess of iron absorption, leading to iron overload and its
related atypical findings and clinical problems as elevation of liver enzymes, liver cirrhosis,
hepatocellular carcinoma, diabetes mellitus, arthralgia and arthritis, cardiomyopathia and arrhythmia,
impotence and loss of libido, fatigue, and anterior pituary failure [1, 2]. In 1996, the genes leading to
the HFE-related form of HH were for the first time described by Feder et al [3]. The prevalence of the
most pathogenic HFE-mutation, the homozygous C282Y mutation, varies throughout the world.
However, it occurs that approximately 9% of the North European population is heterozygous and
0.4% homozygous for the C282Y mutation [4].
Five stages have been proposed to be recognized in the development of HFE-related HH [5] (FIGURE
1). Still the pathogenesis of HFE-related iron overload is not yet fully elucidated. Mutations in the
HFE-gene seem are associated with relative low hepcidin concentrations [6]. Hepcidin regulates the
iron metabolism by disturbing the ferroportin release, which transports the iron from the duodenal villi
cells and macrophages [7]. This leads to an elevated transferrin saturation and eventually to an
elevated amount of non-transferrin-bound iron (NTBI) [7-9]. NTBI is thought to be the potential toxic
form of iron responsible for tissue damage and the catalysis of redox reactions in the blood and
endothelium as seen in hereditary hemochromatosis and in cardiovascular diseases [8, 10-14].
Once HH is diagnosed before irreversible organ damage has developed, the severeness of the
disease and the number of deaths can be reduced easily by treatment of the iron condition using
phlebotomies [15-18]. However, despite the high gene mutation frequency and the obviousness of
the iron overload, the diagnosis of HH is often drawn only when irreversible organ damage has
developed, as the early symptoms are relatively aspecific and often presenting at age of 40-50 years
(FIGURE 1). So, screening for HH to prevent disease is desirable. There are several ways to identify
for individuals with an elevated risk of HH, through e.g., i) clinical investigation of individuals with
complaints pointing to HH, ii) population screening, or iii) screening of the families members of an
individual clinically diagnosed with HH.
STUDIES INTO THE PATHOGENESIS AND EARLY MANAGEMENT OF HH
The aim of this thesis is to investigate a potential pathophysiological mechanism of NTBI in HH
patients and to reveal an optimal early management strategy for HH. The disease entity of HH has
undergone an evolution during the last decades. In 1889 iron overload was described for the first
time in post mortem patients who died from ‘bronzed diabetes’. Later on it has been adapted to an
autosomal recessive genetic disease with a high prevalence, but with varying, though treatable and
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preventable, clinical features among genetic affected individuals. CHAPTER 2 describes these changing
aspects of HFE-related HH and its related dilemmas in early diagnosis of HH.
male 20 30 40 50 age (yrs)
female 20 40 50 60 age (yrs)
Stage 0 No biochemical or clinical symptoms (normal plasma transferrin saturation and serum ferritin)
Stage I Increased transferrin saturation, but normal serum ferritin values and no clinical symptoms
Stage II Both, increased transferrin saturation, increased serum ferritin, but no clinical symptoms
Stage III Increased transferrin saturation, increased serum ferritin, and clinical symptoms affecting the
quality of life
Stage IV Increased transferrin saturation, increased serum ferritin, and clinical symptoms manifesting
organ damage predisposing to early mortality
FIGURE 1 Schematic view of the five stages of HFE-gene related HH in C282Y homozygous individuals during lifetime.
Adapted from [5].
The raise in transferrin saturation is one of the earliest signs of HH, reflecting the disturbance in iron
homeostasis (FIGURE 1). After transferrin becomes fully saturated, the excess of iron is unable to bind
to transferrin and circulates as the potential toxic NTBI. The chemical structure of NTBI is
heterogeneous and largely unknown, resulting in little consensus on its true level and how it should
be measured. CHAPTER 3 describes the results of the first international interlaboratory evaluation of
NTBI from a common serum sample set, as a first step towards the standardization of NTBI
quantification methods. In tandem with this laboratory research much work has been undertaken to
clarify the pathophysiology of the molecular interactions of the various NTBI species with other
molecules and cells, for instance the mechanism by which NTBI is involved in atherosclerosis and,
HFE-gene related, cardiovascular diseases [11, 19, 20]. In CHAPTER 4 the relationships between
serum iron parameters, including NTBI, with plasma markers of inflammation and LDL oxidation, as
part of the cholesterol metabolism, are investigated.
It is crucial that patients with HH are detected before irreversible organ damage has occurred.
However, despite the high frequency of C282Y homozygosity in the Northern European countries, HH
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is not often clinically diagnosed. Scepticism from physicians about the incidence of the condition is a
serious barrier to early diagnosis through effective screening. This is also true for misunderstanding
of the diagnostic criteria for HH, unfamiliarity with the multi-disease caused by iron overload and the
belief that only those persons with skin bronzing, diabetes mellitus and hepatic cirrhosis have HH [2,
21-23]. This illustrates the importance of educating physicians on disease prevention strategy [24,
25], e.g. the implementation of a guideline for physicians to detect HH in an early, symptomatic stage
[25]. In this respect CHAPTER 5 gives an impression of the impact of the implementation of a guideline
for targeted detection of HH in an outpatient department of a university hospital.
Rather than targeted screening for clinical disease, population screening would offer the possibility of
early detection of HH on a large scale, even before disease or irreversible organ damage has
developed. Many reports have been written on the option of early screening on HH in the general
population [26-37]. In fact, HH fulfils important criteria for mass screening programmes described by
Wilson and Jungner four decades ago in 1968 [38]: There is a recognizable latent or early stage,
there is a suitable test for examination, there are facilities for diagnosis and treatment, and there is
an accepted effective treatment (TABLE 1). However, the first, most important, item of these World
Health Organization (WHO) [38] guidelines has remained unanswered: Is the disease for which
screening is aimed an important health problem? Surprisingly and in contrast to most of the earlier
studies, large and population controlled studies reported that a significant proportion of the C282Y
homozygotes had no symptoms of disease at all [39-44]. Even more, studies which determined the
degree at which homozygotes disappeared from the population as it ages, revealed no significant
differences in the prevalence of untreated homozygotes among elderly populations compared to
younger groups in several European countries [45-48]. These findings suggest that the penetrance of
HH-related disease is by far not as high as was expected formerly. Indeed, the penetrance of the
HFE-gene mutations is probably influenced by other not yet distinguished factors, making population
screening not a first choice method for screening for HH anymore.
As a third option of HH screening, family screening has been suggested, as method that lies in
between screening of symptomatically suspect and screening of apparently healthy individuals. In
family screening first-degree relatives of C282Y homozygous patients with clinically overt HH are
screened for HH. After all, these family members are at relatively high risk of inheriting the same
HFE-gene mutations (risk for a sibling to be also C282Y homozygous is 25%) [49]. Moreover, the
first-degree family members are most probably under the same genetic and environmental influences
as is the diagnosed proband, which may determine also their phenotypic HH expression.
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TABLE 1 Principles for mass screening programs (World Health Organization, 1968) [38]
Principles for mass screening programs (World Health Organization, 1968)
The condition sought should be an important health problem
There should be an accepted treatment for patients with recognized disease
Facilities for diagnosis and treatment should be available
There should be a recognizable latent or early symptomatic stage
There should de a suitable test or examination
The test should be acceptable to the population
The natural history of the condition, including development from latent to declared disease, should be
adequately understood
There should be an agreed policy on whom to treat as patients
The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically
balanced in relation to possible expenditure in medical care as a whole
Case finding should be a continuing process and not a ‘once and for all’ project
In CHAPTER 6 the rationale of family screening for hereditary hemochromatosis is explored. A
database with anamnestic, biochemical and genetic data from probands with clinically proven C282Y
homozygous HH, and their first-degree family members was built by performing the multicentre
HEmochromatosis FAmily Study (HEFAS) study. First of all the morbidity and mortality in the first-
degree family members of the HEFAS population is compared with the morbidity and mortality of an
age and gender matched general population to determine whether there indeed is an important
health problem among the first-degree family members of hemochromatosis patients. With this study,
for the first time, the importance of the existing health problem within these hemochromatosis families
can be demonstrated.
The design of HEFAS also made it possible to estimate the biochemical penetrance of the HFE gene
mutations in the HEFAS families and to determine groups within these families at risk for iron
overload condition. CHAPTER 7 evaluates the levels of iron parameters among the first-degree HEFAS
family members and identifies factors determining these levels, and as such attempts to predict who
is at risk for iron accumulation within these families.
Understanding more about the expression of elevated iron parameters in the HEFAS families is only
one stepping stone in a pathway from genetic predisposition to iron accumulation and the measured
HH related disease among the first-degree HEFAS family members. This issue is addressed in
Chapter 1
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CHAPTER 8, which is aimed to quantify the relation between the genotype and the HH related sickness
of the HEFAS population.
Finally, the results of the previous chapters are discussed in CHAPTER 9 and future perspectives on
the realization of an effective strategy on early management of HFE-gen related HH are considered.
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ABSTRACT
HFE-related hereditary hemochromatosis (HH) is an iron overload disease attributed to the highly
prevalent homozygosity for the C282Y mutation in the HFE-gene. The pathophysiology of this error in
the iron metabolism is not yet elucidated. Hepcidin is thought to be a crucial player nowadays. It is
produced in the liver and regulates iron homeostasis by internalisation and subsequent degradation
of ferroportin, thereby influencing iron transport out of the duodenal villi cells and macrophages. Iron
overload is among others diagnosed by measurement of the serum iron parameters, i.e. serum
transferrin saturation and serum ferritin, by a liver biopsy or by calculating the amount of mobilizable
body iron withdrawn by phlebotomies. Clinical signs attributed to HFE-related HH include liver failure,
arthralgia, chronic fatigue, diabetes mellitus and congestive heart failure. Organ failure can be
prevented by phlebotomies starting before irreversible damage has occurred. Therefore, screening to
facilitate early diagnosis is desirable in individuals at risk for developing HFE-related iron overload. In
time it appeared that the clinical penetrance of the HFE-mutations was much lower than the 100%
earlier assumed. This changed the opinion on a suitable screening facility from case detected
screening, via population screening, to family screening as most appropriate method to restrict HFE-
related disease. However, before implementation of family screening is a fact, for good evidence
based screening policy, it is vital to have profound background information on the relevance of the
specific health problem involved, on the clinical penetrance of C282Y homozygosity and on the
effectiveness of the screening approach.
INTRODUCTION
Classical hereditary hemochromatosis (HH) is a disease related with iron overload with increasing
physical complaints, organ failure, and poor survival. Therapy is relatively simple: Removing iron
overload by phlebotomies, thereby preventing disease and increasing survival. After the discovery of
its prime gene mutation, the C282Y mutation of the HFE-gene, large scale screening for HFE-related
HH became feasible. However, along with the years it became clear that the traditionally low
prevalence of patients with HH could not be fully ascribed to the ignorance of the medical workers,
but mainly to the limited penetrance of the HFE-gene mutation. This review describes new insights in
pathophysiology, diagnosis and penetrance of HFE-related HH, and its implications for secondary
prevention and early treatment of the clinical disease.
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HISTORY OF HFE-RELATED HEREDITARY HEMOCHROMATOSIS
One of the first to describe a clinical syndrome characterized by portal cirrhosis, diabetes mellitus
and bronze skin pigmentation was Trousseau [1]. The name hemochromatosis was first used by von
Recklinghausen (1889), describing post-mortem findings in patients who had died from ‘bronzed
diabetes’ [2]. In 1935 Sheldon suggested a familial form of hemochromatosis [3], but it was not until
1975 that Simon et al described an autosomal recessive form of idiopathic hemochromatosis related
to the HLA-A3 allele in the major histocompatibility complex (MHC) on chromosome 6. In 1996 Feder
et al were able to isolate the HH gene in 85 percent of HH patients [4]. It was initially called HLA-H,
as its organization and structure was similar to genes in the HLA region that coded for HLA-class I
heavy chains. However, as a HLA-class I pseudo gene had already been named HLA-H, the newly
identified hemochromatosis gene was renamed HFE (the abbreviation of HFE being surprisingly not
otherwise specified) as proposed by the Genome Databank [5].
Until now, more than 30 allelic variants of the HFE-gene have been reported [6]. The most common
mutation is C282Y that results from a transition at nucleotide 845 (845G  A), leading to substitution
of tyrosine for cysteine. This alters the HFE protein and its association with ß2-microglobuline,
resulting in a decreased presentation of the HFE protein on the cell surface [7-9]. A second, though
less important, HH-associated mutation occurs at nucleotide 187 of the HFE-gene, with a substitution
of histidine for aspartate at nucleotide 63 (63H  D) [4]. Several other mutations of unknown
significance are described.
PREVALENCE OF THE C282Y HFE-GENE MUTATION
The prevalence of the C282Y HFE-gene mutation varies throughout the world. The overall
prevalence of homozygosity and heterozygosity for the C282Y mutation in European countries is
0.4% and 9.2%, respectively, with heterozygosity ranging form 1% in the Southern European
countries to 24.8% in Ireland [10]. In North America an overall frequency of C282Y heterozygosity,
regardless of the ethnical roots, was reported as 9.0%, whereas in the Indian subcontinent, and
African, Middle Eastern and Australian populations prevalences of 0 to 0.5% percent were found [10].
For the Netherlands the percentages of C282Y homozygosity and heterozygosity are calculated at
0.2% and 12.0%, respectively [11].
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PATHOPHYSIOLOGY
The evidence that the HFE protein is involved in regulating iron homeostasis was initially provided by
the development of iron overload similar as in human HH in the ß2-microglobulin knockout mouse,
later confirmed in a mouse homozygous for the C282Y HFE-gene mutation and in human studies
[12-17]. However, the exact role of the mutated HFE in the pathophysiology of iron overload remains
to be elucidated. It has been suggested that the HFE protein modulates uptake of transferrin bound
iron by undifferentiated intestinal crypt cells, thereby programming the absorptive capacity of
enterocytes derived from these cells [18]. However, this so called crypt model remained controversial.
Indeed, recently a normal iron metabolism was described despite the lack of HFE-gene expression in
the duodenum [19]. In 2003, mice studies by Nicolas et al suggested that it is mainly the failure of
hepcidin induction contributing to the pathogenesis of HH [20]. Hepcidin has been shown to regulate
iron homeostasis by internalisation and subsequent degradation of ferroportin, a major cellular iron
exporter protein in the duodenal villi cells and macrophages, which transport iron from the duodenal
villi cells and macrophages to the plasma [21]. Consequently, the absence of hepcidin in mice leads
to excessive iron release by enterocytes and macrophages, followed by circulatory and body iron
overload [22]. This has even been demonstrated, before the detection of ferroportin, as HH
monocytes and macrophages from HFE C282Y homozygotes released twice as much Fe(II)
compared to cells from normal subjects [23]. Absent or very low hepcidin concentrations in man lead
to a juvenile onset of the clinical iron overload disease, whereas moderate decreased hepcidin
concentrations, in case of mutations in the HFE-gene, lead to relatively low and late onset of iron
overload disease [24-27].
CLINICAL SIGNS AND SYMPTOMS IN HFE-RELATED HH
In 2000 an expert group described HFE-related HH as: “HH is an inherited disorder resulting from an
inborn error of iron metabolism which leads to progressive loading of parenchymal cells in the liver,
pancreas and heart. In its fully developed stage organ structure and function are impaired” [28]. Early
clinical complaints encompass weakness, joint pain, palpitations, and abdominal pain, whereas
massive iron overload will ultimately lead to arthritis, severe fatigue, chronic abdominal pain, liver
enzyme elevations, liver cirrhosis, primary liver cancer, diabetes mellitus, hypopituarism,
hypogonadism, congestive heart failure, cardiac dysrhythmias, increased skin pigmentation and an
increased risk of certain bacterial infections [28-35]. All symptoms are relatively unspecific, making it
difficult to recognize them as related to iron overload. In addition the clinical penetrance of the HFE-
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gene mutations is very variable [36-38]. First of all, this is due to gender and age of testing for iron
overload. In men symptoms of the disease often become manifest at 40-50 years of age, in women
mostly a decade later. Compared to women, men with HH have more mobilizable body iron [33].
Women are relatively spared by menstrual blood loss (15-25 mg) and pregnancies (750 mg each
pregnancy) [33, 39, 40]. This does not mean, however, that (pre-) menopausal women cannot
develop iron overload [41].
Next to age and gender, many other factors have been described to act in some degree upon the
clinical penetrance of the HFE-gene mutations, including dietary iron intake, body mass index,
pathological iron loss and the presence of toxins (e.g. alcohol) [42-44]. In addition, several other
genes involved in the iron metabolism may act as HFE-genotype modifiers, although the results of
the studies published are controversial. Described are e.g. hepcidin antimicrobial peptide (HAMP)
mutations, transferrin receptor-2 missense variants, HJV mutations and haptoglobin variants are
thought to amplify the amount of iron overload [45-48]. Although these multiple sequence variations
are rare and still cannot explain most of the variation in the penetrance of the HFE-hemochromatosis,
identification of the various iron overload determinants hopefully will improve our insights in the iron
metabolism and help to predict which HFE-gene mutated patients are particular at risk for developing
(early) iron overload and clinical complications.
DIAGNOSIS OF IRON OVERLOAD
Abnormal values for iron parameters in the serum, i.e. serum transferrin saturation (TS) and serum
ferritin (SF) are strong indication for altered iron metabolism (FIGURE 1). In the literature different
reference ranges are mentioned due to different populations examined. An elevated serum transferrin
saturation above 45%, when doubting the value eventually measured a second time after fasting, in
combination with an elevated SF level is highly suggestive for the presence of primary iron overload
in the absence of other pathology like liver diseases and secondary causes of iron overload or
alcohol abuse [41, 49-52]. The traditional gold standard for diagnosing iron overload is provided by a
liver biopsy, although it is generally only required in presence of co-morbidities or strong suspicion of
liver cirrhosis. A liver biopsy allows histochemical grading of iron (Perl’s Prussian blue stain) or
biochemical determination of hepatic iron concentration and calculation of the hepatic iron index (HII)
(= ratio of hepatic iron concentration divided by age in years) [28, 49, 50]. A non-invasive tests which
enables an appreciation of the amount of iron stored in the liver is the hepatic magnetic resonance
imaging (MRI) [53-55]. The severity of iron overload can also be calculated from the number of
phlebotomies required to deplete iron stores [28, 30]. Furthermore, HFE mutation analysis may help
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to support the existence of iron overload [51, 56] and to detect individuals at risk for iron overload at
younger age, when TS is often elevated, but SF still is normal (FIGURE 1).
Five stages of HFE-related HH [51] Five stages Composition of the population
FIGURE 1 Schematic view of the five stages of HFE-related hereditary hemochromatosis (HH) together with the various
strategies for screening on HH.
Green, population screening strategy; yellow, family screening strategy; red, individuals who develop clinically
important HH, targeted screening; horizontal red bar, individuals with C282Y homozygosity.
TREATMENT OF HH
The treatment of HH consists of venesection, as described by Davis [57]. It is safe, inexpensive and
appeared to be effective, although the latter has never been proved. With the removal of 500 ml of
blood, about 200 to 250 mg of iron is withdrawn from the body. Venesection is started when the SF
levels are consistently above the upper limit of the reference range, pointing to body iron excess.
Meanwhile, other causes for increased SF must be eliminated [41, 49-52]. Weekly phlebotomies are
performed to withdraw excessive amount of iron, followed by yearly measurement of the serum
C282Y homozygosity with increased transferrin
saturation, increased serum ferritin, and clinical
symptoms manifesting organ damage
predisposing to early mortality
C282Y homozygosity with increased transferrin
saturation, increased serum ferritin, and clinical
symptoms affecting the quality of life
C282Y homozygosity with both increased
transferrin saturation, increased serum ferritin,
but no clinical symptoms
C282Y homozygosity with increased transferrin
saturation, but normal serum ferritin values and
no clinical symptoms
C282Y homozygosity without biochemical or
clinical symptoms (normal plasma transferrin
saturation and serum ferritin)
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ferritine and when necessary maintenance phlebotomies 1 to 8 times a year to maintain low body
iron stores [28, 49, 58]. An alternative treatment for phlebotomy could be the less time consuming,
though more expensive erythrocytapheresis, which extracts iron more quickly, as plasma and
thrombocytes are not extracted from the circulation during the procedure. However, up to now it has
been only utilized in small patient groups [59, 60]. A comparative study between the two treatment
options is currently ongoing and will hopefully learn us more about the differences in (cost-)
effectiveness of both treatments.
According to the experts’ opinion is that treatment should be continued until SF level is below the
reference value [61]. Even so, diverse experts advise that next to venesection, dietary advices
concerning iron overload management should be given, including moderation of alcohol intake and
avoidance of iron, vitamin C supplements, uncooked seafood and drinking tea with meals which
decreases iron absorption by formation of non-absorbable iron complexes [58, 62-66].
EVIDENCE OF PHLEBOTOMY BENEFITS
Before the introduction of phlebotomy treatment in 1935, survival of HH patients has been described
as poor [30, 67]; the time from symptomatic presentation to death was 18 months [68]. However,
many studies revealing a diminished survival among HH patients are based on clinical cohorts
including mainly patients presenting themselves with late symptoms of severe iron overload [30, 67,
69, 70]. No controlled studies are available of phlebotomy treatment that allow a valid comparison of
early versus delayed treatment. Niederau et al showed that iron depletion does attenuate weakness
or lethargy, elevated liver enzymes and pigmentation. In contrast, arthralgia, impotence,
electrocardiographic changes and diabetes mellitus remained in most cases, although the insulin
dose could be reduced in 19 of the 46 insulin-dependent patients [30]. The HH participants included
in McDonnell’s study also mentioned improvement in fatigue, skin bronzing, depression and
abdominal pain [32]. Recently, Powell et al showed that phlebotomy treatment in 672 essentially
asymptomatic C282Y homozygous subjects identified by either family screening or health checks,
reduced the mean liver fibrosis score 7.5-fold [71]. In the best available evidence on the effects of
phlebotomy treatment, Bomford and Niedereau reported that 7% to 23% of the patients clinically
diagnosed with iron overload showed improvement of disease in the liver biopsies, 1% to 3% showed
worsening [30]. Improvement in histological characteristics was more common in patients with less
severe, precirrhotic liver disease (33% improved) compared to patients with cirrhosis (14% improved)
[30]. Therefore, early diagnostic and therapeutic phlebotomy may reduce disease progress, especially
when treatment is started before irreversible liver damage occurs [30, 71-73]. It has even been
Chapter 2
26
suggested that timely started phlebotomy treatment is able to increase the survival to equal that of
the general population [30, 67, 69, 74].
FROM EARLY DIAGNOSIS AND TREATMENT TO DEATH PREVENTION
Despite the high frequency of the C282Y mutation and the obvious iron overload, the clinical
diagnosis of HH is often delayed until irreversible organ damage has developed, as early symptoms
are relatively non-specific. Even the more advanced complications are not always recognized as
symptoms of HH, unless specifically looked for. This is underlined by the findings of Powell et al [71]:
Through assessment of disease manifestation by clinical examination and liver biopsy in their
population of asymptomatic C282Y homozygous subjects, they found that hepatic iron overload was
already present in 56% of the males and 35% of the female subjects. Moreover, at least one, not yet
clinically diagnosed, HH related disease condition (arthropathy, diabetes mellitus, hepatomegaly,
hypogonadism or cardiac arrhythmia) was present in 30% of the males and 12% of the females [71].
This supports the statement that early screening for HFE-related HH is the key in early detection of
HFE-related iron overload, thereby preventing organ failure and death.
In an attempt to reappraise in general terms the evidence for screening and to determine what
attitude to screening should be adopted, in 1974 Whitby made a restatement of the principles of early
disease detection set up by Wilson and Jungner a few years earlier (TABLE 1) [75, 76]. Thereafter,
many reports have been written on the feasibility of early screening on HH in the general population
[77-86]. Indeed, HFE-related HH fulfils important criteria as described by Wilson & Jungner, and
Whitby: A recognizable latent or early stage, a suitable test for examination, facilities for diagnosis
and treatment and an accepted treatment [75, 76, 78, 87]. Still, one important item of these
guidelines remained unanswered: Is HH indeed an important health problem, not only for the
community, but also for the individual? [70, 75, 76]. Before the discovery of the HFE gene it was
assumed that every person homozygous for the, then unknown, C282Y mutation would eventually
accumulate sufficient iron to cause tissue damage and the resulting disease [41]. However, selection
bias, differences in case definition and population characteristics made it difficult to typify attributable
disease. This led to the troublesome fact that some authors found hemochromatosis related disease
in a high percentage of C282Y homozygous individuals, whereas others barely found any penetrance
of the HFE-gene mutations [29, 40, 71, 88-90]. Even more, some large and controlled studies
reported that a significant proportion of the C282Y homozygotes had no symptoms of disease at all,
questioning the importance of the involved health problem [37, 38, 91-94].
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TABLE 1 Restatement by Whitby of the Wilson and Jungner principles for mass screening programs (World Health
Organization, 1968) [75]
Restatement of principles for mass screening programs
The condition being sought should be an important health problem, for the individual and the community
There should be an acceptable form of treatment for patients with recognizable disease
The natural history of the condition, including its development from latent to declared disease, should be
adequately understood
There should be a recognizable latent or early symptomatic stage
There should be a suitable screening test or examination for detecting the disease at the latent or early
symptomatic stage, and this test should be acceptable to the population
The facilities required for diagnosis and treatment of patients revealed by the screening program should be
available
There should be an agreed policy on whom to treat as patients
Treatment at the pre-symptomatic, borderline stage of a disease should favourably influence its course and
prognosis
The cost of case-finding (which would include the cost of case finding and treatment) needs to be
economically balanced in relation to possible expenditure on medical care as a whole
Case finding should be a continuing process and not a “once and for all” project
Next to settling the pre-screening prerequisite of the impact of the health problem of HFE-related HH,
another principle of screening still not profoundly resolved, is the statement 8 added by Whitby
(TABLE 1): Treatment at the presymptomatic, borderlines stage of a disease should favourably
influence its course and prognosis. In other words, early treatment should be more effective than
started later in its developments and/or clinical phase.
The last screening issue to address is to decide which population is to be screened. In essence,
searching for individuals with an elevated risk on HH can be performed at three population levels: i)
clinical examination of individuals with complaints pointing to HH, i.e. targeted screening or case
detection; ii) screening the families of a person clinically diagnosed with HH; and iii) population
screening (FIGURE 1).
AD I) CASE DETECTION
Medical examination of individuals with complaints pointing to HH would be a very direct way of
detecting patients with HH. However, despite the high frequency of C282Y homozygosity in the
Northern European countries HH was not often clinically diagnosed. This fed misunderstandings of
physicians on the diagnostic criteria for HH, that used to encompass only the late stage combination
of skin bronzing / hyperpigmentation, diabetes mellitus and hepatic cirrhosis, but should include more
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disease entities. Furthermore, there is still unfamiliarity with the existence of the multiorgan disease
and scepticism about the prevalence of the condition, all leading to a serious barrier to effectively
screen for HH [52, 95, 96]. Therefore, it is important to educate physicians about HFE-related HH,
e.g. the gene mutation frequency and its clinical penetrance, the diagnostic pathway and therapeutic
options, when choosing this type of screening [97]. Thus, the implementation of a guideline for
physicians on the targeted detection of HH in an early, symptomatic, stage could be beneficial [95].
Jacobs et al indeed introduced such a guideline and studied the impact of this introduction. They
concluded that indeed the awareness for HH increased, though the implementation was troublesome
at the cost of an increased rate of false positively new diagnosed HH patients, whereas 70% of the
patients eligible for HH were still not tested [98].
Another drawback of this type of case detection is the risk that the newly discovered patients might
have irreversible disease or organ failure at time of being diagnosed, diminishing the profits aimed
for. Taken together, this screening strategy of case detection has its shortcomings for early disease
detection.
AD II) FAMILY SCREENING
In family screening first-degree relatives of C282Y homozygous patients with clinically detected HFE-
related HH are screened for HH. After all, these family members are at relatively high risk of
inheriting the same HFE-genotype (risk for sibling to be homozygous is around 25%) [36]. Moreover,
they are likely to share genetic and environmental factors with the clinically diagnosed proband,
which may also engrave their phenotypic expression of HH. From a theoretical point of view this
screening strategy has potential, with an expected increased detection rate as well as higher
effectiveness of early intervention [99-102].
AD III) POPULATION SCREENING
In comparison to family screening, population screening offers the possibility of an even earlier and
larger-scale detection of HFE-related HH. However, as mentioned above, although C282Y
homozygosity is associated with health-threatening symptoms, these symptoms have been shown to
occur in only a minority of the population derived C282Y homozygotes, making population screening
not the first option of HH screening [70].
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FUTURE INTERVENTION
HFE-related HH is a recognized clinical entity, with variable clinical penetrance. Screening and
detecting those individuals at high risk of iron overload, before irreversible damage evolved, is likely
to prevent organ detriment and death. From all the mentioned present screening options at this
moment family screening is prone to be the most appropriate approach. However, before starting
screening programs questions remain to be answered: Do C282Y homozygous individuals have a
relevant health problem? What individuals are at risk to develop HFE-related iron overload and its
accompanied disease? and; Is screening for these individuals cost-effective? To solve these
questions we initiated the HEmochromatosis FAmily Study (HEFAS). From 224 probands
homozygous for the C282Y mutation and presenting with clinically recognized symptoms of HH and
735 of their first-degree family members data have been collected regarding demographics, lifestyle
(smoking, use of alcohol, diet), health, disease, family structure, including familial death rate, iron
parameters and HFE-genotype. These data, that are currently analyzed, are likely to provide answers
that are instrumental to prevent morbidity among yet unidentified individuals at risk for HFE-related
HH.
In conclusion, the changing insights in the pathophysiological mechanisms of HFE-related iron
overload, in the penetrance of the HFE-mutations and in the difficulties of early HH diagnosis,
endeavour to investigate and develop more appropriate screening strategies to prevent iron overload
related morbidity in those individuals at risk for iron accumulation.
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ABSTRACT
Non-transferrin-bound iron (NTBI) appears in the circulation of patients with iron overload. Various
methods to measure NTBI were comparatively assessed as part of an international interlaboratory
study. Six laboratories participated in the study using methods based on iron mobilization and
detection with iron chelators or on reactivity with bleomycin. Serum samples of 12 patients with
hereditary (n=11) and secondary (n=1) hemochromatosis were measured in a three-day analysis,
using four determinations per sample per day, making a total of 144 measurements per laboratory.
Bland and Altman plots for repeated measurements are presented. The methods differed widely in
mean serum NTBI (range 0.12-4.32 µmol/L), between sample variation (SD range 0.20-2.13 µmol/L
and CV range 49.3-391.3%) and within sample variation (SD range 0.02-0.45 µmol/L and CV range
4.4-193.2%). The results obtained with methods based on chelators correlated significantly (R2 range
0.86-0.99). On the other hand, NTBI values obtained by the various methods related differently with
those of serum transferrin saturation (TS) when expressed both in terms of regression coefficients
and NTBI levels at TS of 50%. Recent studies underscore the clinical relevance of NTBI in the
management of iron-overloaded patients. However, before measurement of NTBI can be introduced
into clinical practice, there is a need for more reproducible protocols as well as information on which
method best represents the pathophysiological phenomenon and is most pertinent for diagnostic and
therapeutic purposes.
INTRODUCTION
Iron is an essential metal in human metabolism. It is absorbed from the food in the intestine, entering
the circulation bound to transferrin [1]. Under normal conditions 20-35% of the serum transferrin is
saturated with iron. By sequestration on transferrin, iron is excluded from catalyzing reactions leading
to the production of highly toxic reactive oxygen species and is safely transported through the blood
[1]. However, when the transferrin becomes fully saturated, for example in hereditary and secondary
hemochromatosis, excess iron is unable to bind transferrin and circulates as non-transferrin-bound
iron (NTBI) [1-8]. NTBI may bind to putative ligands such as phosphates, citrate and albumin. Its
exact biochemical nature, however, is unknown and it probably consists of a heterogeneous mixture
of complexes whose composition might vary with the degree and type of iron-overload [2, 3, 9]. It is
even known that some iron-overloaded patients with partially saturated transferrin also possess
plasma NTBI [2, 10, 11]. This fraction of NTBI seems inaccessible to unsaturated transferrin and
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apparently needs to be processed first by macrophages and liver and then discharged into the
circulation as transferrin-accessible iron [2].
As iron binding to ligands such as phosphates, citrate and albumin is not as avid as its binding to
transferrin, it is hypothesized that NTBI iron might be more readily available for catalyzing redox
reactions in the blood and endothelium [9, 11, 12]. Additionally, various tissues might take up this
loosely bound iron by a mechanism that is not as strongly regulated as the cellular uptake of
transferrin bound iron, resulting in tissue iron accumulation and damage [13]. These mechanisms
may contribute to pathologies seen in cardiovascular diseases and hereditary and secondary
hemochromatosis [2, 4, 9, 12-15].
While few now doubt that NTBI exists, its nature is largely unknown, resulting in little consensus on
its true level or how it should be measured. This may be the reason that research laboratories
throughout the world measure NTBI using a variety of analytical approaches that differ in test
principle and their exact practical application (i.e. choice of reagents and instruments).
The test principles of the methods described to quantify serum NTBI can roughly be divided into two
groups. The first group of methods mobilizes NTBI by a shuttle molecule (e.g. EDTA or nitrilotriacetic
acid (NTA)), followed by separation of the chelated iron from serum proteins using micro filters with a
molecular weight cut-off of 30 000. The ultra filtrate can then be analyzed by atomic absorption, by
spectroscopy, by high performance liquid chromatography (HPLC) and by inductive conductiometric
plasma spectrometry (ICP) [16, 17]. Although these detection methods have a high reliability, they
are very labour-intensive.
The second group of methods mobilizes and detects NTBI in the same reaction mixture, without
separation of the serum proteins from chelated iron. One example is the bleomycin method which
estimates the serum NTBI by measuring the redox active iron [18]. Ascorbic acid added to the serum
reduces iron(III) to iron(II), which is then chelated by the anti-tumour antibiotic bleomycin. This
complex binds to DNA and causes oxidative degradation of the deoxyribose moieties. These
degradation products are measured by a colorimetric assay as their concentration is proportional to
the iron present [18]. The problem with this assay is that it is an indirect measurement method that
may be influenced by other substances in the serum with similar properties to iron [9]. Furthermore,
not all iron(III) may be converted to iron(II) by ascorbic acid, and it is unclear whether all oligomeric
iron will be detected in this assay [9]. Another example of the second group of NTBI measuring
methods are the methods that use iron sensitive fluorescence probes, such as fluorescein labelled
deferoxamine (Fl-DFO) or fluorescence labelled apotransferrin (Fl-aTf) to quantify NTBI in 96-well
plates [19, 20]. These methods detect a diminished fluorescence signal when NTBI is present,
compared to the signal given by normal serum. Originally DFO-coated wells were used, the DFO
acting as a chelator to extract the NTBI from the sample, and a calcein-iron solution of which free
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calcein induced the fluorescence signal. The free calcein originated from the calcein-iron complex of
which the remaining available DFO extracted the iron when no more NTBI was available. Later, DFO-
coated wells were replaced by normal wells and Fl-aTf solution was used to bind NTBI, thereby
decreasing the fluorescence signal [19, 20]. A drawback of these methods is that they have the
tendency to be affected by the local environment, such as serum colour or turbidity. This can be
overcome by measurement of serum NTBI in absence and presence of an excess of chelator. The
difference measured is the net NTBI related signal. The advantage of this method is its simplicity,
making it suitable for routine screening of large numbers of serum samples.
An alternative way of ordering the NTBI detection methods is by separating them by means of the
chemical characteristics of NTBI they measure. Redox activity of the serum iron is measured by the
bleomycin method [18] and the method recently described by Esposito et al [21], whereas other
methods measure the chelatable NTBI [9, 16, 17, 19, 20]. These latter chelating methods mutually
differ in the choice of the chelator molecules for NTBI ( i.e. NTA, oxalate), in reagents that block the
unsaturated transferrin (i.e. Ga(III), Co(III), Mn(II)) and in final detection methods (i.e. ICP, HPLC,
fluorescence).
There are diverse obstacles in the measurement of serum NTBI. First of all, the scavenging
molecules used to bind the loose non-specific bound iron, can in principle also take iron from
transferrin and ferritin [9, 16]. This can be minimized by using for example nitrilotriacetic acid (NTA),
a scavenging molecule which is known to only mobilize a small fraction of transferrin and ferritin
bound iron in the plasma [9, 16]. Secondly, scavengers can facilitate the transfer of NTBI to
apotransferrin or monomeric forms of transferrin, falsely lowering the detectable load of NTBI,
resulting in an underestimation or even negative NTBI results [2, 9, 17, 19]. This problem can be
minimized by selectively blocking vacant transferrin sites, for example with Co(III) or less strong
blockers as Ga(III) or Mn(III), prior to the mobilization of iron [2, 16, 17, 20].
The NTBI-levels quantified by the diverse methods mentioned above might differ due to variation in
assay principles, differences between laboratories in execution of the methods and by the mode and
extent of the iron overload in the serum samples measured. All these methods currently continue to
be used for various applications in the number of papers on NTBI without their results being mutually
comparable. To investigate the relevance of the methods in the absence of a gold standard we
compared i) the between sample variation of each method representing their suitability to measure
NTBI in a wide variety of hemochromatosis samples and ii) the within sample variation of each
method representing their reproducibility, iii) the repeatability of the methods with Bland and Altman
plots and iv) the relation of each method to the transferrin saturation (TS). Therefore, we undertook a
comparative study between the methods used routinely for research purposes throughout
independent laboratories in Europe and Israel, using a common set of serum samples from
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hemochromatosis patients. Here we report the results of the first international interlaboratory
evaluation of NTBI from a common serum sample set. This may be the first step towards
standardization of NTBI quantification methods.
MATERIAL & METHODS
STUDY DESIGN AND PARTICIPANTS
A prospective, repeated measurement design with 12 replications, for 12 different serum samples
from iron overloaded patients, was used to assess concordance in quantitative NTBI analysis.
Samples were analyzed in six laboratories, that routinely measured NTBI for research purposes,
using eight NTBI determining methods, which consisted of five different chelating assays and one
bleomycin assay (TABLE 1). The participating laboratories included laboratories in Israel (Jerusalem,
n=1) and throughout Europe: Austria (Vienna, n=1), United Kingdom (London, n=1), Finland (Helsinki,
n=1) and the Netherlands (n=2; Bilthoven and Nijmegen). They all received three identical vials with
serum from each of the 12 patients. They were asked to quantify NTBI using their routine method(s)
and to perform four measurements on each vial, on three different days, making a total of 12
measurements per patient sample. The participating laboratories were not informed on the
biochemical characteristics of the samples. Samples were numbered in random order and shipped on
dry ice to each of the participating centres. Laboratories were instructed to report their actual results.
SPECIMENS
Twelve serum samples were selected from the sample collection of iron overloaded patients on
phlebotomy treatment in the Radboud University Nijmegen Medical Centre, the Netherlands. The
patients of the selected samples were diagnosed with iron overload according to their serum TS and
serum ferritin (SF) levels. Eleven of them were diagnosed as HFE-related hereditary
hemochromatosis patients by the presence of either homozygosity for the C282Y mutation or
compound heterozygosity for the C282Y / H63D mutations in the HFE gene. One patient was
diagnosed with secondary hemochromatosis. Samples were selected as spanning a broad range of
levels of serum iron parameters (serum TS, SF concentration). All patients were in different stages of
their phlebotomy therapy.
Twelve ml of blood was drawn during phlebotomy therapy of each patient and collected without
anticoagulant. Serum was separated after clotting by centrifugation of the blood at 2231g (within 60
min of sampling) and dispensed in polyethylene cryovials for storage at -40º C. Samples were
defrosted and divided among cryovials, before freezing for shipment on dry ice at -70º C.
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TABLE 1 Methods for the quantification of serum NTBI
Method Lab* Scavenger Blocker Detection Reference
I 1 NTA Co(III) ICP-MS [16]
II 1 NTA Co(III) HPLC [16]
IIIA 2 oxalate Ga(III) fluorescent-apo-transferrin [20]
IIIB 3 oxalate Ga(III) fluorescent-apo-transferrin [20]
IIIC 4 oxalate Ga(III) fluorescent-apo-transferrin [20]
IV 5 oxalate low Mn(III) calcein-Fecomplex [19]
CHELATION
V 5 oxalate high Mn(III) calcein-Fecomplex [19]
OTHER VI 6 bleomycin, DNA [18]
NTBI (non-transferrin-bound iron) is mobilized from its serum iron binding ligands by means of the scavengers
listed. The blocker prevents binding of the released iron to unsaturated transferrin.
Lab, laboratory; NTA, nitrilotriacetic acid; ICP-MS, inductively coupled plasma mass spectroscopy; HPLC, high
performance liquid chromatography; * The same numbers indicate the same laboratory.
NTBI METHODS
The methods used were divided into methods based on iron mobilization and detection with iron
chelators (method I to V) and an assay to measure redox active iron (method VI, the bleomycin
method) (TABLE 1). The first chelating method is named method I, using NTA to scavenge the serum
NTBI, Co(III) to block any unsaturated transferrin sites available for the iron after NTA-scavenging
and inductively coupled plasma mass spectrometry (ICP-MS) to detect the NTBI [16]. The method
differed from the originally described method as follows. The samples were diluted 1:9, with NTA (8
mmol/L, pH 7.0) and Indium (10 mg/L), to obtain a sufficient amount of sample volume. Method II is
similar to method I, except that samples were not diluted and that high performance liquid
chromatography (HPLC) was used to detect the NTBI [16]. An ordinary HPLC system rather than a
non-metal HPLC system was used for analysis. Method I and the second chelating method (method
II) were carried out in the same laboratory. Methods IIIA, IIIB and IIIC were performed in three
different laboratories. All three methods are based on the chelating assay described and published in
2001 by Breuer et al [20]. This assay uses oxalate as mobilizing agent, Ga(III) as blocker of vacant
transferrin sites and fluorescein-apo-transferrin (Fl-aTf) to provide the fluorescence signal detectable
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with a fluorescence plate reader.
Methods IV and V are also fluorescence methods based on the chelation of NTBI. These methods
however, use Mn(II) as blocker of vacant transferrin sites and the iron chelator deferoxamine (DFO)
to immobilize NTBI on the 96-well plate [19]. The fluorescence signal is provided by calcein, added to
the assay as a calcein-iron complex. To mobilize the iron, oxalate is included in two different
concentrations: a low concentration of 100 mmol/L (method IV) and a high concentration of 200
mmol/L (method V). Method VI estimates the serum NTBI by measuring the redox active iron and is
termed “the bleomycin method” [18]. The method determinates NTBI by using a biological reagent,
bleomycin, which forms a complex with redox active iron, causing a biochemical reaction that can be
measured [18]. Standard curves were calculated for each series. Data were transformed to
logarithmic values before calculation of the standard curve by linear regression in order to give
weight to the standards with a low iron concentration (0.1-1 µmol/L) before fitting the curve.
SERUM IRON PARAMETERS MEASUREMENTS
Total serum iron was measured colorimetrically with use of ascorbate/FerroZine reagents (Hitachi
747, Roche). The interassay coefficients of variation or CVs were 4.3% and 5.9% for a low (15.7
µmol/L) and a high (46.0 µmol/L) control, respectively. The normal range was 10-25 µmol/L. Latent
iron binding capacity (LIBC) was measured by adding a known quantity of Fe(III) to the serum
sample, reducing it with ascorbate to Fe(II) and measuring it with FerroZine reagent as described
above (Hitachi 747, Roche). The total iron binding capacity (TIBC) was calculated from Fe + LIBC =
TIBC. The interassay CV was 2.0% and 4.3% for a low (36.7 µmol/L) and a high (72.0 µmol/L)
control, respectively. Normal values ranged from 45-75 µmol/L. Serum TS was calculated as follows:
(serum iron / TIBC) * 100% = serum TS (%). The SF was measured by a solid-phase, two-site
chemiluminescent immunometric assay (Immulite 2000, Diagnostic Products Corporation, Cirrus).
Normal ferritin values for pre- and postmenopausal women were 6-80 µg/L and 15-190 µg/L,
respectively, and for men 15-280 µg/L.
STATISTICAL METHODS
The means of the four measurements (or three in case of an incidental outlier, see below for
treatment outliers) were calculated, representing the NTBI outcome of one sample of one day. A
linear mixed model was used to estimate the within sample SD and the between sample SD, for
each method separately. The dependent variable was NTBI outcome and the independent random
variable was sample (12 levels). The within sample SD and the between sample SD of each method
are presented with the corresponding coefficient of variation (CV). Note that the SD reflects on
average the absolute error and the CV reflects the relative error. The latter may be preferred in
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cases in which the SD raises with increasing mean level, not unusual in laboratory measurements.
A NTBI value was defined as an outlier within the four measurements of one sample on one day of a
specific method, when its value was below or above three times the corresponding standard
deviation (SD) from the mean. For this purpose the SD was calculated by using the resulting three
measurements.
Pearson’s correlations between the individual sample mean values (of all 12 measurements per
sample) obtained by the various methods were calculated.
The Bland and Altman plots for repeated measurements are presented [22]. A linear regression
model was used to study differences between the methods in their relationship between NTBI and
TS. Again the dependent variable was the NTBI outcome. The independent covariable was TS and
the independent class variable was method. As the relation between the SD (dependent) and the
serum TS (independent) showed a correlation of 0.9, a linear scale for plotting the NTBI outcomes
was chosen. The estimated regression coefficient of each method is presented with standard error
(SE). Differences between regression coefficients were tested for statistical significance. Finally, the
relation between the NTBI levels at a serum TS of 50% are presented, with differences in levels
tested for statistical significance.
RESULTS
SERUM SAMPLE CHARACTERISTICS
TABLE 2 presents the serum sample characteristics. All samples are obtained from patients with iron
overload disease, eleven patients with hereditary hemochromatosis and one patient with secondary
hemochromatosis. The Hb varied from 6.9-9.7 mmol/L (normal range for men 8.1-10.7 mmol/L, for
women 7.3-9.7 mmol/L), the serum iron concentration ranged from 5-45 µmol/L (normal values 10-25
µmol/L). The serum TS ranged from 7.4-97.0% (normal 10-45%), the SF concentration varied from
13- 2361 µg/l (normal values up to 280 µg/l). All the values are in agreement with the original iron
overload disease and the different stages of treatment.
SERUM NTBI
A total of 955 NTBI measurements (of the scheduled 1152) were available for analysis (TABLE 3).
The difference in numbers of results scheduled and actually presented are due to both missing
samples and outliers. Missing values were obtained for method I for all the samples measured on the
first day. For method II, one measurement of sample 5 was missing, next to the four measurements
on the first day of sample 7. For method IIIC one measurement for all the three days was missing for
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the samples 2, 5-12. Missed sample assignation can be ascribed to both deviations from the study
design (missings in method I, IIIC and of sample five in method II) and failures (missings of sample
seven in method II). TABLE 3 shows several missing values for the methods IV and V, due to
execution difficulties with the prescribed protocol. All measurements of these methods were excluded
for further analysis, as the obtained values turned out to be unreliably high, that is many exceeding
the serum total iron concentration recorded in TABLE 2. Outliers were seen in the methods I (n=3,
samples 3,4 and 8) and II (n=5, samples 1, 3, 5, 7 and 11) and these were also excluded from
further analysis. Note that negative values of NTBI concentrations were found for the methods I, II,
IIIB and IIIC. These values were accepted, as negative NTBI values are known to occur due to the
combination of facilitated transport of NTBI by the scavengers to the vacant transferrin sites, which
are not completely blocked by the used blockers Ga(III), Co(III), Mn(II), thereby falsely diminishing
the measured amount of NTBI.
TABLE 2 Characteristics of the 12 serum samples of the hemochromatosis patients
Sample Disease ofpatients Hb (mmol/L)*
Serum total
iron (µmol/L) Serum TS (%)
Serum
ferritin (g/L)
1 homoz 7.6 5 7.4 13
2 comp 8.1 9 13.0 13
3 comp 7.6 20 29.6 27
4 homoz 9.7 20 42.0 142
5 homoz 9.4 29 52.5 308
6 homoz 9.1 24 59.0 887
7 homoz 8.3 28 67.1 47
8 homoz 8.2 30 71.5 518
9 homoz 7.4 43 83.9 125
10 homoz 9.1 45 85.5 50
11 sec 6.9 34 90.6 2361
12 homoz 9.4 36 97.0 1347
For presentation, the samples were ordered by increasing serum transferrin saturations.
homoz, HFE-gene related hereditary hemochromatosis with C282Y homozygosity; comp, HFE-gene related
hereditary hemochromatosis with C282Y/H63D compound heterozygosity; sec, secondary hemochromatosis;
TS, transferrin saturation.; * measured in whole blood.
Chapter 3
46
TABLE 3 shows the mean and SD of the serum NTBI concentrations by sample and by method. The
mean NTBI varied considerably between the methods under consideration i.e. methods I, II, IIIA-IIIC
and VI. This was clearly demonstrated by the mean serum NTBI of sample 5 obtained by method
IIIA, which was obviously higher than the outcome obtained by the related method IIIB; 4.26 µmol/L
versus 0.43 µmol/L Fe, respectively. The bleomycin method (VI) generally showed remarkably lower
values in mean NTBI concentrations compared to the other assays.
TABLE 4 presents the between and within sample SD and CV of each method. The within sample
absolute (SD) and relative variations (CV) give an indication of the reproducibility of the individual
assay and is based on repeated measurements of the same sample in a particular assay. This within
sample variation varies considerably between assays. Methods IIIA and IIIB reveal both a lower
absolute and relative within sample reproducibility compared to the other methods, as their SDs and
CVs were 0.19 µmol/L, 4.4% and 0.18 µmol/L, 29.5%, respectively. Especially the within sample SD’s
of method I and method II are relatively high compared to their mean NTBI levels (i.e. method I, CV
96.5% and method II, CV 193.2%).
The between sample variation gives an indication whether the method is suitable to measure a wide
variation of NTBI levels in different hemochromatosis samples. This between sample SD and CV also
varied greatly across the methods used. Method IIIA shows a relatively high between sample
variance (SD 2.13 µmol/L) compared to the other chelating methods (SD 0.90-1.49 µmol/L) and
especially to method VI (SD 0.20 µmol/L). Furthermore, the between sample SD of the methods is
very high compared to the mean NTBI level measured in the sample population, except for method
IIIA (method IIIA CV 49%, compared to CV of 108.6% to 391.3% for the other methods). Note that
the method I, method II, method IIIB and method IIIC measured NTBI values below zero. This
demonstrates that, although method IIIA seems to be preferable based on the between and within
sample variation, further standardization of the chelating methods, is required to make a full
comparison between these methods possible.
The Pearson correlation between the individual sample NTBI mean values obtained by the bleomycin
method and that by the chelating methods was poor (p ns or p <0.05; range R2 0.51 to 0.64), whereas
the mutual correlation between the NTBI sample means obtained by chelating methods was clearly
significant (p <0.001, range R2 0.86 to 0.99).
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TABLE 3 Mean serum NTBI (SD)n presented by sample and by method
Chelation Redox activity
ICP-MS HPLC Fluorescence (Fl-aTF) Bleomycin
METHOD
SAMPLES I II IIIA IIIB IIIC IV V VI
1 -1.25 (0.50)11 -1.35 (0.87)11 1.22 (0.20) -1.58 (0.31) -1.30 (0.32) 3.41 (2.77)5 24.68 (10.97)7 0.02 (0.01)
2 -1.05 (0.45)11 -1.33 (0.64) 0.51 (0.36) -1.04 (0.35) -0.47 (0.41)9 5.08 (2.57)6 6.88 (3.52)4 0.02 (0.01)
3 -0.21 (0.54)10 -0.22 (1.15)11 2.80 (0.41) -0.66 (0.20) 0.07 (0.31) 9.57 (7.37)6 52.00 (30.45)7 0.03 (0.00)
4 0.19 (0.51)10 -0.15 (0.36) 3.24 (0.45) -0.37 (0.28) 0.41 (0.17) 18.31 (11.27)5 74.65 (15.77)6 0.03 (0.01)
5 1.04 (0.95)11 -0.02 (0.53)10 4.26 (0.38) 0.43 (0.22) 1.12 (0.48)9 27.38 (7.24)6 159.85 (47.60)6 0.02 (0.01)
6 0.38 (0.42)11 0.31 (0.90) 4.10 (0.28) 0.48 (0.38) 1.07 (0.12)9 24.87 (9.25)6 123.51 (33.45)6 0.04 (0.01)
7 0.73 (0.90)11 1.13 (0.58)7 4.13 (0.22) 0.70 (0.41) 1.32 (0.30)9 34.92 (5.66)6 153.99 (49.36)7 0.04 (0.01)
8 1.66 (0.70)10 0.28 (0.70) 5.22 (0.17) 1.44 (0.32) 2.61 (0.57)9 38.69 (7.23)5 175.67 (968.07)7 0.06 (0.01)
9 1.59 (0.81)11 1.72 (0.70) 7.02 (0.24) 2.27 (0.30) 3.18 (0.44)9 70.27 (19.73)6 236.63 (78.80)4 0.61 (0.06)
10 1.10 (0.46)11 0.64 (0.73) 6.76 (0.26) 2.13 (0.26) 3.18 (0.50)9 56.05 (11.21)6 220.95 (66.76)7 0.04 (0.02)
11 0.97 (0.42)11 1.03 (0.74)11 6.09 (0.10) 1.63 (0.56) 2.37 (0.42)9 65.37 (14.96)6 200.85 (6.69)7 0.11 (0.04)
12 1.31 (0.63)11 1.08 (0.82) 6.56 (0.19) 1.89 (0.34) 2.92 (0.37)9 79.37 (16.00)6 202.37 (119.33)6 0.48 (0.03)
The mean and SD are expressed in µmol/L Fe; Sample, blood sample from a patient as indicated in table 2; n, number of measurements (when not indicated n =
12, i.e. four measurements at three different days); ICP-MS, inductively coupled plasma mass spectroscopy; HPLC, high performance liquid chromatography; Fl-
aTF, fluorescent-apo-transferrin; Calcein-Fe, calcein-iron complex.
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FIGURE 1 shows the difference in mean serum NTBI (µg/L) between two methods against the average of
the mean values of these two methods. Method VI, i.e. the bleomycin method, was not evaluated for
this relation as i) the NTBI means of method VI remained close to zero for the samples 1-8 and ii) the
Pearson correlation between the sample NTBI mean values obtained by this bleomycin method and that
by the chelating methods was poor. FIGURE 1 shows clearly nonuniform differences throughout the
range of the measurements.
Consequently, the limits of agreement are too far apart suggesting in some plots a (very) poor
agreement. In such cases log transformation or regression techniques may help to provide better
(nonuniform) limits. However, in our case it is more obvious to study the methods in relation to the
serum TS of each sample (representing the true quantity) as described in the next section.
TABLE 4 Between sample and within sample variation in NTBI concentration, by method
Mean Between samples Within samples
Method SD CV SD CV
I (ICP) 0.59 0.90 152.5 0.57 96.5
II (HPLC) 0.23 0.90 391.3 0.45 193.2
IIIA (FL-aTF) 4.32 2.13 49.3 0.19 4.4
IIIB (FL-aTF) 0.61 1.30 213.1 0.18 29.5
CHELATION
IIIC (FL-aTF) 1.37 1.49 108.6 0.34 24.7
OTHER VI (Bleomycin) 0.12 0.20 166.7 0.02 15.3
The mean is calculated as the mean outcome of the means of each of the three days (each day four
measurements) found for each method on one patient sample. SD and CV are calculated using a linear mixed
model. Mean and SD are presented in µmol/L; CV is presented in %; between sample SD and CV reflect the
variation in the population; within sample SD and CV reflect the variation between the replicates of one
method.
SERUM TS VERSUS NTBI
FIGURE 2 displays the relation of the serum NTBI with the serum TS for the methods I to IIIC. For the
same reasons as mentioned in the previous section method IV was not evaluated for this relation.
NTBI levels rise linearly with TS in all assays shown. TABLE 5 shows the regression coefficients of
this relation between the increase in serum NTBI (µmol/L) and the rise in serum TS of the different
methods, calculated as increase in NTBI per unit increase in TS. This regression coefficient
increases from method I (and II) to method IIIB (and IIIC) being highest for method IIIA (i.e.
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FIGURE 1 The difference in mean serum NTBI (µg/L) between two methods against
the average of the mean values of these two methods.
The solid lines represent the mean difference with 95% limits of agreement of an individual sample. The limits of
agreement are obtained by using the within-sample standard deviation of the methods as required in case of repeated
measurements.
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regression coefficient of 0.028 µmol/L/% (0.029 µmol/L/%) to 0.048 µmol/L/% (0.042 µmol/L/%) and
0.068 µmol/L/%, respectively). A similar pattern was observed for the mean level of NTBI at serum
TS of 50%, except that here the mean level of method I (0.35 µmol/L) and IIIB (0.26 µmol/L) did not
differ significantly.
FIGURE 2 The mean serum NTBI (non-transferrin-bound iron) against serum TS (transferrin saturation) of a sample, by
method.
The lines indicate the estimated mean NTBI using a multivariate linear regression model, the symbols indicate
the observed mean NTBI.
Method I: , thick solid line, R = 0.82; method II: x, thick long dashed line, R = 0.85; method IIIA: , thick
short dashed line, R = 0.96; method IIIB: , thin solid line, R = 0.96; method IIIC: , thin long dashed line, R
= 0.94.
Results of an international round robin for the quantification of serum NTBI
51
TABLE 5 The estimated regression and the estimated mean level at the TS concentration of 50% of serum
NTBI, by method
Method Regression coefficient (SE) NTBI level at TS 50% (SE)
II (HPLC) 0.029 (0.003)1 0.01 (0.09)1
I (ICP) 0.028 (0.003)1 0.35 (0.09)2
IIIB (FL-aTF) 0.048 (0.003)2 0.26 (0.09)2
IIIC (FL-aTF) 0.042 (0.003)2 0.98 (0.09)3
CHELATION
IIIA (FL-aTF) 0.068 (0.003)3 3.76 (0.09)4
Different numbers in the same column indicate statistical significant difference, p <0.05, using a multivariate
linear regression model.
SE, standard error; NTBI, non-transferrin bound iron; TS transferrin saturation; NTBI level at TS is presented
in µmol/L. The regression coefficient indicates the amount of increase in NTBI (in µmol/L) with an increase of
1 unit (1%) of serum TS.
DISCUSSION
The present round robin comparatively assessed serum NTBI concentrations measured with different
NTBI quantification methods, 5 different chelating methods and a bleomycin assay. The study
showed a considerable intra- and inter-method variation for the quantification of serum NTBI levels of
hemochromatosis patients in different stages of their phlebotomy treatment. Moreover, serum NTBI
values obtained by the various methods correlated differently with those of TS. Despite these
differences between methods, the serum NTBI concentrations obtained with the methods based on
chelators correlated significantly.
Correlations of NTBI values were most significant between NTBI values found by the methods that
belonged to the same method group, as was illustrated by the strong mutual correlations between the
NTBI means measured by the chelating methods. In contrast, correlations between the chelating
methods and the bleomycin method were either weak or non-existent. As the bleomycin method was
originally developed to measure NTBI levels in serum samples with a TS of 80% or higher, it could
very well be that the correlation between the chelating methods and the bleomycin method increases
when more samples with iron saturations above this level are included.
Although the methods significantly correlated, they widely differed in mean NTBI as well as in the
between sample variation and the within sample variation. NTBI results by methods with a high
between sample variation, such as method IIIA (SD 2.13 µmol/L) showed a wider variation of levels
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for the different hemochromatosis samples in comparison with methods with a low between sample
variation such as the bleomycin method (SD 0.20 µmol/L). The low SD for the bleomycin method
suggests that this method is less suitable to measure NTBI in a variety of samples of
hemochromatosis patients. However, the absence of a gold standard assay and an international
calibrator precludes the definite choice of the most optimal method based on these between sample
variations. Methods with a relatively low within sample variation, such as method VI (SD 0.02 µmol/L)
and IIIA (SD 0.19 µmol/L) and IIIB (SD 0.18 µmol/L) gave more reproducible NTBI outcomes than
methods with more elevated within sample variations such as I (SD 0.57 µmol/L) and II (SD 0.45
µmol/L). The combination of both a relatively high between and low within sample variation, as for
the methods IIIA (SD between 2.13 µmol/L; SD within 0.19 µmol/L) and IIIB (SD between 1.30
µmol/L; SD within 0.18 µmol/L) suggest that these methods have the most optimal profile
for.reproducible measurements of a wide range of NTBI levels of hemochromatosis patients. In this
respect, the between and within sample SD profile of methods I and II suggest a less favourable
assay. However, the negative values of the methods I, II, IIIB and IIIC make a full comparison
difficult.
The differences between the methods I and II and the other chelating methods IIIB and IIIC were
also reflected in differences between the regression coefficients considering the relationship of the
measured NTBI levels with serum TS, i.e. with increasing TS, the NTBI levels obtained by the
methods I and II raise less than those obtained by methods IIIB and IIIC.
The observed absolute and relative variation in serum NTBI results of the diverse methods might
have several causes. First of all, the use of different chelating methods with each their own specific
scavengers and blockers could have influenced the results, as these various scavengers and
blockers each have their own chemical behaviour [2, 16]. A second explanation for the variation in
NTBI outcomes could be that all laboratories differently interpreted the original method description
and made various minor adjustments, which might have influenced their results. For example,
chelating methods IIIA, IIIB and IIIC that originated from the same source [20] used identical blockers
and scavengers, but differed in the use of equipment (i.e. quality of glassware, plastics and the
fluorescent plates), reagents (i.e. the preparation and final concentration of the Ga(III) solution, use of
iron free reagents, fluorescence labelling procedures) and the construction of the calibration curves
(i.e. ratio of Fe to NTA, Fe concentration range). It is outside the scope of the present study to
exactly identify the main cause(s) of the differences between these 3 methods. Also, some published
methods are difficult to reproduce. This is illustrated by the unreliably high NTBI concentrations
obtained by the methods IV and V. In a multistep assay of this type, instability of calcein complexes
or iron contamination might have played a role [23].
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Since the NTBI assay needs to detect very low concentration of iron, contamination can be a serious
problem and a third source of variation between labs. Iron can be present in the whole laboratory
environment, reagents materials and equipment. It appeared to us that is was very difficult for
laboratories to exclude contaminant iron to prevent erroneous outcomes. The effect of iron
contamination can be illustrated by the measurements performed on sample seven with method II on
day one, using only routinely cleaned tubes, leading to four NTBI results with a mean of 3.85 µmol/L.
This in contrast to the quadruplicate measurements on the same sample on the following 2 days,
when especially iron-free prepared tubes were used, revealing mean NTBI outcomes of only 0.93
µmol/L and 1.28 µmol/L, respectively. A fourth explanation for the observed differences in mean NTBI
levels between methods might be the existence of various NTBI isoforms. The various methods may
select for different forms of NTBI; in other words, isoforms may not be equally well detected by each
of the NTBI assays. This might particularly explain the differences in NTBI values between the
chelating methods and the bleomycin method. Furthermore, isoforms might vary with the degree and
type of iron overload [9]. So, the results of the present NTBI method comparison study on samples of
patients with hereditary hemochromatosis may not simply be extrapolated to samples of patients with
other diseases such as ß-thalassemia, or patients on chemotherapy. This dependency of the
measured NTBI concentrations on both mode and extent of disease and the method used, might
explain the results of the following three recent studies: i) Esposito et al, using serum samples of
patients with ß-thalassemia instead of hereditary hemochromatosis, did find a correlation between the
serum NTBI concentration measured by a chelating method and a new and alternative method for
measuring the serum redox active iron (Labile Plasma Iron) [21]; ii) Sahlsted et al, using serum from
haematological stem cell transplant patients, found lower serum NTBI concentrations when NTBI was
measured by the bleomycin method, than when the amount of NTBI was calculated from the shift of
apotransferrin into the monoferric form of transferrin after a single apotransferrin infusion [24] and iii)
von Bonsdorff et al, using serum from patients with haematological malignancies, found higher NTBI-
values by their chelating method than by their bleomycin method [18]. The latter results were
confirmed by the present study with samples from a different patient group.
From the differences between the methods described above we conclude that standardization of a
research method such as NTBI is urgently needed before it continues to be used in diverse fields of
research or even in clinical practice. We propagate that all papers on NTBI-methods should include
thorough characterization of the methodology, analytical control and construction of standard curves.
Furthermore the linearity for an indicated dynamic range, within and between day variability, and
information on how iron contamination was avoided, should be described.
In conclusion, the present study shows that NTBI values differ considerably between methods. These
differences are largely caused by i) variations in the procedures, ii) iron contamination and iii)
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differences in the nature of the NTBI complexes or isoforms measured by the methods. Although
recent studies underscore the clinical relevance of NTBI [2, 10, 13, 14, 25], it remains unclear which
method best represents the pathophysiological phenomenon and is most pertinent for diagnostic and
therapeutic purposes. Furthermore, our study clearly shows that laboratory protocols should be more
thoroughly standardized, to decrease the variation of NTBI results within and between laboratories.
Therefore, we conclude that before NTBI can be introduced into clinical practice additional
information is needed on its nature and relevance and more robust quantification-methods should be
developed.
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ABSTRACT
Background: Excess body iron is associated with increased cardiovascular disease risk, possibly via
non-transferrin-bound iron (NTBI)-mediated enhancement of inflammation and oxidation of low-
density lipoprotein (LDL). Methods: We assessed this proposed atherosclerotic mechanism of body
iron by determining the relationship of levels of serum iron parameters, including NTBI, with plasma
markers of inflammation and LDL oxidation in 232 subjects who visited the outpatient clinic for
hemochromatosis family screening. Results: Plasma level of soluble intercellular adhesion molecule-1
(sICAM-1) was positively related to serum ferritin (SF) (standardized beta coefficient 0.16) and to
NTBI (0.185) and negatively to total iron-binding capacity (TIBC, -0.166). Significant higher levels of
sICAM-1 were found for subjects in the highest quartile of NTBI compared to the lowest quartile of
NTBI (122 µg/L (107-141) and 106 µg/L (89-125), median (interquartile range), p<0.001). Odds ratio
of subjects having sICAM-1 level above 134 µg/L (75th percentile) in the highest and lowest quartile
of NTBI amounted 2.3. White blood cell count was positively related to SF (0.149). High sensitivity C-
reactive protein, interleukin 6, interleukin 8, oxidized LDL, oxidized LDL/apolipoprotein B and IgG and
IgM antibodies to oxidized LDL were not related to any of the markers of iron status. Conclusion:
Excess body iron, reflected by elevated SF and NTBI and decreased TIBC, is associated with
increased plasma level of sICAM-1 but not with markers of in vivo LDL oxidation.
INTRODUCTION
Although not confirmed by a meta-analysis of prospective studies [1], epidemiological and
experimental data suggest evidence for a potential role of iron in atherosclerosis [2]. It is
hypothesized that free iron-catalyzed oxidation of low-density lipoprotein (LDL) is causally involved [3,
4]. In healthy adult men, intracellularly most iron is contained in haemoglobin, myoglobin and SF, and
in plasma the glycoprotein transferrin efficiently binds iron. Thus, levels of free iron are reduced to
nearly zero. When body iron rises to levels above normal, however, part of it may not be safely
stored. Iron then binds to ligands with less affinity than transferrin, such as citrate, phosphates, and
albumin, and may be available for redox reactions [5]. Moreover, also in the presence of unsaturated
transferrin, non-transferrin-bound iron (NTBI) can be detected in serum [6, 7]. NTBI can catalyze the
production of reactive hydroxyl radicals out of the relatively innocuous phagocyte- and endothelium-
derived superoxide radicals [8]. Hydroxyl radicals can damage DNA, lipids and proteins. Oxidized
LDL are pro-inflammatory, they attract monocytes via induction of chemokines, and upregulate
scavenger receptor expression on macrophages. The scavenger receptors subsequently recognize
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oxidized LDL and mediate their uptake into the cells. This process leads to lipid accumulation in the
vessel wall and fatty streak formation, the beginning of atherosclerosis. This proposed atherosclerotic
mechanism of iron can be verified by measuring serum levels of NTBI in relation to markers of LDL
oxidation and markers of inflammation. Assays to measure NTBI and oxidized LDL are available [9-
11], and we have recently compared different methods to measure NTBI [12]. Although the
comparability of the methods appeared to be rather low and (inter)national standardization is still
lacking, one of the methods has an optimal profile for reproducible measurements of a wide range of
NTBI. Therefore, this method is suitable to relate NTBI with other variables within one population. Up
to now, in no study oxidized LDL and NTBI were measured in one population. Others did previously
find that in healthy subjects who participated in feeding studies, NTBI was not associated with
measures of in vitro LDL oxidation (lag-time, rate of oxidation, and total dienes formed) [13].
However, this is a non-physiological assessment of LDL oxidation. Furthermore, in a few studies
oxidized LDL has been studied in relation to other variables of iron status in populations having
normal or sub-normal iron status [14-17]. These studies, however, did not yield concordant results,
probably because the stored body iron marker used (SF) is an inappropriate marker of free (redox-
active) iron [18].
In this study we explore the relation of variables of iron status, including NTBI, with serum markers of
inflammation and of LDL oxidation, including oxidized LDL, in a population of subjects expected to
cover a wide range of serum iron status.
MATERIALS & METHODS
SUBJECTS
Study subjects were patients diagnosed with hereditary hemochromatosis and family members
(n=173 from 69 families) and spouses (n=59) who visited the outpatient clinic for hemochromatosis
family screening at the Radboud University Nijmegen Medical Centre between February 2002 and
September 2004. Excluded were subjects with cardiovascular disease (CVD), diabetes mellitus or
infectious diseases (C-reactive protein > 20 mg/L), and subjects receiving statin therapy or iron
chelation medication, or using antioxidants. Pregnancy and alcohol abuse were also exclusion
criteria. A participant was considered to have CVD when he had been diagnosed with angina
pectoris, myocardial infarction, arrhythmia, stroke, or peripheral arterial disease, or when he had
undergone intervention procedures (balloon angioplasty, coronary bypass surgery or aortic aneurysm
surgery)
Of each participant a self-reported medical history, including current drug use and family history of
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premature vascular disease (onset <60 years in first degree family), and information on alcohol
consumption, physical activity, smoking behaviour and blood donorship, were attained by
questionnaire and reviewed by a research assistant. The waist circumference was measured at the
level of the umbilicus, the hip circumference was measured at the level of the trochanter major, and
the waist-to-hip ratio was calculated. Height and weight were measured and body mass index (kg/m2)
was calculated. Blood pressure was measured using an automated monitor (Welch Allyn Medical
Products, model 5200-103A, Skaneateles Falls, NY, USA) in supine position and blood was drawn by
venipuncture. Iron status (except NTBI) and plasma lipids were determined in fresh samples. For
determination of NTBI, apolipoprotein B (apoB), and markers of inflammation and LDL oxidation,
aliquots of serum and EDTA-plasma (with and without saccharose (0.6% w/v) as cryopreservant)
were stored at –80 ºC. The protocol was approved by the hospital ethics-committee and written
informed consent was obtained from all participants.
BIOCHEMICAL MEASUREMENTS
IRON STATUS
Serum total iron and serum total iron binding capacity (TIBC) were determined by routine clinical
chemistry methods on the Hitachi 747 (Roche) and SF was measured by a solid-phase two-site
chemiluminescent immunometric assay using the Immulite 2000 (Diagnostic Products, Cirrus); serum
TS was calculated as a percentage of serum total iron divided by TIBC. NTBI was measured in
serum by a method using iron-sensitive fluorescence-labelled apotransferrin, as described previously
[9] and recently evaluated by our group in an interlaboratory comparative study [12]. The assay has
an optimal profile for reproducible measurements of a wide range of NTBI levels (range 0-7 µmol/L,
within-samples CV = 4.4%).
LIPIDS AND APOLIPOPROTEIN B
Plasma cholesterol and triglycerides were determined using commercially available reagents on the
Hitachi 747 analyser (Boehringer Mannheim, Germany). High-density lipoprotein (HDL)-cholesterol
was determined with the phosphotungstate/Mg2+ method [19]. LDL-cholesterol was calculated with
the Friedewald formula. ApoB was quantified by immunonephelometry [20].
MARKERS OF INFLAMMATION AND LDL OXIDATION
High-sensitivity C-reactive protein (hsCRP) was measured by enzyme-immunoassay according to the
instructions from the manufacturer (Dako, Glastrup, Denmark). Coefficient of variation was less than
6%.
Concentration of soluble intercellular adhesion molecule-1 (sICAM-1) in plasma was measured with a
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sandwich ELISA described elsewhere [21]. The lower detection limit of the assay was 400 pg/ml.
Interleukin-6 (IL-6) and interleukin-8 (IL-8) were determined with Pelipair® reagent sets purchased
from Sanquin (Amsterdam, The Netherlands).
White blood cell count was determined automatically using the Advia 120 haematology analyser
(Bayer, Tarrytown, USA).
For measurement of oxidized LDL we used commercial non-competitive ELISA (Mercodia, Uppsala,
Sweden). The assay uses monoclonal antibody 4E6 to specifically capture oxidized apoB from the
sample, which is subsequently detected with an antibody to apoB. Intra- and interassay coefficients
of variation of the assay amounted 6% and 7%, respectively. As shown previously by our group [22]
and confirmed recently by Holvoet et al [23], duration of storage at –80ºC did not influence the
amount of oxidized LDL measured, provided that the EDTA samples had been collected carefully and
had not been thawed.
Circulating antibodies (IgG and IgM) to oxidized LDL were measured as described previously [24]. In
short, samples were incubated in wells of microtiter plates precoated with native or oxidized LDL, and
bound antibodies were detected using peroxidase-conjugated antibodies from goat specific for human
IgG or IgM (Sigma-Aldrich, Steinheim, Germany). Results are expressed as the mean optical density
values at 450 nm from duplicate measurements, and the antibody titer to oxidized LDL is calculated
by subtracting the binding to native LDL from the binding to oxidized LDL. With this substraction
method our assay not only corrects for specific binding to native LDL, but also for non-specific
binding of each sample to the wells of the microtiter plate. The same batch of native and oxidized
LDL was used for all determinations of antibodies to oxidized LDL in this study.
HFE GENOTYPING
The HFE C282Y genotype was determined by an automated method using minor-groove-binding
DNA oligonucleotides (MGB probes) as described previously [25]. The presence of a C282Y allele
was confirmed by conventional PCR with restriction fragment length polymorphism analysis.
STATISTICAL ANALYSIS
Levels of SF, TS, hsCRP, sICAM-1, IL-6, IL-8 and IgG antibodies to oxidized LDL showed skewed
distribution and statistical analyses were based on transformed (natural logarythm) data. ANOVA was
used to test for differences between sexes and between subgroups of smoking, alcohol consumption,
physical activity and blood donation. Correlations between numeric variables were assessed with
Spearman’s correlation. Multiple linear regression analysis was used to analyse the relation between
markers of iron status and markers of inflammation and LDL oxidation. Age, gender, systolic blood
pressure, waist/hip, plasma LDL cholesterol, smoking status, and alternately serum iron, TIBC, TS,
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SF and NTBI were entered into the model as explanatory variables. Markers of inflammation and LDL
oxidation were used as outcome variables. No adjustments for multiple comparisons were made,
following the arguments of Rothman [26] and Perneger [27, 28], which suggest that a Bonferroni
adjustment is overconservative in a study with many non-independent variables. To take into account
the concern of multiple comparisons, a P-value of 0.025 was taken as the level for statistical
significance. All of the analyses were performed using SPSS 12.0.1 for Windows.
RESULTS
The study population consisted of 232 subjects with a mean age of 46 year, almost equal distribution
of sexes, and relatively normal body mass index, blood pressure and plasma lipids (TABLE 1). About
equal numbers of subjects smoked, had quitted smoking, or had never smoked. A quarter of the
study population consumed no alcohol and one third did not sport regularly (less than two
hours/week). Twenty percent of the study subjects donated blood regularly (500 ml twice a year as a
donor, letting blood by the patients excluded). Iron status of the study population is presented in
TABLE 2. Levels of serum iron ranged from 4 to 56 µmol/L and were higher in males than in females;
24% of subjects had levels above 25 µmol/L, the upper border for normal values. TIBC varied from
35 to 89 µmol/L and was similar in males and females; 13.9% of subjects had levels lower than 45
µmol/L and 3.4% of subjects had levels higher than 75 µmol/L (lower and upper border for normal
values, respectively). TS ranged from 4.8 to 102.2% and was higher in males than in females; 6% of
subjects had TS above 80%. SF levels ranged from 2 to 3010 µg/L; 23% of the males had levels
above 280 µg/L and 21.8% of the females had levels above 190 µg/L (upper borders for normal
values of males and females, respectively). NTBI levels varied from 0.44 to 6.21 µmol/L.
Within the whole population, as expected, NTBI correlated positively with serum iron (r=0.81,
p<0.001), TS (r=0.84, p<0.001) and SF (r=0.28, p=0.001), and negatively with TIBC (r=-0.37,
p<0.001). These correlations were similar for males and females.
Markers of inflammation and LDL oxidation were not different between sexes (TABLE 2). HsCRP
correlated positively with oxidized LDL (r=0.21, p=0.001), sICAM-1 (r=0.26, p<0.001) and white blood
cell count (r=0.26, p<0.001), and sICAM-1 correlated with IL-8 (r=0.27, p<0.001). Other correlations
between variables of inflammation and LDL oxidation were weaker (r<0.20) or not significant.
Seventy-one subjects (29 males and 42 females) did not carry the C282Y mutation in the HFE gene,
111 were heterozygous (53 males and 58 females) and 50 subjects (28 males and 22 females) were
homozygous for the mutation. Of the subjects homozygous for the mutation, 78% underwent regular
bloodletting to lower their body iron. Still, the homozygous subjects had significantly higher levels of
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serum iron, TS and NTBI, and lower levels of TIBC compared to subjects not carrying the mutation
(TABLE 3). Levels of markers of iron status of subjects heterozygous for the C282Y mutation in the
HFE gene were intermediate between those of homozygotes and non-carriers. Similar differences
between genotypes were found within males and females separately, although significance was not
always reached due to lower numbers (not shown). No differences were observed in markers of
inflammation and LDL oxidation between the different genotypes of C282Y of the HFE gene (not
shown).
TABLE 1 Characteristics of the study population (n=232)
Demographics
Age (y) 46 (14)
Gender (m/f)* 47/53
Physical examination
Body mass index (kg/m2)# 25.0 (22.9-27.7)
Waist/hip 0.86 (0.08)
Diastolic blood pressure (mm Hg) 81 (11)
Systolic blood pressure (mm Hg) 133 (19)
Plasma lipids and apolipoprotein B
Total cholesterol (mmol/L) 5.3 (1.0)
Total triglycerides (mmol/L)# 1.29 (0.96-1.86)
HDL cholesterol (mmol/L) 1.32 (0.37)
LDL cholesterol (mmol/L) 3.3 (0.9)
Apolipoprotein B (mg/L) 962 (233)
Life style characteristics
Smoker (present/past/never)* 28/35/37
Alcohol consumer (yes/no)* 76/24
Sporting regularly (yes/no)* 65/35
Blood donor (yes/no)* 20/80
Data are presented as mean (SD), unless indicated otherwise.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; # presented as median (interquartile range);
* presented as percentage.
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TABLE 2 Plasma markers of iron status, inflammation and LDL oxidation of the study population (n=232)
Variable Males(n=110)
Females
(n=122)
Iron status
Serum iron (µmol/L) 22.9 (9.4) 19.8 (7.4)†
Serum TIBC (µmol/L) 54.3 (8.8) 56.5 (9.8)
Transferrin saturation (%)# 37.8 (28.7-53.7) 33.3 (24.9-42.4)†
Serum ferritin (µg/L)# 125 (50-280) 70 (38-173)†
Serum NTBI (µmol/L) 2.96 (1.25) 2.47 (1.07)†
Inflammation
HsCRP (mg/L)# 1.1 (0.4-2.5) 1.5 (0.7-3.6)
sICAM-1 (µg/L)# 113 (100-132) 115 (94-135)
IL-6 (pg/ml)# 1.2 (0.5-2.3) 1.0 (0.5-2.0)
IL-8 (pg/ml)# 6.0 (3.2-9.2) 4.8 (3.0-4.8)
White blood cells (109/L) 6.4 (2.0) 6.7 (1.8)
LDL oxidation
Oxidized LDL (U/L) 58 (21) 55 (17)
Oxidized LDL/apoB (U/mg) 0.059 (0.011) 0.058 (0.010)
IgG antibodies to oxidized LDL (OD450)# 0.36 (0.24-0.49) 0.34 (0.23-0.52)
IgM antibodies to oxidized LDL (OD450) 0.54 (0.34) 0.62 (0.37)
Data are presented as mean (SD), unless indicated otherwise. TIBC, total iron-binding capacity; NTBI, non-
transferrin-bound iron; hsCRP, high-sensitivity C-reactive protein; sICAM-1, soluble intercellular adhesion
molecule-1; IL-6, interleukin-6; IL-8, interleukin-8; LDL, low-density lipoprotein; apoB, apolipoprotein B; IgG,
immunoglobulin G; IgM, immunoglobulin M; OD, optical density.
# presented as median (interquartile range); † p < 0.025 compared to males (ANOVA).
Next, we analysed the contribution of iron status to plasma levels of markers of inflammation and
LDL oxidation. Age, gender, waist/hip ratio, systolic blood pressure, smoking status and plasma LDL
cholesterol (not for oxidized LDL/apoB ratio) were included in the model as possible confounders (as
established by bivariate correlation analyses (Spearman) and ANOVA). After adjustment, hsCRP, IL-
6, IL-8, oxidized LDL, oxidized LDL/apoB and IgG and IgM antibodies to oxidized LDL were not
related to any of the markers of iron status (TABLE 4). Plasma level of sICAM-1 was positively related
to SF (standardized beta coefficient 0.16) and to serum NTBI (0.185) and negatively to serum TIBC
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(-0.166) (FIGURE 1). White blood cell count was positively related to SF (0.149). When the population
was divided into quartiles of NTBI, significant higher levels of sICAM-1 were found for subjects in the
highest quartile of NTBI compared to the lowest quartile of NTBI (122 µg/L (107-141) and 106 µg/L
(89-125), median (interquartile range), p<0.001). Odds ratio of subjects having sICAM-1 level above
134 µg/L (75th percentile) in the highest and lowest quartile of NTBI amounted 2.3 (0.98-5.6, 95%
confidence interval).
TABLE 3 Iron status of the study population stratified by the C282Y genotype of the HFE-gene
C282Y non-carriers
(n=71)
C282Y heterozygotes
(n=111)
C282Y homozygotes
(n=50)
Serum iron (µmol/L) 18.4 (4.8) 21.4 (8.4)* 25.2 (11.0)*
Serum TIBC (µmol/L) 59.4 (8.9) 55.7 (9.0)* 49.4 (7.7)*,†
Transferrin saturation (%)# 30.4 (24.7-36.1) 37.1 (27.4-46.6)* 47.7 (32.7-77.7)*,†
Serum ferritin (µg/L)# 94 (44-174) 88 (50-231) 54 (25-199)
Serum NTBI (µmol/L) 2.25 (0.75) 2.78 (1.19)* 3.18 (1.42)*
Data are presented as mean (SD), unless indicated otherwise.
TIBC, total iron binding capacity; NTBI, non-transferrin-bound iron. # presented as median (interquartile range);
* p < 0.025 compared to non-carriers; † p < 0.025 compared to heterozygotes (t-test).
DISCUSSION
The present study comprises the first in vivo data supporting an association between NTBI and
plasma levels of sICAM-1. We observed a significant positive correlation of serum NTBI with the
plasma level of sICAM-1, but not with variables of in vivo LDL oxidation. Recently, Kartikasari et al
showed that NTBI from human sera upregulates the expression of adhesion molecules on human
umbilical vein endothelial cells (HUVEC) in vitro and promotes the extent of monocyte adhesion [29].
The increase of adhesion molecule expression was shown to be due to increased intracellular
oxygen-derived free radical formation, resulting from an augmentation of the level of metabolically
and catalytically reactive cytoplasmic labile iron [29, 30].
The presently observed association of NTBI with plasma level of sICAM-1 could contribute to the
suggested increased risk on CVD at excess body iron. Endothelial ICAM-1 plays a critical role in the
monocyte recruitment to the extravascular compartment by mediating adhesion and transmigration of
the cells to the vascular endothelial wall [31]. In addition, adhesion molecules have an important role
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TABLE 4 Linear regression analysis of the association of markers of inflammation and LDL oxidation with markers of
iron status
Iron TIBC TS SF NTBI
HsCRP -0.069 p=0.29) 0.021 (p=0.75) -0.090 (p=0.17) 0.056 (p=0.39) -0.045 (p=0.50)
sICAM-1 0.025 (p=0.71) -0.166 (p=0.02) 0.064 (p=0.34) 0.16 (p=0.02) 0.185 (p=0.007)
IL-6 -0.150 (p=0.27) -0.040 (p=0.57) -0.124 (p=0.07) -0.077 (p=0.25) -0.086 (p=0.21)
IL-8 0.073 (p=0.28) 0.038 (p=0.58) 0.045 (p=0.50) 0.083 (p=0.21) 0.100 (p=0.14)
White blood cell
count -0.101 (p=0.12) 0.012 (p=0.86) -0.088 (p=0.17) 0.149 (p=0.02) -0.114 (p=0.08)
Oxidized LDL 0.046 (p=0.33) 0.088 (p=0.08) 0.025 (p=0.60) 0.06 (p=0.21) 0.007 (p=0.88)
Oxidized
LDL/apoB# 0.117 (p=0.08) 0.03 (p=0.63) 0.137 (p=0.04) 0.054 (p=0.42) 0.036 (p=0.59)
IgG antibodies to
oxidized LDL -0.001 (p=0.99) 0.029 (p=0.69) 0.023 (p=0.74) -0.061 (p=0.38) -0.073 (p=0.30)
IgM antibodies to
oxidized LDL -0.023 (p=0.73) -0.081 (p=0.24) -0.032 (p=0.63) -0.001 (p=0.99) -0.011 (p=0.87)
Statistics based on linear regression; given are standardized beta coefficients (p-value) adjusted for age,
gender, waist/hip ratio, systolic blood pressure, smoking status and plasma LDL cholesterol.
# not adjusted for LDL cholesterol; TIBC, total iron binding capacity; TS, transferrin saturation; SF, serum
ferritin; NTBI, non-transferrin-bound iron; hsCRP, high-sensitivity C-reactive protein; sICAM-1, soluble
intercellular adhesion molecule-1; IL-6, interleukin 6; IL-8, interleukin 8; LDL, low-density lipoprotein; apoB,
apolipoprotein B.
in the initiation and progression of atherosclerotic disease [32, 33], probably through alterations in
gene expression that lead, for example, to secretion of cytokines and metalloproteases. Previously,
Ridker et al found a significant association between increasing concentration of sICAM-1 and risk of
future myocardial infarction in apparently healthy men [34]. More recently, Kondo et al, in a
longitudinal study, observed that sICAM-1 was associated with carotid atherosclerosis progression,
independently of traditional risk factors and CRP, in outpatients treated for traditional risk factors for
CVD [35]. These findings suggest that levels of sICAM-1 may have potential value to predict
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FIGURE 1 Regression plots of sICAM-1 with SF, TIBC and NTBI.
Linear regression analysis of plasma soluble ICAM-1 levels with SF (A), TIBC (B) and NTBI (C).
sICAM-1, soluble intercellular adhesion molecule-1; SF, serum ferritin; TIBC, total iron-binding capacity; NTBI,
non-transferrin-bound iron.
atherosclerosis progression.
Up to now serum NTBI and plasma markers of inflammation and in vivo LDL oxidation were not
studied before in one population. A few studies addressing the inflammation/oxidation hypothesis of
iron-overload, used SF as variable reflecting iron status [14-17]. Weak but significant relationships
were observed for SF with plasma levels of oxidized LDL, normalized for serum LDL cholesterol
concentration, in the male subgroup of healthy Caucasians [14], with the cholesterol autoxidation
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products 7-hydroxycholesterol and 7-ketocholesterol in eastern Finnish men [16], and with C-
reactive protein in young women but not in young men [36]. On the other hand, no association was
found between blood donation-induced low SF levels and plasma levels of adhesion molecules and
oxidized LDL [17], and among the participants of the Atherosclerosis Risk in Communities (ARIC)
study, no association existed for SF with auto antibodies to malondialdehyde-modified LDL [15].
However, SF is an inappropriate marker of free (redox-active) iron [18]. In contrast to NTBI, ferritin is
hypothesized to be not available for catalyzing free radical formation. In addition, serum NTBI and SF
correlate only weakly. Furthermore, SF is an acute phase reactant that is elevated by infection and
may be elevated by inflammation. For these reasons, associations of markers of inflammation and in
vivo LDL oxidation with NTBI differ from those with SF, and we feel that measurement of NTBI itself
should be preferred when assessing a possible association between iron status and inflammation and
oxidation. Moreover, in the studies mentioned above, iron status of the participants was normal or
even subnormal. We assume that, if a relationship exists between iron status and measures of
inflammation or LDL oxidation, this will be most apparent when subjects with elevated serum iron
status are included.
In the present study, we used a population of subjects covering a wide range of serum iron status,
and we found a clear association of serum NTBI with sICAM-1 and weaker, but also significant,
associations of SF and total iron binding capacity with sICAM-1. These data are in favour of a direct
in vivo oxidative stress-promoting effect of NTBI. The oxidative stress, however, does not reach a
level high enough to promote oxidative modification of apolipoprotein B, since we did not find an
association of circulating oxidized LDL with NTBI. Previously, we measured copper-induced LDL
oxidizability of two groups (23 subjects each) of hereditary hemochromatosis heterozygotes
(heterozygous for the C282Y mutation and wild-type for the H63D mutation in the hemochromatosis
gene) showing clear differences in serum NTBI [37]. We found no difference in lag-time between the
groups with high and low serum NTBI. Only the rate of in vitro LDL oxidation and the amount of
dienes formed were slightly but significantly decreased at elevated serum NTBI. We hypothesized
that at increased level, NTBI may cause a continuous low-grade oxidative pressure in such a way
that molecules most prone to lipidperoxidation are constantly oxidized, and due to this decrease in
oxidizable substrates, the rate and extent of in vitro oxidation is reduced. In line with this, others
found that levels of F2-isoprostanes, one of the most specific measures of lipidperoxidation available,
esterified in plasma lipoproteins, were increased soon after rapid infusion of iron in excess of
transferrin binding capacity [38]. Consistent with lag-time, we found no difference in the vitamin E
content of LDL between the groups with high and low serum NTBI [37], probably because vitamin E
is successfully regenerated by antioxidants abundantly present in plasma. Thus, although oxidized
LDL particles would be rapidly cleared from the circulation by the reticulo-endothelial system, our
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previous and present findings of unaltered vitamin E and oxidized LDL levels at elevated NTBI,
suggest that it is improbable that elevated NTBI enhances formation of oxidized LDL. Therefore, our
findings do not support the hypothesis that increased body iron status is associated with increased
oxidative modification of LDL. Still, the early lipidperoxidation products that do get formed, may
contribute to atherogenesis directly. For instance, oxidized phospholipids have been demonstrated to
mediate many atherogenic processes, from monocyte migration into the vessel wall to thrombus
formation.
In conclusion, elevated iron status is associated with increased plasma level of sICAM-1 but not with
measures of in vivo LDL oxidation. Enhanced recruitment of inflammatory cells to the extravascular
compartment by increased endothelial expression of ICAM-1 may contribute to the suggested
increased risk on CVD at excess body iron.
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ABSTRACT
Background: In 1998 a clinical guideline for the targeted and accurate and early detection and
treatment of HFE-related hereditary hemochromatosis (HH), that comprises a test for the causative
HFE-gene mutations, was introduced at the outpatient department.
Methods: The impact of this guideline was evaluated retrospectively. Data were acquired from
medical records of patients with discharge diagnosis codes suggestive for HH (n=878 patients),
obtained from a period before (n=422) and after guideline introduction (n=456).
Results: Combined measurements of serum transferrin saturation and serum ferritin rose from 12.2%
(n=53) to 29.5% (n=138, p<0.001), leaving 70% of the patients eligible for HH not tested for iron
parameters. The HFE-gene mutation detection test was correctly used in 11 (40.7%) of 27 tested
patients and improperly interpreted in 6 (22.2%) of these 27 patients. Five new HH patients were
diagnosed before and 13 after introduction. Seven of these 13 patients appeared to be incorrectly
diagnosed, due to misinterpretation of laboratory results.
Diagnostic costs of case detection for each accurately diagnosed patient were 2,380 Euro before and
2,600 Euro after introduction of the guideline.
Conclusion: Evaluation of the introduction of a practical guideline for targeted HH detection, reveals a
low compliance with the guideline, resulting in both a small percentage of patients tested for HH and
overdiagnosis of HH. Therefore, the introduction of the guideline should be combined with a more
appropriate implementation strategy, which includes education on its most critical points, i.e. the
indication and interpretation of the iron parameters and the HFE-genotype.
INTRODUCTION
The medical and scientific interest in HFE-related Hereditary Hemochromatosis (HH), iron overload
disease, quickly expanded after the discovery of the causative C282Y and H63D mutations in the
hemochromatosis (HFE-) gene in 1996 [1]. The C282Y-mutation is now the most common autosomal
recessive mutation in people of northern European descent, with an estimated prevalence of the
genetic susceptibility for HH by homozygous C282Y mutation, of 1 in 200-250 persons [2, 3].
Complaints that can be attributed to iron overload are fatigue, arthralgia and cardiac rhythm disorders
[4-6]. Furthermore, diabetes mellitus, elevated liver enzymes, liver cirrhosis, hepatocellular carcinoma
and cardiac failure can be considered as signs of HH [5, 7, 8]. The latter three being the most
common cause of death in untreated HH patients [6, 7].
The first step in the diagnosis of HH consists of the recognition that these symptoms and signs in
Impact of the introduction of a guideline on the targeted detection of hereditary hemochromatosis
75
combination with persistent elevated serum transferrin saturations (TS) and elevated serum ferritin
(SF) concentrations may be attributed to HH, especially when these laboratory values remain
unexplained [4, 5, 9, 10]. The diagnosis HH is confirmed by the presence of homozygosity for the
C282Y mutation, by compound heterozygosity for the C282Y and H63D mutation in the HFE-gene
and by iron overload shown in a liver biopsy, on exclusion of secondary causes of iron tissue
accumulation such as ineffective erythropoiesis, haemolysis, concomitant liver pathology and
recurrent blood transfusions [2, 5, 10]. Treatment consists of extraction of the excessive amount of
iron from the body by phlebotomy [4, 5, 11]. When these phlebotomies are initiated before the
development of irreversible symptoms and damage, HH patients have a normal life expectancy [11,
12]. Therefore, it is crucial that patients with HH are detected early in the course of the disease by
measurement of their (elevated) serum iron parameters. However, these parameters are often not
evaluated, as HH patients frequently present at ages between 50 to 60 years, with non-specific
complaints, which are often ascribed to age related and common disorders [5, 13]. This non-specific
presentation of the disorder reduces recognition of the disease and leads to high medical
consumption and associated medical and non-medical costs [14, 15]. To enhance the awareness
among physicians of HH in patients with these non specific symptoms and to improve the quality and
effectiveness of the diagnostic pathway of HH, including the new HFE mutation analysis, a guideline
for case detection and treatment of HFE-related HH was developed in our university hospital in 1998
by a multidisciplinary hemochromatosis study group.
In the present study we aimed to evaluate retrospectively i) physicians’ compliance with the
diagnostic procedures, ii) the number of detected HH patients, iii) the correctness of the HH
diagnoses, and iv) costs per detected patient, during a 2-year period before and after introduction of
the clinical guideline.
METHODS
The multidisciplinary guideline was introduced in 1998 and contained recommendations to screen for
HH when a patient presented with signs or symptoms as described in FIGURE 1. The guideline was
developed in our university hospital by a multidisciplinary hemochromatosis study group. This group
consisted of physicians of the departments of general internal medicine, haematology, rheumatology,
clinical genetics, gastroenterology and clinical chemistry. International evidence based studies and
expert opinion were translated into a guideline suitable for the local situation [8, 11, 16-20]. The
guideline was introduced and explained during sessions held at the outpatient department of internal
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Hereditary Hemochromatosis suspected in the presence of
- Unexplained chronic fatigue for more than 6 months
- Elevation of liver enzymes without known cause
- Arthralgia of unknown origin existing longer than 6 month
- Poly-arthrosis before the age of 50
- Cardiac rhythm disorders without diagnosis
- Unexplained heart failure
- Porphyria cutanea tarda
- Unexplained impotence and infertility
- Diabetes mellitus with elevated liver enzymes
- Unexplained iron storage in liver biopsy
- First-degree family members diagnosed with HFE-related PH
Serum transferrin saturation > 50% and
serum ferritin concentration > 280 µg/l
at least on two occasions
Hereditary
Hemochromatosis1
Liver biopsy
when ALAT or ASAT
are at least twice the normal
value2
HFE-testing
C282Y and H63D mutation3
Hereditary Hemochromatosis
(confirmed)
Treatment with phlebotomies
withdrawal and maintenance phase4
Family screening
biochemical and genetic in first
degree family members5
medicine of our university medical hospital. After its introduction, the guideline was available on the
intranet of our hospital server.
FIGURE 1 Flowchart on the diagnosis of HH.
Legend; see next page.
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FIGURE 1 Flowchart guideline for targeted detection of hereditary hemochromatosis (HH) as introduced in 1998.
1 Provided that concomitant factors which influence the iron parameters, such as blood transfusions, iron
supplementation, haemolytic anaemia, non-HH related liver disease and acute or chronic infection, could be
excluded. Whenever doubt with respect to liver pathology, liver biopsy was recommended; 2 To exclude
concomitant liver pathology or to obtain a prognosis for the condition of the iron overloaded liver; 3 For
confirmation of the diagnosis HFE-related HH. C282Y homozygosity and C282Y/H63D compound
heterozygosity confirm the diagnosis HFE-related HH. HFE-testing was also advised when the patient had
first-degree relatives with known HFE related HH; 4 Two blood donations a year with control of the iron
parameters once in 3 years, was recommended for C282Y homozygous and C282Y/H63D compound
heterozygous first degree family relatives, of a HFE-related proband clinically expressing HH, who had not yet
developed iron overload; 5 Genetic HH screening was recommended only when the proband was diagnosed
with HFE-related HH; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.
According to the guideline, HH is diagnosed in these symptomatic patients, when the serum TS was
equal or above 50% on at least 2 different occasions (one of which after overnight fasting), in
combination with a SF concentration at least twice 280 µg/L or higher. For the diagnosis HH it was
recommended to exclude other factors that are known to influence the iron parameters, such as
blood transfusions, iron supplementation, haemolytic anaemia, (alcoholic) hepatitis, non-HH related
liver disease and acute or chronic infections. Thus, a correctly diagnosed HH patient was defined as
a patient with an elevation of both serum iron parameters in the absence of concomitant factors that
influence iron parameters.
After detection of the biochemical iron overload the guideline recommended to test for the C282Y
and H63D-mutation in the HFE-gene, to determine whether the patient had an HFE-related form of
HH (FIGURE 1). Genetic testing was also recommended for first-degree relatives of a symptomatic
HFE-related HH proband. Liver biopsy was advised when a persisted elevation of both iron
parameters was combined with a serum alanine aminotransferase (ALAT) or aspartate
aminotransferase (ASAT) concentration more than twice the normal value, to either exclude
concomitant liver pathology or to obtain a prognosis for the condition of the iron overloaded liver.
When either HFE-genotype (C282Y homozygosity and C282Y/H63D compound heterozygosity) or
liver biopsy confirmed the diagnosis of HH, family screening and treatment was recommended
(FIGURE 1). The latter consisted of phlebotomy therapy in 2 phases. The first phase of weekly
phlebotomies was meant to withdraw iron from the overloaded tissues, the second phase, of 2 to 8
phlebotomies a year, to maintain a low body iron level. For first-degree relatives that appeared to be
C282Y homozygous or C282Y/H63D compound heterozygous and had not yet developed iron
overload, a phlebotomy schedule consisting of 2 blood donations a year, similar to that used for
regular blood donors, was recommended.
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We retrospectively compared the diagnostic procedures for patients with features suggestive for HH
visiting the outpatient department of internal medicine, between a period before (January 1995 to
December 1996) and after (May 2000 to April 2002) introduction of the guideline. The choice of the
latter period allowed sufficient time for uptake of the novel procedures from the in 1998 introduced
guideline, whereas the first period was chosen before the discovery of the HFE-gene mutation [1].
PATIENTS
Patients were selected for evaluation by using discharge diagnose codes (classification system ICD-
9-CM-codes) [21]. Some patients had received more than one diagnosis code. Discharge codes
included were: “unexplained chronic fatigue for more than half a year”, “elevated liver enzymes or
liver cirrhosis without explanation”, “unexplained arthralgia”, “diabetes mellitus”, “hereditary
hemochromatosis” or “iron metabolism disorders” and “porphyria cutanea tarda”. Inclusion of diabetes
mellitus patients was restricted to patients with concomitant elevation of liver enzymes (more than
twice the upper limit of the reference value). Excluded were diabetes mellitus type 1 patients under
the age of 35, patients suffering from chronic viral hepatitis, chronic alcohol abuse at the time of the
study, cholestatic pathology and HH patients diagnosed with iron overload HH elsewhere. By means
of an inventory form the following data were extracted from the medical records: serum TS, SF
concentration, HFE-mutation analysis, liver biopsy, HH diagnosis and the presence of co-factors that
might result in falsely elevated iron parameters (such as blood transfusions, iron supplementation,
haemolytic anaemia, (alcoholic) hepatitis, acute or chronic infections, hepatic injury and end-stage
liver disease).
COMPLIANCE AND STATISTICS
Compliance of the physicians with the guideline was calculated by (number of guideline items
followed) / (items followed + items not followed) x 100%. These items consisted of serum TS, SF
concentration, HFE-gene testing and liver biopsy. For the period before guideline introduction the
same items, except the HFE-gene testing, were scored.
Differences in diagnosis codes, gender, age and compliance scored before and after guideline
introduction were tested for significance using a chi-square test.
COSTS
The impact of the guideline introduction on resource utilization was assessed, taking into account
direct medical costs only. The costs for diagnosing HH were approximated from laboratory costs
(serum TS, SF and HFE-mutation detection) and the costs for ultrasound guided liver biopsy, with
one-day hospital stay. For unit cost prices, national tariffs were used as proxies of actual resource
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utilization, except for hospitalization, for which a standard cost price was used [22]. Volumes of tests
used were derived from chart review. Costs per case of correctly diagnosed HH patients were
calculated and expressed in Euro.
RESULTS
PATIENT SELECTION AND CHARACTERISTICS
During the 2 observation periods, a total of 9096 individual patients visited the outpatient department
of internal medicine, providing us with 902 discharge diagnoses codes consistent with the possible
presence of HH representing 878 patients, 422 patients from the period before and 456 patients from
the period after guideline introduction (TABLE 1). In addition, 16 patients could not be included as
their medical records were missing; 4 from the period before and 12 from the period after guideline
introduction.
Three hundred fifty-two (40%) of the patients were male; 177 (41.9%) before and 175 (38.4%) after
guideline introduction (TABLE 2). Overall, 561 (63.8%) of the patients were 50 years of age or older
(TABLE 2).
DIAGNOSTIC ACCURACY
SERUM IRON PARAMETERS
In the period before guideline introduction, serum TS was measured in 29.7% (n=129) of all
diagnosis codes. After introduction of the guideline, this percentage rose to 36.8% (n=172, p<0.05)
(TABLE 3). The SF measurements were performed in 17.3% (n=75) of the patients before and in
71.8% (n=336, p<0.001) after introduction. This significant rise in SF measurements was observed
for patients from all diagnosis codes, except for those with “liver cirrhosis of unknown origin”.
There was a pronounced rise in SF measurements for the diagnosis codes of “chronic fatigue of
unknown origin” (from 10.9% (n=32) before to 74.7% (n=245, p<0.001) after), “diabetes mellitus with
elevated liver enzymes” (from 18.0 % (n=11) before to 44.9% (n=22, p<0.01) after) and “elevated
liver enzymes of unknown origin” (from 29.6% (n=8) before to 73.1% (n=38, p<0.01) after). The
hallmark test for the diagnosis HH, i.e. the combination of serum TS and SF measurement, also
increased by guideline introduction from 12.2% (n=53) in the period before, to 29.5% (n=138,
p<0.001) in the period after guideline introduction. This rise in combined measurement of serum TS
and SF concentration was significant for all diagnosis codes, except for the small groups of patients
diagnosed with “arthralgia of unknown origin” and “liver cirrhosis of unknown origin”.
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TABLE 1 Discharge diagnosis codes included in the study for both the periods before and after introduction of
the guideline
Diagnosis codes Number of diagnosis codes
Before introduction After introduction
n %1 n %1
Arthralgia, of unknown origin,
> 6 months 16 3.7 18 3.8 ns
2
Chronic fatigue, of unknown origin,
> 6 months 294 67.7 328 70.1 ns
2
Diabetes mellitus with elevated
liver enzymes3 61 14.1 49 10.5 ns
2
Hemochromatosis or disturbed iron
metabolism 6 1.4 13 2.8 ns
2
Liver enzyme elevation of unknown
origin4 27 6.2 52 11.1 p<0.05
2
Liver cirrhosis of unknown origin 26 6.0 8 1.7 p<0.0012
Porphyria Cutanea Tarda 4 0.9 0 0.0 n.d.
Medical records not available5 4 0.9 12 2.6 ns2
Total number of included diagnosis
codes 434 468
Total number of included patients6 422 456
ns, non significant; n.d., not determined, 1 100% = total of diagnosis codes included in that period;
2 Significance of difference in number of patients included between the periods before and after implementation
of the guideline; 3 All patients diagnosed with diabetes mellitus type 2 or diabetes mellitus type 1 after the age
of 35 years. Liver enzymes were elevated when they were more than twice the normal values; 4 Cholestatic
diseases, viral hepatitis and chronic alcohol abuse at time of diagnosis were excluded; 5 Diagnosis codes of
patients’ medical records that were not available: before introduction 3 codes “diabetes of unknown origin” and
1 code “chronic fatigue”, after introduction 12 codes “adult onset diabetes mellitus of unknown origin”; 6 One
patient could have more than 1 diagnosis code.
For all the discharge codes the absolute number of serum TS measurements was comparable to the
absolute number of SF measurements after guideline introduction. Only the “chronic fatigue of
unknown origin” defined group showed a striking difference between the 2 measurements; 87 serum
TS measurements versus 245 SF measurements in the period after guideline introduction.
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TABLE 2 Gender and age ( > 50 years) of the patients included
Before implementation After implementation Total
n % n % n %
Gender
All 422 48.13 456 51.93 878 100.03
Male 177 41.91 175 38.42 352 40.03 ns4
Female 245 58.11 281 61.62 526 60.03 ns4
Age > 50 years
All 268 63.51 293 64.12 561 63.83
Male 113 26.81 97 21.22 210 23.93 ns4
Female 155 36.71 196 42.92 351 39.93 ns4
n, number of patients; 1 100% = total included patients in the group before implementation (n=422); 2 100% =
total included patients in the group after implementation (n=456); 3 100% = total included patients of the two
periods together (n=878); 4 Significance of difference between the periods before and after implementation of
the guideline.
HFE-MUTATION ANALYSIS
HFE-gene mutation analyses were performed in 27 patients after protocol introduction (TABLE 4).
According to the guideline HFE-testing was recommended for only 11 (40.7%) of these 27 patients
(numbers 1-11); 9 of them had a combination of elevated serum TS and elevated SF concentration
and 2 of them were screened within the framework of family screening. In 6 of these 11 patients the
clinical diagnosis HH could be confirmed on follow-up, since both iron parameters remained elevated
and no other explanation that could account for these elevated levels was found (TABLE 4). One of
them had a non-HFE related form of HH, confirmed by the amount of iron withdrawn by phlebotomy
to obtain normal serum iron parameters (number 6). In 3 of these 11 patients the HH diagnoses
could not be confirmed (numbers 7-9); 1 patient’s liver biopsy contained no iron, 1 patient’s serum TS
returned to normal levels when measured on a second occasion and 1 patient had normal TS levels,
that alternated with high TS levels upon blood transfusion. The physicians were correct, not
diagnosing HH in these 3 patients. The 2 patients, who were HFE-gene tested in the context of
family screening (numbers 10 and 11), were falsely diagnosed as to be iron overloaded and treated
as HH patients. The guideline recommended follow up of these patients and phlebotomize them only
twice a year. The remaining 16 (of the 27) HFE-tested patients should not have been tested following
the guideline, since only 1 of the 2 serum iron parameters was elevated. Moreover, 5 of these 16
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patients (numbers 12-16) were incorrectly diagnosed with HH by the physicians, for some of them
most likely based on their HFE-gene genotype only.
Three patients in the period after guideline introduction were not tested for the HFE-gene mutations
despite their combination of elevated serum iron parameters. In 2 of these 3 patients serum iron
parameters appeared to be temporarily influenced by blood transfusions. The remaining patient
underwent a liver biopsy to exclude liver pathology. This liver biopsy revealed no iron.
TABLE 3 Diagnostic test use for serum iron parameters before and after guideline introduction
Serum iron parameters Diagnosis codes
Before implementation After implementation
n % n %
Serum TS 129 29.7 172 36.8 p<0.051
SF 75 17.3 336 71.8 p<0.0011
Combination of TS and SF
concentration 53 12.2 138 29.5 p<0.001
1
Diagnostic test use is expressed as the percentage of the total number of diagnosis codes included in that
period. Data are obtained from the medical records. Both the serum TS and the SF concentration were scored
no more than once per diagnosis code.
TS, transferrin saturation; SF, serum ferritin; 1 Significance of difference in increase in serum iron parameter(s)
between the periods before and after implementation of the guideline.
LIVER BIOPSY
Liver biopsies were taken for 60 diagnosis codes, representing 53 patients, 26 (49.1%) before and 27
(50.9%) after guideline introduction. In 49 of these 53 patients, the decision to perform a liver biopsy
was based on a suspicion of concomitant liver disease. In 4 of these 53 patients, liver biopsy was
performed in the absence of elevated liver enzymes or (probable) liver disease. Three of these latter
4 patients underwent liver biopsy before guideline introduction and the availability of the HFE-gene
test. All 3 patients had elevated serum TS (>50%) and SF levels (>280 µg/l). The presence of an
increased amount of iron in their liver biopsy (diagnosed by an independent pathologist) confirmed
the diagnosis HH. The remaining fourth patient underwent his biopsy after guideline introduction in
the presence of an elevated serum TS and in absence of an increased SF level. The liver biopsy
revealed no increased amount of iron and HH was correctly excluded.
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TABLE 4 Characteristics of patients of whom HFE-gene analysis was performed or who were diagnosed with hereditary
hemochromatosis according to the physicians or the guideline
serum iron parameters HFE genemutations
HH diagnosis
according topatient evaluationperiod1 TS
 50%2
SF  280
µg/L2 C282Y H63D
liver biopsy
phys3 guid3
1 after + + het het n.d. + +
2-5 after + + hom neg n.d. + +
6 after + + neg neg n.d. + +4
7 after + + het neg n.d. - -5
8 after + + neg neg
micro nodular
cirrhosis, Perls
negative
- -
9 after + + neg het n.d. - -5
10-11 after + - hom neg n.d. + -6
12 after + - hom neg Perls negative + -
13 after - + het neg n.d. + -
14 after - - het neg n.d. + -
15 after - + neg hom n.d. + -
16 after - + neg neg n.d. + -
17-18 after - + neg het steatosis, Perlsnegative - -
19 after - + neg neg steatohepatitis,Perls negative - -
20 after + - neg het Perls negative - -
21 after - + neg n.d. n.d. - -
22-23 after - + neg neg n.d. - -
24 after - - het het n.d. - -
25 after - - neg het n.d. - -
26 after - + neg neg n.d. - -
27 after - - neg neg n.d. - -
28-29 before + + n.a n.a n.d. + +7
30 before + + n.a n.a
Perls positive,
hepatocellular
carcinoma
+ +7
31 before + + n.a n.a Perls positive + +7
32 before + + n.a n.a Perls positive,cirrhosis + +
7
33 before n.a n.a n.a n.a
Autopsy liver:
Perls positive,
cirrhosis
- +
Legend; see next page.
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TABLE 4 Characteristics of patients of whom HFE-gene analysis was performed or who were diagnosed with hereditary
hemochromatosis according to the physicians or the guideline
TS, transferrin saturation; SF, serum ferritin; phys, Hereditary Hemochromatosis (HH) diagnoses according to
the physician: diagnoses of iron overload based on clinical grounds and treatment started for HH; guid, HH
diagnoses according to the guideline: HH diagnoses that should have been given according to the guideline;
het, heterozygous; hom, homozygous; neg, negative; n.d., not determined; n.a., not available; Perls, Perls’
staining, Prussian blue reaction used to detect iron in a liver biopsy;; 1 before, period before guideline
implementation; after, period after guideline implementation; 2 - transferrin saturation < 50% or serum ferritin <
280 µg/L; + transferrin saturation  50% or serum ferritin  280 µg/L; 3 phys., physician; guid, guideline; - no
HH diagnosed, + HH diagnosed; 4 non-HFE related HH; 5 serum transferrin saturation that normalized when
measured at a second occasion; 6 patient was a first-degree relative of an HFE-gene related HH patient; 7 HH
diagnoses confirmed with either liver biopsy or number of phlebotomies.
NUMBER OF DETECTED PATIENTS
The introduction of the guideline led to an increase in diagnoses of HH, from 5 patients (1.2%) before
to 13 patients (2.9%) after introduction of the guideline (TABLE 4). This increase, however, was not
statistically significant. Phlebotomy treatment was started for all 18 patients.
The physicians’ diagnoses of iron overload appeared to be incorrect for 7 of the 13 patients, as at
least 1 of the serum iron parameters was not elevated (patients 10-16, TABLE 4). Three of these
patients were at risk of developing iron overload based on their C282Y homozygosity, though had not
yet developed iron overload as their SF levels were normal (patients 10-12). All 3 were female and
aged 41, 45 and 55 years, respectively. There was no over-diagnosis of HH before guideline
introduction.
In total, we found 1 case of a missed HH diagnosis (patient 33, TABLE 4). This patient, included in the
group before guideline introduction, was only diagnosed post mortem with HH by autopsy. During life,
the patient was diagnosed with liver cirrhosis of unknown origin. No iron parameters had been
measured.
For 9 patients with a combination of an elevated serum TS and SF, HH was not diagnosed. Three of
these patients were included in the period before and 6 patients were included in the period after
guideline introduction. One patient from the first period was diagnosed with porphyria cutanea tarda
and transferred to another hospital before further diagnosis and treatment could take place. For all
the remaining 8 patients the diagnosis HH was correctly excluded either based on clinical evidence
(blood transfusions recently given or spontaneous normalization of iron parameters), or by a liver
biopsy containing no increased amount of iron.
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COSTS
The total cost associated with the detection of new HH patients before introduction of the guidelines
amounted to 11,900 Euro. After the introduction, these costs rose to 15,600 Euro. When these costs
were ascribed to patients correctly diagnosed with iron overload proven HH this resulted in 2,380
Euro per correctly diagnosed patient before and 2,600 Euro per correctly diagnosed patient after
introduction of the guideline.
DISCUSSION
The introduction of the guideline for targeted HFE-related HH detection in the outpatient department
of general internal medicine of our university hospital in 1998, led to an increased number of patients
with complaints consistent with HH, that were tested for serum iron parameters (serum TS and SF).
The number of HH diagnoses rose when compared to a period before guideline introduction. This
rise, however, was not statistically significant. Shortcoming of the introduction of the guideline was
the increase in the number of patients falsely diagnosed with HH.
The increase in both, serum TS and SF measurements, in the period after introduction of the
guideline, was likely to result from the guideline introduction. This increase might have been
positively influenced by more recently (after 1998) introduced guidelines at the department of internal
medicine i.e. on “arthralgia” and on “liver cirrhosis” that incorporated the recommendations of the HH
guideline of 1998. It should, however, be noted that despite these increased numbers of iron
parameters measured after guideline introduction, still approximately 70% of the patients with
complaints and signs consistent with HH were not tested for these parameters.
There was a remarkable difference in magnitude of the raise in serum TS and that in SF
measurements in the diagnosis code group “chronic fatigue of unknown origin” after guideline
introduction. This could be explained by the implementation of a guideline on “chronic fatigue”, at the
outpatient department in 1999, which recommended only the measurement of SF, not combined with
serum TS, to detect HH among patients with complaints suggestive for chronic fatigue.
Guideline compliance was also evaluated by the use of liver biopsies in the diagnosis of HH.
According to the guideline liver biopsies should be used to exclude additional liver pathology or to
obtain a prognosis for the condition of the iron overloaded liver. Before the discovery of the HFE-
gene, liver biopsy was the gold standard for the confirmation of the diagnosis of hereditary iron
overload. The compliance for the use of liver biopsies after the introduction of the guideline was
good. Only 1 patient underwent a liver biopsy without elevation of both serum iron parameters or a
possible liver disease.
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The current study did not provide solid information on compliance with family screening for HH.
However, the few notations made on this subject in the medical files suggested that physicians
recommended the proband to inform his or her family on the necessity of clinical, biochemical and/or
genetic screening for HH.
Medical costs due to diagnostic procedures for each accurately diagnosed patient were similar before
and after guideline introduction. However, these costs do not include costs due to incorrect
diagnoses: i.e. patients with HH missed or patients that are incorrectly diagnosed as having HH, nor
does it include costs for treatment.
Compliance with the therapeutic aspects of the guideline was not thoroughly evaluated in the present
study. However, it appeared that 3 homozygous C282Y patients of the 13 subjects diagnosed with
HH were phlebotomized despite the absence of iron overload. For non-iron overloaded homozygous
C282Y relatives of HH patients as well as for C282Y/H63D compound heterozygous relatives, the
guideline recommended the guideline recommended to perform preventive 2 blood donations twice a
year. However, treatment of these non-iron overloaded patients is controversial and various treatment
protocols have been proposed. Shortly after the discovery of the HFE-gene, therapeutic protocols for
these patients, such as the protocol described here, were based on the assumption of a high
penetrance of the HFE-gene mutation and advised: i) to perform phlebotomies several times a year
to prevent iron accumulation, in order to maintain the SF level around 50 µg/l [5] and ii) 2 yearly
blood donation, with control of the iron parameters once in 3 years (present guideline) [23]. Since
evidence is accumulating that the phenotypic penetrance of homozygosity for the C282Y mutation is
low, it is currently advised to only start treatment when iron overload is proven and control for clinical
and biochemical manifestations of HH every 10-20 years [24].
A drawback of the guideline introduction was the incorrect diagnoses of iron overload for several
patients after guideline introduction (n=7). This was mainly due to erroneous use and interpretation of
the HFE-genotype (n=6). It appeared that HFE-testing was more often used than strictly indicated
and that once the HFE-gene was genotyped, it dominated the results of the serum iron parameters
and the liver biopsy. This dominant use and overestimation of the value of the HFE-genotype in the
diagnostic process of HH might be attributed to misinterpretation of the huge amount of international
literature since 1996 that suggested the clinical relevance of the C282Y-mutation due to the high
clinical penetrance [3, 25-28]. Only recently, evidence accumulated that this penetrance of the
homozygosity for the HFE-gene C282Y-mutation might be very low [9, 29-32]. But also, the fact that
the diagnostic strategy of the present guideline lacks solid scientific evidence on its most crucial
points (similar to the strategies throughout literature) [4, 10, 11, 33, 34] and is mainly based on
professional expertise, might have decreased the compliance.
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While awaiting for the calculation of the cost-effectivity of both population and cascade screening,
most HH patients in the Netherlands are still detected by case detection, i.e. early detection of
patients with HH that seek medical attention for symptoms suggestive for HH. According to a recent
report of Cadet et al this strategy of targeted HH detection has been proven to be cost-effective [35].
Also the present study shows the potential cost-effectivity of targeted case detection in comparison to
population screening as approximately 1 in 80 patients (1:84 (5 in 422) patients before, to 1:76 (6 in
457) patients after guideline introduction) have biochemical proven iron overload in comparison to 1
in 280 to 1 in 400 patients in the general population of northern European origin [36, 37]. A
disadvantage of this targeted approach however, is the potential diagnostic delay in the course of the
disease.
There were some limitations inherent to the study. First of all it was a retrospective study. This
implicated that we had to interpret the thoughts of the physicians on the differential diagnosis of their
patients’ complaints by looking at the diagnostic investigations performed on each patient. E.g. we
cannot be sure that every SF or serum TS was performed in the light of HH diagnostics. Even more,
elevated iron levels might have been missed and with this also potential patients with HH, with a risk
for organ damage and early death [2, 26, 26]. It is not possible to give solid numbers for these
patients not recognized to have HH for the current study. As 87.8% (n=381) of the diagnosis codes
eligible for HH before and 70.5% (n=330) of these diagnosis codes after guideline introduction, were
not evaluated for serum iron parameters, there could have been a fair number of missed HH
diagnoses. However, for all those patients that were tested for both their serum iron parameters, we
conclude that no eligible HH patients were incorrectly judged as being healthy. This also implicates
that when HH was not diagnosed, despite the elevation of both serum iron parameters, this was done
on correct clinical grounds, taking into account concomitant treatment or diseases, as the guideline
recommended. Second limitation was the lack of control group. Therefore we cannot exclude that the
rise in diagnostic procedures be explained by the increase of the number of physicians that adhered
to a more ‘defensive’ kind of medicine by adding test and/or the general trend in time of an increased
use of iron parameters (i.e. SF) in the last decade.
We conclude that due to a relatively low compliance to the guidelines: i) approximately 70% of the
patients with complaints and signs consistent for HH were not tested for serum iron parameters and
consequently patients with HH might have been missed and on the other hand ii) indication and
interpretation of the genetic and iron parameters were misunderstood with as a result overdiagnosis
of HH. The reason why physicians do not follow clinical practice guidelines are described by several
groups [38-40]. One of them, Cabana et al, clearly reviewed and summarized the literature on this
subject in 1999. This resulted in the recognition of a variety of barriers to guideline adherence, that
include: i) knowledge (awareness, familiarity), ii) attitude: (agreement, self-efficacy, outcome
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expectancy, ability to overcome the inertia of previous practice) and iii) external barriers to perform
recommendations. We believe that in general these barriers all attributed partly to the less optimal
compliance of the “hemochromatosis” guideline. We expect the most critical points of misuse and
interpretation of iron parameters and genetic tests, observed in the present study, can be removed by
a more professional evidence based development and dissemination of the guideline, that is
combined by an appropriate education strategy on its most decisive aspects. In fact this approach is
adopted by a multidisciplinary team of medical professionals in the Netherlands, that recently started
with the development of an evidence based guideline under auspices of the Medical Scientific Board
of the Dutch Institute for Healthcare CBO, in close cooperation with the Order of Medical Specialists.
These guidelines will be evidence based and formulated along strict rules (www.cbo.nl). Among all,
attention will also be paid to applicability in daily routine and the implementation strategy. Also, this
team may learn from the shortcomings from the present study. It is expected that implementation of
this guideline around early 2007 in medical practice throughout the Netherlands, will increase the
compliance of the guideline, also on the decisive points.
We summarize that introduction of a guideline for targeted approach for HH screening increased the
amount of diagnostic procedures appropriate for HH investigation. The number of detected HH
patients increased non-significantly, at comparable costs per case detected, with a drawback of
falsely positive HH diagnoses. The HH over-diagnoses reflected the difficulties in indication and
interpretation of both serum iron parameters and HFE-genotypes. Therefore, the implementation
strategy of the guideline should be improved to increase the awareness and to guarantee the
compliance with the indication and interpretation of both the iron and genetic parameters.
This work was supported by grant No. 00231 of the Health Insurance Council of the Netherlands.
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ABSTRACT
Recent studies have suggested family screening as a sophisticated model for the early detection of
HFE-related hereditary hemochromatosis (HH). However, until now, reports on the empirical
demonstration of the relevance of an iron accumulation related health problem in families with this form
of HH are lacking. We therefore compared the morbidity and mortality of first-degree family members of
probands with clinically diagnosed HH with that of the general population.
Between May 2003 and August 2005, data on iron parameters, morbidity and mortality were collected
from 224 Dutch C282Y-homozygous probands with clinically overt HH and from 735 of their first-degree
family members, all participating in the HEmochromatosis FAmily Study (HEFAS). These data were
compared with results obtained from an age- and gender-matched normal population, collected by
means of a population-based survey conducted in the Netherlands, the Nijmegen Biomedical Study
(NBS). HEFAS and NBS participants filled out similar questionnaires on demographics, lifestyle factors,
health, morbidity and mortality.
A significantly higher proportion of the HEFAS first-degree family members reported to be diagnosed
with hemochromatosis related diseases, e.g. 45.7% vs. 19.4% of the matched normal population
(McNemar test, p<0.001). Mortality among siblings, children and parents in the HEFAS population was
similar to that in the relatives of the matched controls.
This is the first study to demonstrate that morbidity among first-degree family members of C282Y-
homozygous probands previously diagnosed with clinically proven HH is significantly higher than that in
an age- and gender-matched normal population. This justifies further studies on the value of a family-
screening program.
INTRODUCTION
HFE-related hereditary iron overload is characterized by iron deposition in parenchymal organs [1, 2].
Early detection and phlebotomy prevent tissue damage and result in long-term survival similar to that
seen in the general population [2-6]. Of northern European patients diagnosed with hereditary
hemochromatosis (HH), 80% appear to be homozygous for the C282Y mutation in the HFE gene. The
carrier frequency of this C282Y mutation in the general Caucasian population is estimated to be as high
as 1 in every 10 persons [7]. Altogether, this would favour population screening to prevent disease-
related morbidity. Recently, however, it was shown that not all C282Y-homozygous individuals develop
symptoms of iron overload disease, questioning the penetrance of the HFE-gene mutations [8-11].
Therefore, family screening has been suggested, since this has proven efficacy in the detection of latent
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homozygotes for frequent recessive mutations [12]. Until now, however, one important item in the World
Health Organization (WHO) guidelines for screening for disease, published in 1968, has remained
unanswered for the HH related family screening: Is HH in these families an important health problem?
[13]. To date, to our knowledge there is no such a study that has extensively compared the morbidity
and mortality in HFE-related HH families, with the morbidity and family-related mortality of a general,
apparently healthy, population, whereas these outcomes are required to legitimate further research on
the implementation of family screening.
Therefore, the objective of the present study is to compare self-reported morbidity among first-degree
family members (FDFM) of C282Y-homozygous probands previously diagnosed with clinically manifest
HH, with data obtained from age- and gender-matched controls from a normal population. Furthermore,
the mortality rates among FDFM in these HH families, as reported by the HEFAS probands, are
compared with the mortality among the FDFM of age- and gender-matched participants from the normal
population. Notably, the study is observational and not designed to explain similarities and/or differences
in outcomes of the morbidity and mortality rate for the 2 populations.
Data for the HH families were obtained from the HEmochromatosis FAmily Study (HEFAS), which was
designed to collect clinical, biochemical, genetic and mortality data from Dutch C282Y-homozygous
probands as well as from their first-degree relatives. All probands in the HEFAS had been previously
diagnosed with symptomatic HFE-related HH. The controls were recruited from the Nijmegen Biomedical
Study (NBS), a population-based survey conducted among 22,400 inhabitants of the Dutch city of
Nijmegen in 2002-2003 [14].
STUDY POPULATION AND METHODS
HEFAS POPULATION
For this study, 280 probands diagnosed with symptomatic HFE-related HH from 5 different medical
centres in the Netherlands were actively approached (FIGURE 1). The local medical ethics committees of
each of these centres approved the study protocol before the start of the study. A total of 224 probands
participated. They provided the HEFAS group with names and addresses of 972 first-degree relatives
(defined in this study as biological parents, full siblings, and biological children), 18 years of age and
older, of whom 735 met the inclusion criteria. Participants were included from May 2003 until August
2005.
INCLUSION
Only subjects who gave written informed consent were included in the study. Probands had to be at
least 18 years old and to have been clinically diagnosed with C282Y-homozygous HH. The iron
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overload had to be confirmed by initial serum ferritin (SF) and transferrin saturation (TS) values
exceeding the thresholds of SF  280 µg/L for men, SF > 80 µg/L for women under the age of 50, SF 
180 µg/L for women  50 years and TS > 50% for both men and women. When either one or both pre-
treatment plasma iron parameters were unavailable, the presence of iron overload was alternatively
confirmed by previously performed liver biopsy (grade 3 iron deposition according to Sindram) or by the
number of phlebotomies required to normalize SF (males  22 phlebotomies = 5 g chelatable iron;
females  13 phlebotomies = 3 g chelatable iron) [1, 15].
FIGURE 1 Flowchart of the invited and participating probands, the accompanying family members and their available
data. Probands were classified as ‘defined proband’ when symptoms consistent with hereditary
hemochromatosis, C282Y homozygosity and iron overload were present, confirmed by either the plasma iron
parameters, iron levels in a liver biopsy or the number of phlebotomies. Laboratory data: iron parameters
(transferrin saturation, serum ferritin) and HFE genotyping.
* Participating hospitals: Atrium Medical Centre, Heerlen/Brunssum, Radboud University Nijmegen Medical
Centre, Rijnstate Hospital Arnhem, University Medical Centre Groningen, and University Medical Centre
Utrecht.
QUESTIONNAIRES
All participants were asked to fill out a questionnaire containing a large number of questions on
demographics, lifestyle (smoking, use of alcohol, diet), health status, general medical history,
Invited probands
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Defined proband
Informed consent
Questionnaire returned
Participating
probands
n=224
Aged >= 18 yr
Invited first-
degree family
members
n=972
Aged >=18 yr
Participating
first-degree family
members
n=735
Informed consent
Questionnaire returned
Questionnaires (100%)
Laboratory data (100%)
Questionaires (100%)
Laboratory data (98%)
Participating hospitals*
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morbidity, medical history for HH, implementation of family screening, legal, psychological and
societal implications, and family structure including familial mortality.
LABORATORY DATA
Data on the included probands and family members were extracted from the medical records of the
participating hospitals. Information on iron parameters (TS and SF) and liver biopsy of the participants
was obtained only at the time of diagnosis of HH or the time of screening for HH, whereas data on the
HFE-genotype and especially on the number of phlebotomies were also collected at points in time after
the initial investigations. When incomplete, the physician involved in the diagnosis and treatment of the
participants was asked to provide the HEFAS team with these data. Finally, when the data remained
deficient or the subjects declared that they had never been tested for HH, participants were offered
counselling and blood testing by their general practitioner (GP).
Iron parameters for HEFAS were collected by several clinical laboratories. The TS and SF were
quantified using validated, standardized, routine laboratory methods. HFE-genetic test results were
obtained from routinely used genetic tests. The amount of iron in the liver biopsies was assessed semi-
quantitatively [15].
THE NIJMEGEN BIOMEDICAL STUDY (NBS)
The Nijmegen Biomedical Study (NBS) is a population-based survey conducted among inhabitants of
the city of Nijmegen in 2002-2003 [16]. Nijmegen is a town in the eastern part of the Netherlands
with 156,000 inhabitants, approximately 87% of Caucasian descent. The aim was to obtain a
representative sample of the normal population in the Netherlands that could be used as a universal
control population for a wide range of medical studies. Randomly selected, age- and gender-stratified
inhabitants of Nijmegen (n=22,452) were taken from the population registry and received an invitation
to fill out a postal questionnaire on lifestyle and medical and family history that was comparable to
the HEFAS questionnaire. Approval to conduct the NBS was obtained from the Institutional Review
Board of the Radboud University Nijmegen Medical Centre. The response to the questionnaire was
41.7% (n=9371). In addition, 69.1% of these responders donated 30 ml of blood each for DNA
isolation, serum and plasma (n=6473). Analysis of the plasma iron parameters was performed in the
Departments of Clinical Chemistry and Chemical Endocrinology of the RUNMC.
STATISTICAL METHODS
In order to compare the demographics, lifestyle, blood loss, Body Mass Index (BMI), general health,
medication and morbidity of the participants in the HEFAS to that of the general population, a one-to-
one age- and gender-matched sample was randomly drawn from the 9371 participants in the NBS. In
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both studies, the general mental health, physical functioning and vitality were measured according to
the SF-36 questionnaire [17] and fatigue was scored according to the shortened fatigue questionnaire
[18]. Each of these scores was rescaled from 0 to 100 and values below 65 were considered to
reflect diminished general mental health, diminished physical functioning, diminished vitality and
increased fatigue, respectively [17]. These cut-off points were used for further evaluation.
The number of hemochromatosis related medication use was calculated by counting for each person
the use of (1) analgesics, (2) anti-rheumatic drugs and of (3) cardiovascular medication (i.e. use of at
least one of the following: anti-hypertensive drugs, cardiovascular drugs and diuretics), resulting in a
score that ranged from 0 to 3. Similarly, the number of hemochromatosis related diseases was
calculated by counting for each person the presence of (1) diabetes mellitus, (2) liver disease, (3)
rheumatism, (4) fatigue (score  18) and (5) cardiovascular disease, resulting in a score that ranged
from 0 to 5. Hemochromatosis related medication use (yes, no) and hemochromatosis related
morbidity (yes, no), were used for further evaluation.
Comparison of iron parameters between HEFAS and NBS might be difficult, because of the large
between-centre variations, especially in the SF. We circumvented this potential setback and
compared HEFAS and NBS with regard to i) the percentage of elevated iron parameters using local
reference values for each of the participating laboratories, and ii) the absolute values of iron
parameters using data obtained in only one single laboratory, that of the RUNMC (ca. 25%). The
rationale for the choice of this laboratory is that the sera of all participants of the NBS were analyzed
at this location. Prior to the analysis, both the actual iron parameters and the BMI were transformed
logarithmically to improve skewness. Differences in the means of the logarithmically transformed data
between the HEFAS and the age- and gender-matched sample from the NBS were tested for
statistical significance using the t-test for paired data. The back-transformed mean differences with
the 95% confidence intervals are presented. These results demonstrate a relative increase in the
median of the HEFAS compared to the median of the NBS.
Differences in single proportions between the HEFAS probands and the age- and gender-matched
sample from the NBS were tested for statistical significance using McNemar's test. The percentage
differences between the HEFAS and the NBS-sample were calculated together with the 95%
confidence intervals (95% CI) that take into account the matched pair design. Because p-values and
the corresponding confidence intervals are then univocally related (i.e., whether or not zero falls
within the confidence interval), presentation of both is redundant; therefore, only the differences with
the corresponding confidence intervals are presented here. As this study enhances a descriptive
study, no corrections for multiple comparisons have been performed.
The mortality within HEFAS families, as reported by the probands, was compared with the mortality
in the families of the matched NBS participants. Differences in mortality between the HEFAS and the
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matched NBS sample were tested for statistical significance using Fisher's exact test, separately
among parents, siblings and children.
A two-tailed p-value  0.05 was considered statistically significant. Analyses were performed using
SAS version 8.2.
RESULTS
STUDY POPULATION
Of the 280 probands, 224 (80.0%) filled out the questionnaires and the informed consent forms
(FIGURE 1). These 224 probands provided names and addresses of 972 FDFM,  18 years of age, of
whom 735 (75.6%) were included. FIGURE 1 shows that 100% of the included probands gave
permission for analysis of their laboratory results, whereas 17 (2%) family members did not approve
retrieval of laboratory data from their records or agree to additional withdrawal of blood for laboratory
tests if data were missing.
TABLE 1 shows the size and structure of the families of the included HEFAS probands. Twenty-four
(10.7%) of the 224 probands that entered the study had more than 5 participating siblings, whereas
78 (34.8%) had no participating siblings. Four probands had more than 5 children included in the
study, whereas 105 probands had no participating children. In total, this study involved 224 probands,
428 siblings, 241 children and 66 parents.
DEMOGRAPHICS
TABLE 2 shows the results of the self-reported demographics and lifestyle characteristics of the FDFM
and the matched NBS participants. The median age at participation was 48 years (range: 18-97
years), and 56.7% of the participants were women. Because of the matched design these values are
identical in both studies. In the HEFAS population, the percentage of FDFM with single households
(with or without children) was 18.8%, which was significantly lower than the percentage with single
households in the matched sample of the NBS population, which was 31.3%. The difference in the
percentage of single households between the HEFAS and NBS populations (HEFAS% minus NBS%)
was therefore -12.3%, with a 95%CI of -16.4% to -8.3% (TABLE 2). Furthermore, the number of
participants with at least secondary education was significantly lower in the FDFM of the HEFAS
population compared to the matched NBS participants (HEFAS% minus NBS%: -9.9%, 95%CI, -
14.5% to -5.3%), while the percentage of participants with paid jobs was similar for both populations
(HEFAS%-NBS%: 2.8%, 95%CI, -4.8% to 10.3%). The HEFAS FDFM reported a significantly lower
alcohol intake compared to the NBS controls (> 2 units alcohol/day, HEFAS%-NBS%: -8.3%, 95%CI,
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-13.2% to -3.4%). Yet, the smoking behaviour of both groups was similar (ever smokers, HEFAS%-
NBS%: 0.8%, 95%CI, -0.4% to 5.7%). The number of participants that donated blood voluntarily was
similar in both populations (TABLE 2).
TABLE 1 Size and structure of the families of the HEFAS probands
Siblings
0 1 2 3 4  5 Total
0 45 17 15 9 10 9 105
1 13 9 6 7 3 6 44
2 13 7 7 8 4 7 46
3 6 3 0 5 3 2 19
4 1 1 1 2 1 0 6
Children
 5 0 1 1 0 2 0 4
Total 78 38 30 31 23 24 224
Both parents 5 3 3 1 3 3 18
Father or mother 3 4 9 6 2 6 30
No parent 70 31 18 24 18 15 176
GENERAL HEALTH, MEDICATION, MORBIDITY AND IRON PARAMETERS
TABLE 3 summarizes the general health, medication, morbidity and iron parameters of the FDFM in
the HEFAS population and the age- and gender-matched NBS participants. The median BMI of the
HEFAS FDFM was slightly but significantly higher than that of the population-based controls of the
NBS (HEFAS%-NBS%: 1.7%, 95%CI, 0.1%-2.4%). The HEFAS FDFM had significantly less hours of
exercise during the week, and a significantly higher score on physical functioning and vitality,
indicating a lower level of physical functioning and vitality [17]. Significantly more FDFM of the
HEFAS population used antihypertensive drugs (HEFAS%-NBS%: 8.8%, 95%CI, 4.9%-12.6%),
antirheumatic drugs (HEFAS%-NBS%: 5.9%, 95%CI, 2.9%-9.0%), cardiovascular drugs (HEFAS%-
NBS%: 4.4%, 95% CI, 1.2%-7.5%), diuretics (HEFAS%-NBS%: 3.2%, 95%CI, 0.1%-6.2%) and lipid-
lowering drugs (HEFAS%-NBS%: 3.0%, 95%CI, 0.1%-5.8%) compared to the NBS controls. Iron
supplements were less frequently used by the HEFAS FDFM, than by the matched NBS participants
(HEFAS%-NBS%: -9.0%, 95%CI, -12.7% to -5.2%).
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TABLE 2 Characteristics of the first-degree family members of the HEFAS probands and of the age- and gender-
matched NBS participants
HEFAS NBS HEFAS - NBS
total median (range) /n (%) total
median (range) /
n (%) total*
difference†
(95% CI)
Demographics
age at participation (yr) 735 48 (18 - 97) 735 48 (18 - 97) 735 n.a.
men 735 318 (43.3%) 735 318 (43.3%) 735 n.a.
education ( secondary) 689 198 (28.7%) 732 285 (38.9%) 686 -9.9% (-14.5% ; -5.3%)
household (single with
or without children) 723 136 (18.8%) 734 230 (31.3%) 722 -12.3% (-16.4% ; -8.3%)
paid job ( 32 hrs/week) 342 185 (54.1%) 458 208 (45.4%) 290 2.8% (-4.8% ; 10.3%)
Lifestyle
alcohol (> 2 units/day) 628 163 (26.0%) 702 234 (33.3%) 602 -8.3% (-13.2% ; -3.4%)
smoking (ever) 727 463 (63.7%) 733 460 (62.8%) 725 0.8% (-0.4% ; 5.7%)
Blood loss
blood donation (never) 705 560 (79.4%) 727 544 (74.8%) 698 4.3% (0.0% ; 8.7%)
Women
menarche ( 12 year) 403 128 (31.8%) 404 127 (31.4%) 391 -0.7% (-7.4% ; 5.9 %)
pregnancies ( > 3) 417 79 (18.9%) 417 51 (12.2%) 417 -6.7% (2.0% ; 11.5%)
CI, confidence interval, using the matched pair design; n.a., not applicable, because the first-degree family
members of the HEFAS and the NBS participants are matched one-to-one by age and gender; * number of
matched pairs with valid data; † the increase from HEFAS to NBS, using the matched pair design.
Cardiovascular disease, fatigue, hypercholesterolemia and hypertension were reported significantly
more frequently by the FDFM of the HEFAS population than by the participants in the control
population. Liver disease (HEFAS%-NBS%: 3.2%, 95%CI, 1.0%-5.4%), osteoporosis (HEFAS%-
NBS%: 4.2%, 95%CI, 1.8%-6.6%) and rheumatism (HEFAS%-NBS%: 24.6%, 95%CI, 20.6%-28.6%)
were also diagnosed significantly more frequently among the FDFM of the HEFAS population. In
contrast, diabetes mellitus, infertility and thyroid disease were diagnosed with similar frequencies in
both populations (TABLE 3).
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TABLE 3 General health, medication, morbidity and iron parameters in the first-degree family members of the HEFAS
probands and of the age- and gender-matched NBS participants
HEFAS NBS HEFAS - NBS
total median (range) /n (%) total
median (range) /
n (%) total*
difference†
(95% CI )
Body Mass Index (kg/m2) 717 24.9 (15.2 – 60.6) 718 24.4 (16.9 – 62.4) 701 1.7% (0.1% ; 2.4%)
General health
exercise ( 1 hr/week) 415 109 (26.3%) 412 151 (36.7%) 250 -4.4% (-12.0% ; -3.2%)
health (> 2)‡ 722 204 (28.3%) 733 162 (22.1%) 720 6.5% (2.2% ; 10.9%)
general mental health last
4 weeks ( 23)§ 684 339 (49.6%) 697 461 (51.8%) 650 -1.7% (-7.1% ; 3.7%)
physical functioning at
this moment ( 23) || 656 108 (16.5%) 686 72 (11.5%) 617 6.0% (2.5% ; 9.5%)
vitality last 4 weeks
( 17)¶ 680 376 (55.3%) 701 325 (46.4%) 649 9.1% (3.7% ; 14.4%)
Medication used (yes)
analgesics 627 321 (51.2%) 691 285 (41.2%) 593 9.8% (4.1% ; 15.4%)
antihypertensive drugs 654 146 (22.3%) 690 94 (13.6%) 617 8.8% (4.9% ; 12.6%)
antirheumatic drugs 601 63 (10.5%) 673 35 (5.2%) 556 5.9% (2.9% ; 9.0%)
cardiovascular drugs 614 70 (11.4%) 681 50 (7.3%) 574 4.4% (1.2% ; 7.5%)
diuretics 606 73 (12.0%) 683 61 (8.9%) 572 3.2% (0.1% ; 6.2%)
folic acid 583 67 (11.5%) 655 61 (9.3%) 531 2.4% (-1.0% ; 5.8%)
lipid-lowering drugs 614 57 (9.3%) 682 48 (7.0%) 576 3.0% (0.1% ; 5.8%)
iron supplements 718 87 (12.1%) 674 141 (20.9%) 659 -9.0% (-12.7% ; -5.2%)
tranquillizers 618 148 (24.0%) 696 150 (21.6%) 590 3.0% (-1.5% ; 7.6%)
(multi-)vitamin
preparations 613 221 (36.0%) 675 199 (29.5%) 570 6.0% (0.5% ; 11.5%)
vitamin B complex 593 139 (23.4%) 668 124 (18.6%) 542 5.5% (1.0% ; 10.2%)
vitamin C complex 601 197 (32.8%) 670 174 (26.0%) 556 7.9% (2.7% ; 13.1%)
Hemochromatosis related
medication 677 421 (62.2%) 708 348 (49.2%) 652 13.3% (8.2% ; 18.4%)
CI, confidence interval, using the matched pair design; TS, transferrin saturation; SF, serum ferritin; * number
of matched pairs with valid data; † the increase from HEFAS to NBS, using the matched pair design; ‡ 1:
feeling good to 5: feeling bad; § 5: bad mental health to 30: good mental health, using the SF-36 health survey
score [17]; || 10: bad physical functioning to 30: good physical functioning, using the SF-36 health survey score
[17]; ¶ 4: low vitality to 24: high vitality, using the SF-36 health survey score [17].
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TABLE 3, CONTINUED. General health, medication, morbidity and iron parameters in the first-degree family members of
the HEFAS probands and of the age- and gender-matched NBS participants
HEFAS NBS HEFAS - NBS
total median (range) /n (%) total
median (range) /
n (%) total*
difference†
(95%CI )
Morbidity#
anemia 620 99 (16.0%) 674 90 (13.4%) 575 3.0% (-1.1% ; 7.0%)
cancer 621 35 (5.6%) 683 48 (7.0%) 584 -1.4% (-4.1% ; 1.4%)
cardiovascular disease 620 65 (10.5%) 685 28 (4.1%) 582 5.5% (2.7% ; 8.3%)
cerebrovascular accident 604 17 (2.8%) 675 9 (1.3%) 561 1.4% (-0.1% ; 3.0%)
diabetes mellitus 620 25 (4.0%) 677 31 (4.6%) 574 0.4% (-1.8% ; 2.5%)
fatigue ( 18)** 688 90 (13.1%) 683 54 (7.9%) 643 5.9% (2.7% ; 9.1%)
hypercholesterolemia 623 97 (15.6%) 684 80 (11.7%) 582 4.5% (0.8% ; 8.1%)
hypertension 648 184 (28.4%) 689 138 (20.0%) 609 7.9% (3.5% ; 12.3%)
infertility 604 22 (3.6%) 669 28 (4.2%) 557 -0.5% (-3.0% ; 1.9%)
liver disease 611 31 (5.1%) 669 17 (2.5%) 563 3.2% (1.0% ; 5.4%)
osteoporosis 612 47 (7.7%) 677 25 (3.7%) 570 4.2% (1.8% ; 6.6%)
rheumatism 638 199 (32.2%) 678 41 (6.0%) 594 24.6% (20.6% ; 28.6%)
surgery 722 499 (69.1%) 728 482 (66.2%) 715 2.6% (-2.2% ; 7.2%)
thyroid disease 610 28 (4.6%) 671 30 (4.5%) 565 0.0% (-2.4% ; 2.4%)
Hemochromatosis related
diseases 652 298 (45.7%) 675 131 (19.4%) 599 25.7% (20.9 % ; 30.5%)
Iron parameters††
TS > 50% 599 176 (29.4%) 494 21 (4.2%) 403 25.3% (20.5% ; 30.1%)
SF above normal (µmol/L) ‡‡ 487 198 (40.7%) 409 106 (21.2%) 333 16.5% (9.7% ; 23.3%)
TS (%)§§ 207 38.4 (3.2 - 107.3) 135 29.5 (4.8 - 97.7) 135 37.1% (23.4% ; 52.5%)
SF (µmol/L)§§ 207 119.0 (4.0 - 2308) 137 93.9 (6.6 - 4737) 137 32.4% (7.4% ; 63.1%)
CI, confidence interval, using the matched pair design; TS, transferrin saturation; SF, serum ferritin; * number
of matched pairs with valid data; † the increase from HEFAS to NBS, using the matched pair design; # self
reported diagnosis of morbidity made by a physician; ** 4: fatigue absent to 24: fatigue present, using the
shortened fatigue questionnaire score [18]; †† at time of being tested for hereditary hemochromatosis; ‡‡ serum
ferritin above the local upper reference value. §§ only participants tested in the Radboud University Nijmegen
Medical Centre.
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FIGURE 2 The number of hemochromatosis related medication use and the number of hemochromatosis related
diseases in the first-degree family members of the HEFAS probands (black) and of the age- and gender-
matched NBS participants (grey).
The iron parameters TS and SF were both significantly more elevated in the FDFM of the HEFAS
probands compared to the matched NBS participants, with a difference between HEFAS and NBS for
TS of 25.3% (95%CI, 20.5%-30.1%) and for SF of 16.5% (95%CI, 9.7%-23.3%) (TABLE 3). Similarly,
the relative differences in the absolute values of TS and SF between the FDFM of the HEFAS and
the matched NBS participants were 37.1% (95%CI, 23.4%-52.5%) and 32.4% (95%CI, 7.4%-63.1%),
respectively, using only the samples measured in the RUMCN.
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FIGURE 2 shows both the number of hemochromatosis related medication use and diseases of the
FDFM of the HEFAS population and the age- and gender-matched NBS participants. A significantly
higher percentage of FDFM used hemochromatosis related medication, compared to the NBS
participants, e.g. a difference between HEFAS and NBS of 13.3% (95%CI, 8.2%-18.4%). Similarly, a
significantly higher percentage of FDFM reported to be diagnosed with one or more
hemochromatosis related disease, e.g. a difference between HEFAS and NBS 25.7% (95%CI,
20.9%-30.5%).
MORTALITY
All 224 HEFAS probands provided data on the mortality of their first-degree relatives. The probands
provided information on 427 parents, of whom 70.0% (n=299) had died by the end of our study
(TABLE 4). These mortality figures did not differ significantly from the reported 73.6% (n=310)
deceased parents of the 224 age- and gender-matched NBS participants (p=0.25). Similarly, the
mortality among the siblings and children of the HEFAS families did not differ significantly from that of
the NBS families.
TABLE 4 Mortality among first-degree family members of both 224 HEFAS probands and age- and gender-matched
NBS participants
HEFAS NBS
n deceased n deceased p-value*
parents 427 299 (70.0%) 421 310 (73.6%) 0.25
siblings 709 93 (13.1%) 752 99 (13.2%) 1.00
children 414 8 (1.9%) 372 5 (1.3%) 0.59
Families, number of families reported by the HEFAS probands or the age- and gender-matched NBS
participants; n, number of family members reported by the proband or the age- and gender-matched NBS
participant, respectively; * p-value for difference in proportion between the HEFAS and the NBS group, using
Fisher's exact test.
DISCUSSION
Family screening can be a sophisticated model for screening for HH. To our knowledge, however,
reports on the relevance of an iron overload related health problem in families with HH are lacking to
date. Indeed, the present study is the first to reveal significantly more hemochromatosis related
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diseases in the HEFAS population compared to the normal population. In contrast, the mortality in
the HEFAS population did not significantly differ from the normal population.
Earlier studies have already described fatigue, weakness and arthropathy as being related to HFE
gene mutations, whereas diabetes mellitus, abnormal liver function tests, impotence, hypothyroidism,
cardiomyopathy and hepatocellular carcinoma were mentioned as some of the more specific, organ-
related problems leading to increased morbidity and mortality [1, 2, 5]. Furthermore they described
that, if HH was diagnosed and treated in time, tissue damage could be prevented and a long-term
survival similar to that seen in the general population could be achieved [2-6]. Nevertheless, recent
studies claim that although some iron-overloaded patients with homozygosity for the C282Y mutation
in the HFE gene have a high and probably preventable morbidity, even more subjects with this
genotype had no symptoms at all [8-11]. Moreover, studies performed in several European countries
could not detect significant differences in the prevalence of untreated homozygotes among elderly
populations compared to younger groups [19-22]. This cast doubt on the adequacy of pre-
symptomatic population screening. Thus, family screening was suggested as it was thought to
increase the chances to find both C282Y homozygosity (theoretically existent in 25% of the siblings)
and an elevated penetrance of iron overload due to the sharing of iron metabolism modifying genes
or environmental factors with the clinically expressing proband. Indeed, focusing on FDFM of C282Y-
homozygous patients with clinically overt HH has been shown to produce a significant yield of
C282Y-homozygous individuals with high penetrance of iron accumulation, but with an unknown
increase of morbidity compared to the normal population [23-25]. McCune et al recently reported that
despite the presence of elevated iron parameters, the morbidity among C282Y-homozygous relatives
of probands identified by screening a group of blood donors was similar to that of C282Y-
homozygous relatives of probands presenting as patients [26]. Assuming that the C282Y
homozygous blood donors had less morbidity than the probands of identical genotype presenting
clinically, this doubted the contribution of the higher penetrance of iron overload within HFE-mutated
families and therefore the significance of family screening. In the present study, however, we
demonstrated that first-degree relatives of patients with clinically overt HFE-related HH, do have a
significantly higher morbidity in comparison to the general population, thus supporting the additive
value of family screening. Nonetheless, the present study was not designed to clarify the factor(s)
responsible for the morbidity difference between both HEFAS and NBS populations, e.g. HFE-
genotype, iron metabolism modifying genes or environmental factors.
A remarkable finding in this study is the discrepancy between the higher morbidity and similar
mortality among the FDFM of the HEFAS probands compared to the matched NBS population.
Several explanations can be given. First of all, HEFAS family members as well as their general
practitioners may be more aware of the symptoms typical for HH, leading to an advantage in
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diagnosis and treatment [23]. Secondly, the age of the C282Y homozygous siblings (mean 54 yrs,
interquartile range Q1-Q3 47yrs-62yrs) might be too low for HFE-related mortality and the study
might also comprise too few C282Y homozygous parents to influence the mortality differences
between both parental populations. Next to this, other confounding factors that were not measured
may have influenced the comparative mortality. It has, for instance, been suggested that C282Y
polymorphism may protect against several infectious agents, either by the synthesis of a
dysfunctional HFE protein as target receptor for infectious agents, by lowering the iron levels inside
macrophages and so inducing resistance to ferrophilic micro organisms, or by altering immunological
processes, all leading to an advantage in survival [3, 27-30]. More recent investigations have
demonstrated that non-transferrin-bound iron in the sera of homozygotes and even heterozygotes for
the C282Y mutation promoted the adhesion of monocytes to endothelial cells, which may be another
advantage for immune defence [31]. Furthermore, the HFE gene mutations may provide a survival
advantage by ameliorating the iron deficiency seen in another common HLA-defined condition, such
as celiac disease [32]. Meanwhile, however, questions on the survival advantage of HFE
polymorphism remain.
It should be noted that our study comprehends a self-reporting questionnaire. Therefore, to diminish
a potential registration bias, the questionnaires for both HEFAS and NBS participants were similar,
the participants were asked to report diseases as diagnosed by their physicians and the fatigue and
general health questions were scored by validated questionnaires.
This study was not designed to clarify the causative factor in the observed morbidity differences. It is
evident, however, that HEFAS relatives have a higher possibility of being homozygous for the C282Y
mutation compared to the normal population. It is also likely that the risk of a similar predisposition,
which enhances the biochemical and clinical penetrance of C282Y homozygosity, is highest among
first-line relatives of overt HH patients. Yet, the exact nature of this predisposition is still largely
unknown (reviewed in Swinkels et al [33]).
Taken together, we are the first to demonstrate that the morbidity among first-degree relatives of
probands with clinically overt HFE-related HH is significantly higher than in the normal population.
This finding justifies further evaluation of the value of family screening in the early detection of HH
and challenges us to find environmental or genetic factors that increase the risk for iron overload.
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ABSTRACT
Recently family screening is suggested to prevent morbidity and mortality in families of patients with
clinically detected hereditary hemochromatosis (HH). However, the clinical penetrance of the HFE-gene
mutations is discussed and it is unknown which family members are at risk for the accumulation of iron
and should be screened.
The aim of this study was to identify factors that predict the accumulation of iron in first-degree family
members of probands with clinically detected HH. Between May 2003 untill August 2005 data on HFE-
genotype, iron parameters, demographics, lifestyle factors and health, were collected from 224 Dutch
C282Y homozygous patients with clinically diagnosed HH and 735 of their first-degree family members,
all participating in the HEmochromatosis FAmily Study (HEFAS).
The risk for iron accumulation was significantly higher in C282Y homozygous first-degree family
members, compared to non-HFE mutation carriers, odds ratio (OR) 59.87 (95% Confidence Interval (CI)
21.22-168.84). Other determinants for iron accumulation were compound heterozygosity (OR 5.3,
95%CI 2.26-12.46), severity of iron accumulation in the proband (OR 1.06, 95%CI 1.02-1.10) and age at
testing for serum ferritin (OR 1.03, 95%CI 1.01-1.05). Of the environmental factors supplemental iron
intake was most indicative for iron accumulation (OR 2.16, 95%CI 1.10-4.24), while a low BMI showed a
protective effect (OR 0.25, 95%CI 0.07-0.94).
This study shows that a well-defined group among the first-degree family members of C282Y
homozygous patients with clinically detected HH is at risk for iron accumulation. This outcome will be
helpful achieving an optimal strategy for future family screening programs.
INTRODUCTION
HFE-related hereditary hemochromatosis (HH) is an autosomal recessive disease characterized by a
progressive abnormal deposition of iron in liver, joints, heart, pancreas and other vital organs,
resulting in e.g. liver cirrhosis, arthralgia, cardiac failure, rhythm disorders and diabetes mellitus [1-3].
The subsequent increase in organ failure and early death is prevented through removing the
accumulated iron by phlebotomy before irreversible organ damage occurs [2, 4]. We do know that the
homozygous C282Y HFE-gene mutation is highly correlated to iron accumulation in diverse organs.
To prevent HH related disease and early death, screening of those at risk for the development for
iron overload is warrantable. However, as the penetrance of the C282Y homozygous mutation is by
far not 100%, more parameters than only HFE-gene mutations are needed to separate, during
screening, those who are at risk for iron overload from those who are not [2, 5-9].
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The development of iron overload is well described by a five grade scale [10]. It shows that the first
sign of an increased iron accumulation is an elevation of the serum transferrin saturation (TS) [10].
Indeed, reflecting a pathological iron homeostasis, in 50-100% of the C282Y homozygous population
the measured TS is found to be elevated, depending on the cut-off value used [11, 12].
Subsequently, iron accumulates in the organs during life time, which is reflected by a gradual raise in
serum ferritin (SF) [13, 14]. The SF of the C282Y homozygous individuals is mostly higher than that
of the normal population during whole lifetime, however, its level is strongly influenced by age,
gender and interfering diseases, making it more difficult to interpret its value as reflection of the
amount of accumulated iron [15-18]. Even more, there are indications that the clinical penetrance of
the HFE-gene mutations is influenced by other, not yet well described, environmental, life style or
genetic factors [2, 19, 20]. So for diagnosing HFE-related HH in early stage, as one would like to
achieve during screening, next to information on the HFE-gene mutation, information is necessary on
TS, SF, and factors determining the iron accumulation (SF) during the years.
Individuals with the highest chance of developing HFE-related iron overload are most likely the first-
degree family members (FDFM) of clinically diagnosed C282Y homozygous probands. This because
they have an elevated genetical risk for being C282Y homozygous (25% for siblings) and because
they are prone to share similar unknown environmental, life style and modifiable genetic factors,
leading to a high clinical penetrance of the HFE-gene mutation, and consequently increased iron
accumulation and more severe illness.
In the present study gender, age, HFE-gene mutations, iron parameters, life style factors and family
relation to the clinically detected C282Y homozygous proband (parent, child or sibling) of FDFM are
studied, to detect determinants for iron overload, as reflected by SF. Next to this, an interfamilial
comparison of the accumulated amount of iron was performed, to detect the possibility of other, not
identified (genetic) factors. Taken altogether, the identification of factors that predict for iron overload
in relatives of patients with HFE-related HH will be helpful for the optimization of screening strategies
in these families.
STUDY POPULATION AND METHODS
DEFINITION OF HH IN THE PRESENT STUDY
With HH in this study is meant HFE-related hemochromatosis with iron overload and related disease.
With HH is not meant the HFE-gene mutation alone.
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HEMOCHROMATOSIS FAMILY STUDY (HEFAS) POPULATION
A total of 224 probands participated. They provided the HEFAS group with names and addresses of
972 FDFM, 18 years of age and older, of whom 735 met the inclusion criteria. FDFM are defined in
this study as biological parents, full siblings, and biological children. The FDFM of one proband, form,
together with this proband, one family. Families were recruited from May 2003 until August 2005. The
local medical ethics committees of the participating centres (Atrium Medical Centre
Heerlen/Brunssum, Radboud University Nijmegen Medical Centre, Rijnstate Hospital Arnhem,
University Medical Centre Groningen and University Medical Centre Utrecht) approved the study
protocol before the start of the study.
INCLUSION CRITERIA
Only subjects who gave written informed consent were included in the study. Probands were at least 18
years old and clinically diagnosed with C282Y-homozygous HH. HFE-related accumulation of iron was
confirmed by initial transferrin saturation (TS) and serum ferritin (SF) values exceeding the reference
value thresholds; TS > 50% for both men and women, SF  280 µg/L for men, SF > 80 µg/L for women
under the age of 50, and SF  180 µg/L for women  50 years, or corresponding values for SF
depending on the reference values of the laboratories. When either one or both pre-treatment serum
iron parameters were unavailable, the presence of iron overload was alternatively confirmed by
previously performed liver biopsy (grade 3 iron deposition according to Sindram) or by the number of
phlebotomies required to normalize SF (males  22 phlebotomies = 5 g chelatable iron; females  13
phlebotomies = 3 g chelatable iron) [2, 21].
QUESTIONNAIRES
All participants were asked to fill out a questionnaire compromising a large number of questions on
demographics, lifestyle (smoking, use of alcohol, diet), health status, general medical history,
morbidity, medical history for HH, and family structure.
LABORATORY DATA
Data on the included probands and family members were extracted from medical records of the
participating hospitals or acquired from the physicians involved in diagnosis and treatment of the
patients. Information on iron parameters (TS and SF) and liver biopsy of the participants was
obtained at the time of diagnosis or screening of HH, whereas data on HFE-genotype and especially
on the number of phlebotomies were also collected at points in time after the initial investigations.
Whenever the participants declared never been tested for HH, counselling and blood testing by their
general practitioner was offered.
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The TS and SF were quantified using validated, standardized, routine laboratory methods. HFE-
genetic test results were obtained from routinely used genetic tests.
STATISTICAL METHODS
In this study we aimed at identifying FDFMs, of probands with clinically detected HFE-related HH, at
risk for iron accumulation from those not at risk. For this purpose, elevated TS was defined as TS
above 50%, elevated SF as SF above the gender- and calendar time-specific local laboratory
reference values. It may be noted that some of the laboratories also used different reference values
for premenopausal and post-menopausal women. In some cases where the SF reference values
were not available, the 67th percentile of all reference values was used. Furthermore, different
reference values for premenopausal and postmenopausal women were taken into account when
provided by the laboratories.
In the following analyses the probands were excluded. Univariate logistic regression was used to
study the ability of environmental, life habits and genotype variables to discriminate FDFM with
elevated iron variables from FDFM with non-elevated iron variables, for each variable separately. The
dependent variables were elevated TS and elevated SF, respectively. The crude odds ratios (ORs)
with 95% confidence intervals (CIs) are presented.
Multivariate logistic regression with stepwise selection procedures was used to identify variables that
contributed independently to the risk of elevated iron variables, either next to genotype or next to
family-degree. In this way, genotype models and family-degree models were studied. Again, the
dependent variables were elevated TS and elevated SF, respectively.
Possible iron accumulation determining variables used in the selection procedure were gender, age
at testing, BMI, iron supplements, alcohol use, familial iron severity. The familial iron severity was
defined as the value of TS of the proband in case elevated TS was studied and the value of SF of
the proband divided by the reference value in case of elevated SF. The adjusted ORs with 95%CIs
of the final model are presented. The total R-square is presented to indicate the total percentage
explained variance in the outcome and the area under the curve (AUC) of the receiver operating
characteristic (ROC) curve is presented as measure of predictive discrimination.
The fit of model is visualized in a figure that shows the estimated and observed iron overload. The
results of the final genotype model are also used to estimate the probability of elevated ferritine
levels (with 95% CI) of C282Y homozygous family members by gender, age, BMI, use of iron
supplements and familial iron severity. Note that this estimates the penetrance (of “elevated ferritine
values”), including modifying factors.
All statistical analyses were performed using SAS version 8.2.
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RESULTS
DEMOGRAPHICS AND CLINICAL CHARACTERISTICS
The family members of the HEFAS population consisted of 224 probands, 428 siblings, 241 children
and 66 parents (TABLE 1). The percentage male participants was slightly higher in the group of
probands, 62.5% (n=140), but lower among the siblings, 46.3% (n=198) and children 40.7% (n=98).
The percentage male participants of the parents was even lower (33.3%, n=22), reflecting the higher
age of survival of the women. The ages of the participants varied from a median of 56 years for
probands, 54 years for siblings, 32 years for children, to finally 70 years for parents.
GENOTYPE CHARACTERISTICS AND IRON PARAMETERS
TABLE 1 also presents the genotype characteristics of the HEFAS population. 100% of the probands
were C282Y homozygous (by definition), compared to 29.9% (n=110) of the siblings, 5.7% (n=11) of
the children and 2.2% (n=1) of the parents, whereas C282Y heterozygosity was determined in 39.7%
(n=146), 78.1% (n=150) and 78.3% (n=36) of the siblings, children and parents, respectively.
The mean TS found of the probands was 86.8% (Q1-Q3; 74.0%-96.3%), which was significantly
higher than the mean TS of the other family groups, p<0.0001. The same is true for the TS >50%.
The probands also revealed significantly higher values of absolute SF compared to the other FDFM,
p<0.0001. Notice that not in all probands both the TS value and the SF value were elevated. In that
case however, the excess of iron was confirmed either by liver biopsy or by phlebotomy.
In the homozygous HEFAS population TS >50% was found in 93.2% (n=192) of the probands, 86%
(n=84) of the siblings, 56% (n=5) of the children and 100% (n=1) of the parents. For an elevated SF
these percentages amounted to 86.3% (n=183) of the parents, 80% (n=84) of the siblings, 22% (n=2)
of the children and 100% (n=1) of the parents.
POTENTIAL FACTORS INFLUENCING TS AND SF LEVELS
TABLE 2 shows the odds ratio of the possible predisposing iron storage factors. As expected the
genotype had a profound influence on the TS and SF levels. Being C282Y homozygous was
correlated with a significantly raised risk for both elevated TS and elevated SF compared to being
WT/WT (OR 80.29, 95% CI 36.83 to 175.03 and OR 22.50, 95%CI 12.22 to 41.42, respectively).
Similarly, being compound heterozygous (C282Y/H63D) gave a raised risk for elevated TS and iron
accumulation with OR 4.84, 95%CI 1.96-11.97 and OR 4.02, 95%CI 1.84-8.80, respectively.
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TABLE 1 Characteristics of the HEFAS population by family degree
Probands Siblings Children Parents
total median (Q1-Q3) /n (%) total
median (Q1-Q3) /
n (%) total
median (Q1-Q3) /
n (%) total
median (Q1-Q3) /
n (%)
224 428 241 66
Demographics
male 224 140 (62.5) 428 198 (46.3) 241 98 (40.7) 66 22 (33.3)
age at participation
(yr) 224 56 (48-63) 428 54 (47-62) 241 32 (26-38) 66 70 (63-78)
education
( secondary) 212 59 (27.8) 395 105 (26.6) 233 86 (36.9) 61 7 (11.5)
paid job ( 32
hrs/week) 78 44 (56.4) 178 87 (48.9) 160 97 (60.6) 4 1 (25.0)
Body Mass Index
(kg/m2) 215 25.9 (23.5-27.9) 417 25.4 (23.3-27.8) 238 23.4 (21.6-26.5) 62 26.2 (24.0-29.1)
Lifestyle
smoking (ever) 220 168 (76.4) 421 289 (68.7) 241 129 (53.5) 65 45 (69.2)
alcohol
> 2 units/day 189 44 (23.3) 374 103 (27.5) 204 55 (27.0) 50 5 (10.0)
Iron supplements 218 14 (6.4) 416 52 (12.5) 240 26 (10.8) 62 9 (14.5)
Meat consumption
(>200 gr/d) 214 85 (39.7) 398 129 (32.4) 230 95 (41.3) 59 11 (18.6)
Blood donation (no) 212 152 (71.7) 409 310 (75.8) 239 200 (83.7) 57 50 (87.7)
Menarche
 12 year)** 80 5 (6.3) 223 30 (13.5) 141 18 (12.8) 39 6 (15.4)
Pregnancies ( > 3)** 67 23 (34.3) 196 97 (49.5) 84 33 (39.3) 41 33 (80.5)
Genotype 224 368 192 46
C282Y/C282Y 224 (100%) 110 (29.9%) 11 (5.7%) 1 (2.2%)
C282Y/H63D 0 19 (5.2%) 27 (14.1%) 8 (17.4%)
C282Y/WT* 0 146 (39.7%) 150 (78.1%) 36 (78.3%)
WT/WT† 0 93 (25.3%) 4 (2.1%) 1 (2.2%)
Iron parameters¶
TS (%) 206 86.8 (74.0-96.3) 361 36.7 (27.5-59.6) 189 36.4 (26.3-49.1) 49 36.2 (27.7-46.6)
TS > 50% 206 192 (93.2) 361 119 (33.0) 189 47 (24.9) 49 10 (20.4)
SF (µmol/L) 212 1031 (389-2025) 366 155 (62-383) 191 70 (33-160) 48 113 (74-235)
SF above normal
(µmol/L)§ 212 183 (86.3) 366 133 (36.4) 191 32 (16.8) 48 13 (27.1)
Legend; see next page.
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TABLE 1 Q1-Q3, inter quartile range; n, number with valid data (percentage); TS, transferrin saturation; SF, serum
ferritin; ** only women; * C282Y/WT includes C282Y/WT and C282Y/unknown; † WT/WT includes H63D/H63D;
H63D/WT, WT/WT; ¶ at time of being tested for hereditary hemochromatosis; § serum ferritin above the local
upper reference value.
Compared to the other FDFM, the probands showed the highest chance on elevated TS (OR 53.47,
95%CI 22.15-129.11) and elevated SF (OR 16.99, 95%CI 8.05-35.88), which is not surprising taken
into account the genotype distribution over the probands compared to the FDFM. Being a male also
significantly raised the risk of elevated TS (OR 2.04, 95%CI 1.54-2.70), and of elevated SF (OR 1.91,
95%CI 1.45-2.54). The age at testing was only identified as a significant risk factor for an elevated
SF, as was having an abnormal BMI and higher meat consumption. Alcohol consumption (>2
units/day) and blood donation showed no influence on the iron parameters in this univariate analysis.
The intake of iron supplements lowered the risk of elevated TS (OR 0.59, 95%CI 0.37-0.95), whereas
women who had >3 pregnancies, had a higher risk of elevated TS (OR 1.51, 95%CI 0.96-2.36) and
of elevated SF (OR 1.59; 95%CI 1.01-2.48).
TABLE 3 shows the adjusted odds ratios of the genotype model of elevated TS and of elevated SF.
C282Y Homozygosity and compound heterozygosity increased significantly the risk of elevated TS
compared to WT/WT (OR 59.87, 95%CI 21.22-168.94 and OR 4.89, 95%CI 1.67-14.35, respectively).
Interestingly, BMI > 30 kg/m2 independently diminished the risk for TS elevation. Both the R-square
and the AUC of this genotype model are large. In total 44.6% (R-square) of the variance in elevated
TS could be explained by the selected variables and the discriminatory power is 83.2% (AUC). For
comparison an AUC equal to 50% is equivalent to random guessing.
As with elevated TS the risk for elevated SF was significantly increased by possessing the C282Y
homozygous or compound heterozygous genotype compared to WT/WT (OR 20.87, 95%CI 9.74-
44.75 and OR 5.30, 95%CI 2.26-12.46, respectively). Furthermore, the familial iron severity was
predictive for an elevated SF (OR 1.06, 95%CI 1.02-1.10), as was the age of testing (OR 1.03,
95%CI 1.01-1.05). A BMI <20 kg/m2 was protective for the risk of elevated SF, whereas the intake of
iron supplements induced the risk. Noteworthy is that gender is not statistical significant in this
multivariable logistic regression analysis. This may be indicative for the idea that gender is not an
independently risk factor of an elevated SF that is based on age and gender specific reference
values. The R-square and AUC are similar to those of the genotype model of elevated TS, 45.3%
and 84.7%, respectively.
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TABLE 2 The crude odds ratios with 95% confidence intervals of increased transferrin saturation and serum ferritin
values among all family members, using univariate logistic regression analysis
Elevated TS Elevated SF
odds ratio (95%CI) odds ratio (95%CI)
Genotype
C282Y/C282Y 80.29 (36.83-175.03) 22.50 (12.22-41.42)
C282Y/H63D 4.84 (1.96-11.97) 4.02 (1.84-8.80)
C282Y/WT* 1.73 (0.82-3.66) 0.81 (0.43-1.51)
WT/WT† 1.00 (reference) 1.00 (reference)
Family degree
probands 53.47 (22.15-129.11) 16.99 (8.05-35.88)
siblings 1.92 (0.93-3.98) 1.54 (0.79-3.00)
children 1.29 (0.60-2.79) 0.54 (0.26-1.14)
parents 1.00 (reference) 1.00 (reference)
General characteristics
male 2.04 (1.54-2.70) 1.91 (1.45-2.54)
age at testing 1.00 (1.00-1.02) 1.03 (1.02-1.04)
education ( secondary
education) 0.95 (0.69-1.31) 1.10 (0.80-1.51)
paid job ( 32 hrs/week) 1.00 (0.65-1.53) 1.04 (0.68-1.60)
BMI (kg/m2) 0.99 (0.95-1.02) 1.08 (1.04-1.12)
Alcohol > 2 units/day 0.76 (0.54-1.01) 0.80 (0.59-1.12)
Iron supplements 0.59 (0.37-0.95) 0.85 (0.54-1.33)
Meat consumption
(>200 g/d) 0.85 (0.63-1.14) 1.51 (1.12-2.04)
Blood donation (no) 0.79 (0.56-1.10) 1.11 (0.79-1.56)
Menarche ( 12 year)** 0.83 (0.44-1.56) 1.12 (0.60-2.10)
Pregnancies ( > 3)** 1.51 (0.96-2.36) 1.59 (1.01-2.48)
TS, transferrin saturation; SF, serum ferritin; * C282Y/WT includes C282Y/WT, C282Y/unknown;
† WT/WT includes H63D/H63D, H63D/WT, WT/WT; ** only women.
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TABLE 3 The adjusted odds ratios of the genotype model of elevated TS and SF values, among first-degree family
members, using multivariate logistic regression with selection procedure.
Elevated TS Elevated SF
ORadj (95%CI) ORadj (95%CI)
Genotype
C282Y/C282Y 59.87 (21.22-168.94) 20.87 (9.74-44.75)
C282Y/ H63D 4.89 (1.67-14.35) 5.30 (2.26-12.46)
C282Y/WT* 1.75 (0.72-4.27) 0.99 (0.50-1.93)
WT/WT** 1.00 (reference) 1.00 (reference)
Gender
male 1.66 (0.08-1.66) 1.34 (0.82-2.17)
female 1.00 (reference) 1.00 (reference)
Familial iron severity 1.00 (0.99-1.02) 1.06 (1.02-1.10)
Age at testing 1.00 (0.98-1.01) 1.03 (1.01-1.05)
BMI (kg/m2)
<20 0.42 (0.11-1.53) 0.25 (0.07-0.94)
20-25 1.00 (reference) 1.00 (reference)
25-30 0.66 (0.36-1.02) 1.45 (0.87-2.42)
>30 0.21 (0.07-0.62) 1.12 (0.52-2.41)
Iron supplements - 2.16 (1.10-4.24)
Alcohol > 2 units/day 0.58 (0.32-1.05) -
TS, transferrin saturation; SF, serum ferritin; adj, adjusted for the other variables in the model; familial iron
severity, the value of TS of the proband in case elevated TS was studied and the value of SF of the proband
divided by the reference value in case of elevated SF. Selection was performed when genotype, age, gender
and severity were already included; * C282Y/WT includes C282Y/WT, C282Y/unknown; ** WT/WT includes
H63D/H63D, H63D/WT, WT/WT; -, not selected.
TABLE 4 shows the adjusted odd ratios of the family-degree model of elevated TS and of elevated
SF. The variables to predict elevated TS in this family-degree model only reached the level of
borderline significance resulting in a low fit and a moderate discriminatory power (R-square = 4.0%,
AUC = 61.7%). The factors predicting an elevated risk for increased SF were comparable to the
factors mentioned in TABLE.3, though their influence appeared to be less clearly; familial iron severity
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(OR 1.04, 95%CI 1.01-1.08) and age at testing (OR 1.02, 95%CI 1.003-1.05). The percentage
explained variance and the discriminatory power were only slightly better then in the family-degree
model of elevated TS (R-square= 15.3%, AUC=70.3%).
In conclusion, we found that the genotype models outperform by far the family-degree models using
both the percentage explained variance and the discriminatory power.
TABLE 4 The adjusted odds ratios of the family-degree model of elevated TS and SF values, among first-degree family
members, using multivariate logistic regression with selection procedure.
Elevated TS Elevated SF
ORadj (95%CI) ORadj (95%CI)
Family degree
siblings 1.82 (0.67-4.98) 2.16 (0.84-5.55)
children 1.80 (0.51-6.29) 0.76 (0.21-2.70)
parents 1.00 (reference) 1.00 (reference)
Gender
male 1.51 (0.98-2.33) 1.27 (0.82-1.98)
female 1.00 (reference) 1.00 (reference)
Familial iron severity 1.00 (0.99-1.01) 1.04 (1.01-1.08)
Age at testing 1.01 (0.99-1.03) 1.02 (1.003-1.05)
Meat consumption - 1.61 (1.01-2.56)
Alcohol > 2 units/day 0.65 (0.41-1.04) -
TS, transferrin saturation; SF, serum ferritin; adj, adjusted for the other variables in the model; familial iron
severity, the value of TS of the proband in case elevated TS was studied and the value of SF of the proband
divided by the reference value in case of elevated SF. Selection was performed when genotype, age, gender
and severity were already included; -, not selected.
FIGURE 1 shows the observed elevated SF and estimated probability of elevated SF, using the final
genotype model. This figure shows that black spots in figure A well agree with the larger bubbles in
figure B, indicating the large discriminatory power of our model. The black spots in between the open
spots in figure A may indicate that more variables than age and familial severity alone determine
(completely) the elevated SF level. Small bubbles in between large bubbles in figure B indicate the
effect of other variables than age and familial severity used in the model to predict elevated SF.
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FIGURE 1 The observed (A) and predicted probability (B) of elevated serum ferritin concentration (SF) by severity of iron
overload in the family and by age of first-degree family members with homozygous genotype or with
compound heterozygous genotype. The black spots in panel A indicate family members with elevated SF and
the size of the bubbles in panel B indicate the predicted probability, using the final multivariate logistic
regression model. Severity of iron overload in the family was defined as the value of SF of the proband
divided by the reference value of the local laboratory.
PENETRANCE OF IRON OVERLOAD
Finally the risk for a C282Y homozygous FDFM to develop iron overload is presented in TABLE 5
(males) and TABLE 6 (females) by age, BMI, use of iron supplements and familial iron severity. For
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instance a 50 yr old male, with a BMI of 25 kg/m2, not using iron supplements, with a related
proband presenting with an SF level of 4 times the reference value, has an estimated risk for iron
overload of 0.80 (95%CI 0.69-0.87).
DISCUSSION
The potentially positive effects of family screening for HH to prevent iron accumulation and its related
morbidity and mortality in individuals at risk for HH, calls for a thorough investigation of the
usefulness of family screening for the early detection of HH, in the light of the discussion on the
penetrance of the HFE-gene mutation [22-25]. Recently, we demonstrated an increased HH related
morbidity in family members of probands with clinically detected HH compared to an age and gender
matched healthy population (chapter 6 of this thesis). In the present study we investigated the HFE-
gene mutation penetrance in the FDFM of these families by searching for co-factors determining the
amount of accumulated iron. Studying the FDFM of clinically detected HH patients limits
ascertainment bias and increases the chance on finding genetic and environmental factors that will
predict iron accumulation. As expected, we showed that the risk for iron overload is strongly related
to the genotype of the FDFM, e.g. C282Y homozygosity and compound heterozygosity. Next to this,
an older age at testing for iron accumulation, a more severe iron overload in the related proband at
presentation and the use of iron supplements all contributed significantly to the prediction of iron
overload in the FDFM. In contrast, a low BMI protected against iron accumulation, whereas the family
degree itself (sibling, parents, child) provided no additional information.
In our population HFE-genotype was the strongest predictor for the accumulation of iron, a finding
ascertained by others previously [7, 26-28]. However, we are the first to confirm a positive
relationship between the severity of iron overload found in a proband and that detected in the related
FDFM, indicating the existence of HFE-genotype penetrance modifying factors, such as other co-
inherited genes or environmental family related factors. Previously, Whiting et al already observed a
concordance of iron indices in homozygote and heterozygote sibling pairs in hemochromatosis
families, suggesting the existence of these familial modifiable factors [29]. Mura et al, however, could
not demonstrate a familial predisposition for iron overload, as they found no correlation between TS
or SF between sex matched homozygous sibling pairs of which one was clinically diagnosed as HH
and one exhibited only total body iron overload [30]. McCune et al also looked at a familial
predisposition of HFE-gene expression. They compared the amount of iron overload of C282Y
homozygous relatives of clinically affected C282Y homozygous index cases with the amount of iron
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TABLE 5 The estimated probability (95%CI) of developing iron overload in C282Y homozygous FDFM males by age, BMI, use of iron supplements and familial
severity, using multivariate logistic regression analysis
use of iron supplements
yes no
familial iron severity** familial iron severity**
age
(yr)*
BMI
(kg/m2) 1 2 3 4 5 1 2 3 4 5
30 <20 0.45(0.15-0.78)
0.46
(0.16-0.79)
0.48
(0.17-0.80)
0.49
(0.18-0.81)
0.50
(0.19-0.82)
0.27
(0.09-0.59)
0.29
(0.10-0.60)
0.30
(0.10-0.62)
0.31
(0.11-0.63)
0.32
(0.11-0.64)
20-30 0.79(0.60-0.90)
0.80
(0.61-0.91)
0.81
(0.62-0.91)
0.82
(0.64-0.92)
0.83
(0.65-0.92)
0.64
(0.48-0.77)
0.65
(0.50-0.78)
0.66
(0.52-0.78)
0.68
(0.53-0.79)
0.69
(0.54-0.80)
>30 0.78(0.53-0.92)
0.79
(0.55-0.92)
0.80
(0.56-0.92)
0.81
(0.58-0.93)
0.82
(0.59-0.93)
0.62
(0.40-0.81)
0.64
(0.41-0.81)
0.65
(0.43-0.82)
0.66
(0.44-0.83)
0.68
(0.46-0.84)
40 <20 0.52(0.20-0.83)
054
(0.21-0.84)
0.55
(0.22-0.84)
0.57
(0.23-0.85)
0.58
(0.24-0.86)
0.34
(0.12-0.66)
0.35
(0.67-0.72)
0.37
(0.13-0.68)
0.38
(0.14-0.70)
0.39
(0.15-0.71)
20-30 0.84(0.67-0.93)
0.84
(0.69-0.93)
0.85
(0.71-0.93)
0.86
(0.71-0.94)
0.87
(0.72-0.94)
0.71
(0.57-0.81)
0.72
(0.59-0.82)
0.73
(0.60-0.83)
0.74
(0.62-0.83)
0.75
(0.63-0.84)
>30 0.83(0.62-0.93)
0.84
(0.63-0.94)
0.84
(0.64-0.94)
0.85
(0.66-0.94)
0.86
(0.67-0.94)
0.69
(0.48-0.84)
0.70
(0.50-0.85)
0.72
(0.51-0.86)
0.73
(0.53-0.87)
0.74
(0.54-0.88)
50 <20 0.60(0.25-0.87)
0.61
(0.27-0.87)
0.63
(0.28-0.89)
0.64
(0.29-0.89)
0.65
(0.30-0.89)
0.41
(0.16-0.73)
0.43
(0.17-0.74)
0.44
(0.17-0.75)
0.46
(0.18-0.76)
0.47
(0.19-0.77)
20-30 0.87(0.74-0.95)
0.88
(0.75-0.95)
0.89
(0.76-0.95)
0.89
(0.77-0.95)
0.90
(0.78-0.96)
0.77
(0.65-0.85)
0.78
(0.66-0.86)
0.79
(0.68-0.87)
0.80
(0.69-0.87)
0.80
(0.70-0.88)
>30 0.87(0.69-0.95)
0.87
(0.70-0.95)
0.88
(0.71-0.96)
0.89
(0.72-0.96)
0.90
(0.74-0.96)
0.75
(0.56-0.88)
0.76
(0.58-0.89)
0.78
(0.59-0.89)
0.79
(0.61-0.90)
0.79
(0.62-0.90)
60 <20 0.67(0.31-0.90)
0.68
(0.33-0.91)
0.70
(0.34-0.91)
0.71
(0.35-0.92)
0.72
(0.37-0.92)
0.49
(0.20-0.79)
0.50
(0.20-0.80)
0.52
(0.22-0.80)
0.53
(0.23-0.81)
0.55
(0.24-0.82)
20-30 0.90(0.79-0.96)
0.91
(0.80-0.96)
0.91
(0.81-0.96)
0.92
(0.82-0.97)
0.92
(0.83-0.97)
0.82
(0.71-0.89)
0.82
(0.72-0.90)
0.83
(0.73-0.90)
0.84
(0.75-0.91)
0.85
(0.76-0.91)
>30 0.90(0.75-0.96)
0.90
(0.76-0.97)
0.91
(0.77-0.97)
0.91
(0.78-0.97)
0.92
(0.79-0.97)
0.81
(0.63-0.91)
0.82
(0.65-0.91)
0.82
(0.66-0.92)
0.83
(0.67-0.92)
0.84
(0.69-0.93)
* age at time the SF was measured, ** familial iron severity, the value of SF of the proband divided by the reference value.
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TABLE 6 The estimated probability (95%CI) of developing iron overload in C282Y homozygous FDFM females by age, BMI, use of iron supplements and familial
severity, using multivariate logistic regression analysis
use of iron supplements
yes no
familial iron severity** familial iron severity**
age
(yr)*
BMI
(kg/m2) 1 2 3 4 5 1 2 3 4 5
30 <20 0.37(0.13-0.70)
0.38
(0.13-0.71)
0.40
(0.14-0.72)
0.41
(0.15-0.74)
0.42
(0.16-0.75)
0.22
(0.07-0.50)
0.23
(0.07-0.51)
0.24
(0.08-0.53)
0.25
(0.08-0.54)
0.26
(0.09-0.55)
20-30 0.73(0.54-0.86)
0.74
(0.56-0.87)
0.75
(0.57-0.87)
0.76
(0.59-0.88)
0.77
(0.60-0.89)
0.56
(0.41-0.70)
0.57
(0.42-0.71)
0.59
(0.44-0.72)
0.60
(0.45-0.73)
0.62
(0.47-0.74)
>30 0.72(0.48-0.88)
0.73
(0.50-0.88)
0.74
(0.51-0.89)
0.75
(0.53-0.89)
0.76
(0.54-0.90)
0.54
(0.33-0.74)
0.56
(0.35-0.75)
0.57
(0.36-0.76)
0.59
(0.37-0.77)
0.60
(0.39-0.78)
40 <20 0.44(0.17-0.76)
0.46
(0.18-0.77)
0.47
(0.19-0.78)
0.49
(0.19-0.79)
0.50
(0.20-0.80)
0.27
(0.09-0.57)
0.28
(0.10-0.59)
0.30
(0.11-0.60)
0.31
(0.11-0.61)
0.32
(0.12-0.62)
20-30 0.79(0.63-0.89)
0.80
(0.64-0.90)
0.81
(0.65-0.90)
0.82
(0.67-0.91)
0.82
(0.68-0.91)
0.63
(0.50-0.75)
0.65
(0.51-0.76)
0.66
(0.53-0.77)
0.67
(0.54-0.78)
0.69
(0.56-0.79)
>30 0.89(0.57-0.90)
0.90
(0.58-0.91)
0.90
(0.60-0.91)
0.91
(0.61-0.92)
0.91
(0.62-0.92)
0.75
(0.41-0.79)
0.76
(0.43-0.80)
0.77
(0.44-0.81)
0.78
(0.46-0.82)
0.79
(0.47-0.83)
50 <20 0.52(0.21-0.81)
0.53
(0.23-0.82)
0.55
(0.24-0.83)
0.56
(0.25-0.84)
0.58
(0.26-0.84)
0.34
(0.12-0.65)
0.35
(0.13-0.66)
0.36
(0.14-0.67)
0.38
(0.15-0.68)
0.39
(0.15-0.69)
20-30 0.83(0.70-0.92)
0.84
(0.71-0.92)
0.85
(0.72-0.93)
0.86
(0.73-0.93)
0.86
(0.74-0.93)
0.70
(0.57-0.81)
0.71
(0.59-0.81)
0.73
(0.61-0.82)
0.74
(0.62-0.83)
0.75
(0.64-0.84)
>30 0.83(0.64-0.93)
0.83
(0.66-0.93)
0.84
(0.67-0.93)
0.85
(0.68-0.94)
0.86
(0.69-0.94)
0.69
(0.49-0.84)
0.70
(0.51-0.84)
0.71
(0.52-0.85)
0.73
(0.54-0.86)
0.74
(0.55-0.86)
60 <20 0.60(0.27-0.86)
0.61
(0.28-0.86)
0.62
(0.29-0.87)
0.64
(0.30-0.88)
0.65
(0.32-0.88)
0.41
(0.16-0.72)
0.42
(0.17-0.73)
0.44
(0.18-0.74)
0.45
(0.19-0.75)
0.47
(0.20-0.76)
20-30 0.87(0.75-0.94)
0.88
(0.76-0.94)
0.89
(0.77-0.95)
0.89
(0.78-0.95)
0.90
(0.79-0.95)
0.76
(0.64-0.85)
0.77
(0.65-0.86)
0.78
(0.67-0.87)
0.79
(0.68-0.87)
0.80
(0.70-0.88)
>30 0.87(0.71-0.95)
0.87
(0.72-0.95)
0.88
(0.73-0.95
0.89
(0.74-0.95)
0.89
(0.75-0.96)
0.75
(0.57-0.88)
0.76
(0.58-0.88)
0.77
(0.60-0.89)
0.78
(0.61-0.89)
0.79
(0.62-0.90)
* age at time the SF was measured; ** familial iron severity, the value of SF of the proband divided by the reference value.
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overload found in C282Y homozygous relatives of C282Y homozygous blood donors detected by
genetic screening [31]. After correcting for potential iron accumulation modifying parameters, the
multivariate analyses showed that, in contrast to our findings, being familial related to the clinically
affected proband group was no longer a significant risk factor for iron overload. This could be
explained by the difference in definition of iron overload in the proband, as we defined the severity of
iron overload in the proband by the SF level in contrast to McCune, who defined it by the existence
of clinical symptoms in the proband [32].
Surprisingly, our study revealed that the consumption of alcohol was not a predictor for iron
accumulation in contrast to what others found [32]. This is most likely due to the fact that we chose a
low alcohol intake cut-off value to discriminate between low and high alcohol intake, diminishing the
effect of the severe drinkers. The finding that gender did not add any predictive value for iron
overload in contrast to findings in literature, is explained by the fact that we used normal SF values
already corrected for gender and pre- and post menopausal period. This study also revealed that
further standardisation of the SF measurements is requested to make results between laboratories
better interpretable. The potentially protective effect for iron overload by a low BMI (<20 kg/m2) is
presumably due to the increased number of individuals in this group with severe diseases inducing
iron storage depletion.
Interesting for screening HH patients is the observation that individuals with a high BMI (>30 kg/m2)
had a lower TS. Recently, Laine et al already claimed that the phenotypic expression of C282Y
homozygous women, measured by TS, depended on their BMI, as 82% of the women with a BMI
>27 kg/m2 were non-expressing hemochromatosis patients [33]. Bekri et al gave an explanation as
they found that HAMP (hepcidin) mRNA expression was increased in adipose tissue of obese
patients [34]. As hepcidin decreases the intestinal iron uptake and the reticular endothelial system
iron release, these increased hepcidin levels are predicted to result in lowered TS levels. Indeed,
they found low TS levels in 68% of the obese patients and 24% of them even presented with
anaemia. For HH patients one could postulate that the increased hepcidin expression in the adipose
tissue compensates for the diminished hepcidin expression in the liver, protecting these severe obese
patients from iron overload. It is, however, not clear whether the SF in these patients is an accurate
reflection of the actual iron accumulation found by liver biopsy. Indeed, even more complicating is the
finding that hepatic fat content, visceral fat area and subcutaneous fat are positively correlated with
SF levels, as with metabolic syndrome and insulin resistance in non-HFE related populations [35-37].
This even suggests a (false positive) increase in SF, in contrast to the decrease found for TS in
these obese individuals. Taken together, the relevance of a high BMI for screening for HH remains
unclear. The confirmation of the found decreases in TS levels or elevations in SF levels with
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histological proven iron overload by liver biopsy, in a HFE related population with a BMI>30 kg/m2, is
recommended.
The strong relation between HFE-genotype and iron overload we found in the HEFAS families
underlined the importance of family screening. However, for clinical relevance we still have to prove
the positive relationship between iron accumulation and the development of iron overload related
disease and organ failure in our population. Though, the existence of the relation is very plausible, as
Powell showed recently. He investigated 672 essential asymptomatic C282Y homozygous individuals
identified by family screening or health checks and showed that hepatic fibrosis and cirrhosis
correlated significantly with the hepatic iron concentrations [38]. Even more, a significant hepatic
fibrosis was frequently found in asymptomatic subjects with iron overload, which was reversible by
phlebotomies when no cirrhosis was present urging again early screening on iron overload even if no
complaints yet existed.
In the present study we showed that HFE-genotype, age at testing for HH, severity of iron overload
within the family, BMI and the intake of iron supplements are the most important predictive factors for
developing iron overload in FDFM of clinically diagnosed C282Y homozygous probands.
Incorporating these factors in the screening procedures of FDFM for HH should be helpful to identify
those individuals most at risk for iron overload and subsequently reduces unnecessary follow-up and
treatment of those who will never develop any iron accumulation.
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ABSTRACT
The clinical penetrance of HFE-related hereditary hemochromatosis (HH) is highly variable and may be
influenced by multiple genes, life style and environmental factors, complicating early screening options
to prevent iron overload related disease.
The aim of this study was to assess the presence of HH related disease in C282Y homozygous siblings
of C282Y homozygous probands with clinically detected HFE-related HH and identify factors predictive
for the iron overload related disease within these siblings. To this end C282Y homozygous and non-
homozygous siblings were compared regarding serum iron parameters and using structured
questionnaires covering general health, lifestyle factors and HH related disease.
In total 428 siblings participated in the study of whom 110 were C282Y homozygous, compromising 53
men (48%). Compared to non-homozygous C282Y siblings, C282Y homozygous siblings mentioned to
have more often joint pain (odds ratio (OR) 1.88, 95% confidence interval (95%CI) 1.19-2.99), liver
disease (OR 2.90, 95%CI 1.27-6.62) and rheumatism (OR 2.76, 95%CI 1.71-4.46) Using multivariate
logistic regression modelling genotype (OR 2.29, 95%CI 1.04-5.02), age (OR 1.07, 95%CI 1.04-1.09)
and gender (OR 1.71, 95%CI 1.04-2.80) were predictive for the development of iron overload related
disease. With genotype in the model, neither the serum iron parameters, nor lifestyle factors as BMI,
smoking or alcohol use added to the prediction of iron overload related disease.
We report that HFE-related disease is increased in the C282Y homozygous siblings stressing the
importance of family screening. Knowledge on genotype, gender and age, but not of lifestyle factors,
appear to be instrumental in the design of a family screening program that is most cost-effective.
INTRODUCTION
Hereditary hemochromatosis (HH) is an autosomal recessive disease characterized by excessive iron
absorption in the intestines leading to iron storage in parenchymal organs. Clinical features of adult
onset HFE-related HH are vague and generally consist of complaints such as fatigue, weakness,
arthropathy and abdominal pain. Diabetes mellitus, hepatomegaly, abnormal liver tests, impotence,
hypothyroidism, cardiomyopathy and hepatocellular carcinoma are described as some of the more
advanced problems related to the progressive iron deposition in the internal organs, although the
relation with iron overload is not thoroughly proven for all of them [1-7]. As genetic screening became
possible, HFE-related HH was regarded as one of the most common genetic disorders of northern
Europeans, with approximately five per 1000 individuals being C282Y homozygous [8]. It appeared
that early diagnosis and therapeutic phlebotomy effectively prevented the development of tissue
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damage and resulted in long term survival similar to the general population [9-11]. Regarding the
high prevalence of homozygous individuals and the benefits of an early treatment, population based
screening seemed very compelling.
However, a considerable variability in symptomatology and severity of the HFE-related iron overload
disease exists, even among patients with identical mutations. This is indicative for powerful effects of
other modifying genes, specific environmental influences, other diseases or lifestyle [3, 6, 7].
Predictive DNA testing in asymptomatic individuals seems therefore insufficient to estimate the future
risk of disease. This is expected to be different in families in which HFE-related iron overload exists.
Family members that share the activity of other modifiable genes, environmental influences and
lifestyle with the symptomatic proband, share probably also the clinical penetrance of the HFE-gene
mutation for iron overload, making family screening promising and cost-effective, especially if
contributing factors are elucidated. However, until now no clearly defined laboratory or patient
characteristics are available to risk-stratify patients into groups that are more or less likely to develop
overt disease. Even more, as scored by illness and not iron overload alone, equal clinical penetrance
of HFE-related disease is still not adequately confirmed in the family members of the clinically
diagnosed probands [12].
Therefore, the current study aims to provide evidence for the existence of increased illness in C282Y
homozygous siblings of clinically diagnosed C282Y homozygous probands, compared to their non-
homozygous siblings. Its second objective is to explore factors determining the clinical expression of
the HFE-related disease in these C282Y homozygous siblings. These outcomes will be helpful to
define among the siblings a high-risk group for iron overload related disease, potentially increasing
the effectiveness of family screening.
METHODS
STUDIED POPULATION
The 428 C282Y homozygous siblings studied all participated in the HEmochromatosis FAmily Study
(HEFAS), which encompasses 224 C282Y homozygous probands with clinically detected HH and 735
first-degree family members, all at least 18 years of age, as describe elsewhere (chapter 6 of this
thesis).
INCLUSION CRITERIA
Only subjects who gave written informed consent were included in the study. Probands were formerly
diagnosed by their clinical signs and symptoms related to iron overload and C282Y-homozygosity. Iron
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accumulation was confirmed by initial transferrin saturation (TS) and serum ferritin (SF) values
exceeding the reference value thresholds; TS > 50% for both men and women, SF  280 µg/L for men,
SF > 80 µg/L for women under the age of 50, and SF  180 µg/L for women aged  50 years, or
corresponding values for SF depending on the reference values of the laboratories. When either one or
both pre-treatment serum iron parameters were not available, the presence of iron overload was
alternatively confirmed by liver biopsy (grade 3 iron deposition according to Sindram) performed before
treatment was started or by the number of phlebotomies required to normalize SF (males  22
phlebotomies, 5 g chelatable iron; females  13 phlebotomies, 3 g chelatable iron) [2, 13].
QUESTIONNAIRES
All participants were asked to fill out a questionnaire comprising a large number of questions on
demographics, lifestyle (e.g. smoking, use of alcohol, diet), health status (e.g. exercise and fatigue
(scored by shortened fatigue questionnaire score [14]), general medical history (surgery, diseases
diagnosed or treated), HH related medical history, and family structure.
LABORATORY DATA
Data on the included siblings were extracted from medical records of the participating hospitals or
acquired from the physicians involved in diagnosis and treatment of the patients. Information on iron
parameters (TS and SF) and liver biopsy of the participants was obtained at the time of diagnosis or
screening of HH, whereas data on HFE-genotype and especially on the number of phlebotomies were
also collected at points in time after the initial investigations. Whenever the siblings declared to never
have been tested for HH, counselling and blood testing by their general practitioner was offered.
The TS and SF were quantified using validated, standardized, routine laboratory methods. HFE-genetic
test results were obtained from routinely used genetic tests.
STATISTICAL METHODS
In this study we aimed at distinghuishing the siblings, of probands with clinically detected HFE-related
HH, at risk for iron accumulation related disease from those not at risk. Univariate logistic regression
technique was used to study the differences in HH related illness and iron parameters between
C282Y homozygous siblings vs. non-homozygous siblings. For this purpose, elevated TS was
defined as TS above 50%, elevated SF as SF above the gender-and calendar time-specific local
laboratory reference values. In case no SF reference value was given, the 67-percentile of all
reference values was used. Different reference values for premenopausal and postmenopausal
women were taken into account when provided by the laboratories. Furthermore, ‘Hemochromatosis
related disease’ was defined as presence of diabetes mellitus, liver disease, rheumatism, fatigue and
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cardiovascular disease. The disease prevalences (n) and the crude odds ratios (ORs) with 95%
confidence intervals (CIs) are presented.
Multivariate logistic regression with stepwise selection procedures was used to identify variables that,
in addition to genotype, contributed independently to the risk of ‘Hemochromatosis related disease’.
Putative disease determining variables used in the selection procedure were genotype, iron
parameters, age at participation, BMI, smoking and alcohol use. The adjusted ORs with 95% CIs of
the final model are presented. The R-square is presented to indicate the total percentage explained
variance in the outcome and the area under the curve (AUC) of the receiver operating characteristic
(ROC) curve is presented as measure of predictive discrimination.
All statistical analyses were performed using SAS version 8.2.
RESULTS
DEMOGRAPHICS
In the study participated 428 siblings of whom 110 were C282Y homozygous. Of the homozygous
siblings 48.2% (53) were male, compared to 45.6% (145) of the non-homozygous siblings. The age
at participation was similar for both groups. More homozygous siblings ever smoked, whereas the
alcohol consumption in both groups was similar (TABLE 1). The median (range) values of TS of the
homozygous siblings amounted 78.8% (15.8-108.6%) against 31.5% (2.2-103.9%) for the non-
homozygous subjects. For the SF these values were 585 µg/L (14-1153 µg/L) against 110 µg/L (SD
3-196 µg/L).
DISEASE PREVALENCE
TABLE 2 shows the comparison of disease prevalence of the homozygous and of the non-
homozygous sibling population, together with the ORs. Homozygous siblings show a significantly
higher risk for iron overload than the non-homozygous siblings, with for TS>50% a high OR of 39.08
(95%CI 20.03-76.24) and for SF above normal OR 17.31 (95%CI 9.79-30.61). Furthermore, the
homozygous siblings are distinguished by a significant elevated risk for joint pain (OR 1.88, 95%CI
1.19-2.99), liver disease (OR 2.90, 95% CI 1.27-6.62) and rheumatism (OR 2.76, 95%CI 1.71-4.46)
compared to the non-homozygous siblings. Even so, there is a significant difference in the
hemochromatosis related diseases between the C282Y homozygous siblings and the other
genotypes.
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TABLE 1 Demographics of the siblings of the HEFAS population
C282Y homozygous
genotype
non-homozygous
genotype* p-value
n# (%) / median (SD) n# (%) / median (SD)
Male (%) 53 (48.2) 145 (45.6) 0.66
Age (at participation, yr) 54.0 (9.8) 54.0 (11.3) 1.00
Body Mass Index (kg/m2) 25.4 (3.5) 25.9 (4.4) 0.24
Smoking (ever) 86 (78.9) 203 (65.1) 0.008
Alcohol > 2 units/day 89 (81.7) 261 (83.7) 0.66
* contains C282Y/H63D, C282Y/WT, C282Y/unknown, H63D/H63D, H63D/WT, WT/WT; n#, number of sinlings;
SD, standard deviation.
Of those factors that were thought to influence the disease penetrance in the sibling group,
multivariate analyses show that C282Y homozygous genotype (OR 2.29, 95%CI 1.04-5.02), age (OR
1.07, 95%CI 1.04-1.09) and gender (OR 1.71, 95%CI 1.04-2.80) are correlated with the development
of iron overload related disease (TABLE 3). The iron parameters have no significant input here,
however when the predictive value of the iron parameters is analyzed in a group of siblings above
the age of 55 yrs, the input of the SF value is also significant, with a decreased influence of gender
(data not shown). BMI, smoking and alcohol use have no additional predictive value on the
development of morbidity. In total 20% (R-square) of the variance in this model could be explained by
the selected variables and the discriminatory power is 73% (AUC).
DISCUSSION
Family screening seems very compelling for the early detection of HFE-related HH as the penetrance
of the HFE-gene mutations is thought to be higher in families with HFE-related HH compared to the
normal population, due to the sharing of activity of other iron accumulation modifiable genes,
environmental influences and lifestyle with the symptomatic proband. In former studies we have
already demonstrated the existence of a higher morbidity in first-degree family members of probands
with clinically detected HH and the existence of iron overload in these first-degree family members
related to genotype, severity of iron overload in the proband diagnosed, the age of testing and the
BMI (chapters 6 and 7 of this thesis). In line with these outcomes this study reveals that the clinical
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TABLE 2 Disease prevalence and crude odds ratios of disease outcomes for homozygous siblings vs. other genotype
siblings using logistic regression
Disease prevalence Crude OR
homozygous /
non-homozygous*
homozygous vs.
non homozygous*
n# / n# OR (95%CI)
Iron parameters
TS > 50% 84 / 35 39.08 (20.03-76.24)
SF above normal (µmol/L) 84 / 49 17.31 (9.79-30.61)
Morbidity
anemia 12 / 43 0.80 (0.40-1.60)
cancer 6 / 15 1.20 (0.45-3.19)
cardiovascular disease 12 / 33 1.11 (0.53-2.19)
diabetes mellitus 7 / 13 1.66 (0.64-4.29)
fatigue** 18 / 38 1.44 (0.78-2.66)
fertility disorders 5 / 7 2.13 (0.66-6.91)
hypercholesterolemia 17 / 57 0.88 (0.48-1.61)
hypertension 40 / 92 1.44 (0.90-2.33)
hypothyreoidea 3 / 12 0.69 (0.19-2.48)
impotence (male only) 13 / 23 1.62 (0.75-3.52)
joint pain 67 / 150 1.88 (1.19–2.99)
liver disease 12 / 13 2.90 (1.27-6.62)
osteoporosis 9 / 23 1.21 (0.54-2.74)
porfyria cutanea tarda 2 / 4 0.63 (0.11-3.49)
rheumatism 25 / 84 2.76 (1.71-4.46)
Hemochromatosis related
disease¶ 71 / 131 2.82 (1.73-4.61)
n#, number of siblings; OR, Odds Ratio; CI, confidence interval; TS, transferrin saturation; SF, serum ferritin;
* contains C282Y/H63D, C282Y/WT, C282Y/unknown, H63D/H63D, H63D/WT, WT/WT; ** fatigue scored using
the shortened fatigue questionnaire score [14]; ¶ hemochromatosis related diseases: diabetes mellitus, liver
disease, rheumatism, fatigue (score  18) and cardiovascular disease.
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expression of symptoms described to HFE-related HH are indeed with high morbidity related to
C282Y homozygosity, detecting more HH related illness in homozygous siblings than in siblings with
other genotypes. Clinical penetrance determining factors are gender and age of the siblings.
TABLE 3 The adjusted odds ratios of disease for homozygous siblings vs non-homozygous siblings, using multivariate
logistic regression with forward selection procedure
Homozygous vs. non-homozygous*
OR (95%CI)
Genotype
C282Y/C282Y 2.29 (1.04-5.02)
C282Y/H63D 0.68 (0.22-2.11)
Other genotype 1.00 (reference)
Iron parameters
TS >50% 0.90 (0.43-1.90)
SF above normal (µmol/L) 1.53 (0.79-2.98)
Age (at participation, yr) 1.07 (1.04-1.09)
Gender 1.71 (1.04-2.80)
OR, Odds Ratio; CI, confidence interval; * includes C282Y/H63D, C282Y/WT, C282Y/unknown, H63D/H63D,
H63D/WT and WT/WT; TS, transferrin saturation; SF, serum ferritin; R-square is 20%, as measure of the total
percentage explained variance in the outcome; AUC (area under the curve) is 73%, as measure of predictive
discrimination. For comparison, an AUC equal to 50% is equivalent to random guessing.
Previously, population screening for C282Y homozygosity seemed very compelling, encouraged by
the frequent findings of the homozygous HFE-genotype among overt HH patients. However, large
scale population studies as conducted by e.g. Beutler and Olynyk, revealed only a low penetrance of
clinical symptoms attributed to the HFE-gene mutations, doubting the adequacy of population
screening [15, 16]. As indicated, family members of overt HH patients may form a high-risk group, as
they are likely to possess the same additional genetic and environmental factors, which might be
needed for clinical manifestation. One major problem studying the clinical penetrance though is that
at this moment there is no uniform consensus on the complete clinical disease expression in HH. Of
the family studies performed so far, the majority of the outcomes used the biochemical penetrance,
i.e. iron accumulation, as end point for evaluation, as this is an earlier and more objective symptom
of HH than the clinical symptoms themselves [17-22]. None of the studies, however, provided
Determinants for the hemochromatosis related disease in the HEFAS population
143
evidence for a relation between iron overload and increased clinical illness in these families except
for the development of liver cirrhosis [12]. The HEFAS study was designed to focus on first-degree
relatives of patients with homozygous C282Y related hemochromatosis and to analyse the
biochemical as much as the clinical penetrance. To our knowledge we are the first to publish a family
study with proband related first-degree family members that shows differences in clinical penetrance
scored by disease prevalence between C282Y homozygous and C282Y non-homozygous siblings.
We found an increased disease occurrence for joint pain, liver disease and rheumatism.
To optimize screening effectiveness, it may be worthwhile to also include other factors that predict
the development of HFE-related morbidity. These yet unknown factors may be identified through
large screening studies in which homozygous siblings of C282Y homozygous probands clinically
affected are compared with those of clinically unaffected probands. If factors that putatively influence
disease penetrance can be correlated to HFE related morbidity, these may be included in screening
programs to identify as many individuals at risk with the least effort. Indeed Bulaj et al previously
compared clinically unselected homozygous family members of clinically affected C282Y homozygous
probands, with clinically unselected homozygous family members of C282Y homozygous probands
identified as a result of elevated TS values. Disease related conditions were defined as liver fibrosis
or cirrhosis, elevated liver enzymes of no other known cause than iron overload or radiographically
confirmed hemochromatotic arthropathy of the metacarpal-phalangeal joints. They found a slightly
higher percentage of subjects with clinically complaints among the relatives related to the clinically
affected probands, indicating that it could be worthwhile to further investigate the reason of this
difference [23]. In contrast McCune et al found only a difference in hypertension comparing the illness
of homozygous siblings of clinically detected C282Y homozygous probands with those of non-
clinically detected C282Y homozygous probands [24]. Even more, when illness was stratified for iron
phenotype, only a significant difference for aspartate aminotransferase elevation was found.
However, with another study design we were able to point out that there is, indeed, an elevated
disease prevalence related with C282Y homozygosity, correlating with genotype, age and gender.
TS and SF values seem to have no additional predictive value for the development of HH related
disease in the genotype model. The genotype is most probably such a strong predictor for an
elevated TS, that the predictive value of TS itself disappears. The factor age probably diminishes the
additive effect of SF even further. When the predictive value of SF is measured in a population of
siblings at older age, e.g. above 55 years, SF significantly attributes as predictor for the development
of HH related disease. As McCune et al, we were unable to identify additive value of life style factors
or unknown genetic factors on the development of disease. However, in our multivariate analyses the
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R-square remained low indicating that still other, not measured, co-expressing genes or
environmental influences may influence the disease penetrance.
The consumption of alcohol was not correlated with iron accumulation related disease in contrast to
the findings from others [24]. This is most likely due to the fact that we chose a low alcohol intake
cut-off value to discriminate between low and high alcohol intake, diminishing the effect of the severe
drinkers.
The unique character of the HEFAS consisted of the rigorously completing of biochemical and clinical
data of siblings of clinically overt HH patients and enables a direct comparison of HFE-related
disease among homozygous and non-homozygous siblings and the determinants influencing the
HFE-gene penetrance. This study demonstrates that the presence of diseases and symptoms
classically related to hemochromatosis, such as arthralgia, rheumatism, and liver disorders, are
significantly more manifested in the homozygous group of siblings. The penetrance of disease is
particularly influenced by genotype, age and gender, and at older age by SF.
Taken together homozygous siblings of probands with clinically detected HFE-related HH can be
considered a high-risk group for the development of clinically overt HH. They should therefore be
screened to detect preclinical cases. With proper treatment morbidity and mortality can be
substantially reduced. Therefore, an efficient and cost-effective screening strategy for first-degree
relatives of HH patients should be established.
ACKNOWLEDGEMENTS
We would like to thank the Radboud University Nijmegen Medical Centre co-workers Sonja van
Oosterhout-van Slageren, data manager, Clinical Chemistry, and Lammy Elving, internist, Internal
Medicine, who were of great help in the initial phase of the study, Erny Meij-van Kesteren, Clinical
Chemistry, for her work as data manager, Siem Klaver, technician, Clinical Chemistry, for managing
the prospective blood sample determinations, Angela van Remortele, genetic counselor,
Anthropogenetics, for counseling the HEFAS families and Wim Lemmens, Epidemiology and
Biostatistics, for statistical programming. Furthermore, we would like to thank all the enthusiastic
Radboud University Nijmegen (bio)medical students and co-workers for retrieving missing data and
copying all the available data into the HEFAS database: Anke Borgers, Mirrin Dorresteijn, Marja
Geurts, Rein Houben, Roel Lucassen, Moniek van de Luijtgaarden, Karlijn van Rooijen and Joris
Theunissen.
Determinants for the hemochromatosis related disease in the HEFAS population
145
This study was supported by a grant from the ZoNMW Prevention program, subprogram I; Innovative
research on prevention (No. 2100.0088).
Chapter 8
146
REFERENCES
(1) Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and
age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
(2) Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol
2000;33:485-504.
(3) Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in
women compared with men. Ann Intern Med 1997;127:105-10.
(4) McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, Yip R. A survey of 2,851 patients
with hemochromatosis: Symptoms and response to treatment. Am J Med 1999;106:619-24.
(5) McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab
2005;90:2451-5.
(6) Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis: Clinical
manifestations. Ann Intern Med 1980;93:519-25.
(7) Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: A changing scene. Am J Med
1991;90:445-9.
(8) Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A HuGE review. Human
Genome Epidemiology. Am J Epidemiol 2001;154:193-206.
(9) Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients
with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
(10) Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis.
Gastroenterology 1991;101:368-72.
(11) Milman N, Pedersen P, Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in
Denmark 1948-1985: Epidemiology, factors of significance for long-term survival, and causes of death in 179
patients. Ann Hematol 2001;80:737-44.
(12) Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: A
systematic review for the US. Preventive Services Task Force. Ann Intern Med 2006;145:209-23.
(13) Sindram JW, Marx JJ. Localisation of iron in the hepatic acini and in bile duct epithelium as a tool for
estimation of liver iron overload. Ann N Y Acad Sci 1988;526:361-2.
(14) Alberts M, Vercoulen JHMM, Bleijenberg G. Assessment of fatigue - the practical utility of the subjective
feeling of fatigue in research and clinical practice. Brunner-Routledge 2001;p. 301-27.
(15) Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G--> A (C282Y) HFE hereditary
haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
(16) Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical
expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
(17) Gleeson F, Ryan E, Barrett S, Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes
identified through family screening. Eur J Gastroenterol Hepatol 2004;16:859-63.
Determinants for the hemochromatosis related disease in the HEFAS population
147
(18) Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects
homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998;114:1003-8.
(19) Mura C, Le Gac G, Scotet V, Raguenes O, Mercier AY, Ferec C. Variation of iron loading expression in
C282Y homozygous haemochromatosis probands and sib pairs. J Med Genet 2001;38:632-6.
(20) Whiting P, Fletcher L, Dixon J, Gochee P, Powell L, Crawford D. Concordance of iron indices in homozygote
and heterozygote sibling pairs in hemochromatosis families: Implications for family screening. J Hepatol
2002;37:309.
(21) Brissot P, Troadec MB, Loreal O. The clinical relevance of new insights in iron transport and metabolism. Curr
Hematol Rep 2004;3:107-15.
(22) Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, Subramaniam VN, Hewett DG, Searle
JW, Fletcher LM, Crawford DH, Rodgers H, Allen KJ, Cavanaugh JA, Bassett ML. Screening for
hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-
301.
(23) Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP. Disease-related
conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
(24) McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, Krawczak M, Worwood M. Iron loading
and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or
presenting as patients. Gut 2006;55:554-62.
Chapter 8
148
CHAPTER 9
Viewpoint at the realization of early management of
hereditary hemochromatosis
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The high HFE-gene mutation frequency and the prolonged asymptomatic and early symptomatic
phase of HFE-related hereditary hemochromatosis (HH), in combination with relatively simple therapy
and the gain in life expectancy expected from effective treatment, make this disease an ideal target
for preventive screening. Before considering a specific screening procedure, however, a series of
questions should be addressed that underline the importance and relevance of the screening. In
1968, Wilson and Jungner, together with the WHO, developed their so-called principles of mass
screening [1]. Some of these 10 criteria were revised by Whitby in 1974, particularly on the issue of
clinical course or prognosis [1, 2]. Looking critically at those principles of population screening it
becomes clear that, in contrast to former opinions, relevance of mass screening for HH may be
questioned and other screening methods may prove more efficient.
The most important drawback in respect to population screening is that more and more studies are
being published stressing the incomplete clinical penetrance of HH in the population genetically at
risk, questioning the relevance of the health problem postulated [3-8]. Second, it is not clear which
groups or individuals are more prone to develop iron accumulation than others. It seems that HFE-
genotype alone is not sufficient to induce HH related disease, but other parameters such as
transferrin saturation, serum ferritin levels, age and modifier genes may play a key role. Third, there
is little information about the benefits of early treatment as there are no placebo or usual care
controlled studies of phlebotomy treatment in patients with HH (due to any cause), nor studies that
would allow a valid comparison of early versus delayed medical intervention with curative intention
[9]. Taken into account that it is generally believed that phlebotomy treatment is beneficial and has
no clinical significant side effects, a randomized placebo controlled trial is considered non-ethical as
effective treatment would be withheld from the placebo group or a usual care group [6, 10-13].
Nowadays, only clinically complaint-driven screening is used to identify HH patients and prevent
disease progression. However, as discussed in this thesis, this type of screening turned out to be
inadequate, partly because there is not enough knowledge of HH among the physicians involved in
diagnosing HH and partly because organ damage, causing complaints, is already irreversible.
In HFE-gene related HH a considerable variation in symptomatology and severity of the disease
exists, even among patients with identical mutations. The clinical penetrance of the HFE-gene
mutation in first-degree family members, who probably also share the activity of other modifier genes,
environmental influences and lifestyle, makes it worthwhile to initiate family screening for HH,
particular if other putative mutations and contributing factors can efficiently be screened for in these
first-degree family members. This is the very reason why family screening for HH has been studied,
in particular in this thesis.
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As in population screening, also in family screening, the first important issue was to demonstrate the
existence of an important health problem. By comparing morbidity in first-degree family members of
clinically diagnosed C282Y homozygous probands with morbidity of an age and gender matched
population, it was revealed that indeed important health problems were present in the families of
clinically diagnosed C282Y homozygotes. The next step was to assess which factors determined who
were at particular risk for developing iron overload. Homozygous C282Y mutation and compound
heterozygous HFE-gene mutation appeared to have the highest predictive level for iron overload.
Besides these two genetic factors, age at testing of serum ferritin and severity of iron overload in the
proband correlated very well with iron accumulation in the first-degree family members, as did
supplemental intake of iron. Furthermore, a model was developed to identify those first-degree family
members at high risk for developing iron storage disease. Subsequently, to underline the necessity of
family screening for prevention of further manifestation of HH related disease, the relation between
HFE-gene mutations, iron accumulation and disease had to be confirmed. It appeared that joint pain,
liver disease and rheumatism were significantly more prevalent in the C282Y homozygous siblings
compared to the non-homozygous siblings. Especially age and gender of the C282Y homozygous
siblings were co-predictive factors for disease development. The role of serum ferritin was only
significant at older age, i.e. after the age of 55 years. Now with strong evidence of a health problem
for which acceptable treatment is available, with a distinguished preclinical course from latent to
manifest disease and a suitable screening test for detecting this disease in its early (pre-
)symptomatic stage, it is useful to identify key factors to implement this form of family screening
successfully.
NEXT ON THE IMPLEMENTATION AGENDA
Based on our growing knowledge of the penetrance of the HFE-gene mutations and its co-influencing
factors, first of all a cost-effectiveness analysis of family screening is needed. Secondly, a strategy
plan on the organization of the screening facility should be developed and organisational questions
be answered. What kind of diagnostic facilities and treatment options should be available for the
follow-up of abnormalities revealed by the screenings procedures? What has to be done with findings
that are neither clearly normal nor obviously abnormal? These plans should also address questions
like: What are the implications in terms of resources (education of the public, availability of staff,
operating cost) and in terms of introducing on a large scale a family screening program. Third, the
social and ethical questions should be taken into account. Stigmatization and discrimination are
unwelcome outcomes of screenings procedures. What are the effects on insurance policies? And
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finally, some prefer to start with it, before family screening in the Netherlands is allowed to
commence at all, it is necessary to address the list of criteria developed by the Netherlands Health
Council Committee; “Screening inheritable and congenital disorders” (Gezondheidsraad Commissie;
Screening erfelijke en aangeboren aandoeningen) [14].
For the operational and organizational issues to be addressed much can be learned from the
Foundation for Tracing Hereditary Hypercholesterolaemia (Stichting Opsporing Erfelijke
Hypercholesteroleamia, StOEH) [15, 16]. They have developed a centrally coordinated program for
family screening with input from the physicians (General Practitioners (GPs) and medical specialists)
on probands in the Netherlands. As a matter of fact the HEmochromatosis FAmily Study (HEFAS)
itself was already partially set up using this format, e.g. approximately 40% of the first-degree family
members have been prospectively screened. In analogy with StOEH a database was built with family
trees of all included families. Family members with unknown blood results were invited by mail to let
their blood samples be tested for HFE-gene mutations and iron parameters. Counselling on HH and
blood donation took place by the individuals’ own GPs, who also received the final results of the test
including a recommendation on how to treat their patient. This advice varied from no necessity for
follow-up, to referring the patient to a specialist either for further investigation or for treatment. First-
degree family members were not visited. Those who gave no response on our mail invitation were
contacted by phone. This resulted in an 85% response rate of the first-degree family members, 15%
of them indicated not to desire any further examination. Altogether, a potentially effective family
screening design was conducted.
The StOEH-like approach has another important advantage: Central storage of data and blood
samples facilitates intermediate evaluations on the (cost-)effectiveness of the program and future
research programs on e.g. HFE-mutation penetrance modifying genes, long term disease
development, reversibility of complaints, and on the social or ethical impact of family screening.
Still, before a foundation unit searching for hereditary iron overload disease (Stichting Opsporing
Erfelijke IJzerstapelingsziekte, StOEIJ) can be initiated decisions should be made about medical
knowledge needed in the foundation (for instance on interpreting the outcome results), the most
adequate way of counselling for HH, and the medical teaching in the Netherlands needed on
diagnosing and treating HH. For the latter the recently developed consensus guidelines for HH
diagnosis and treatment (Richtlijn hereditaire hemochromatose, diagnostiek en behandeling van
hereditaire hemochromatose) delivers keynote information, as will the implementation of a predictive
model for HH as emerging from our HEFAS analyses. As far as research and practice has taught us
up to now, for family screening purposes blood samples of screenees need to be tested only for
transferrin saturation, serum ferritin and HFE-gene mutations. This together with gender, age, serum
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ferritin of the proband (when diagnosed with clinical disease), BMI and use of iron supplements will
provide a good estimation of the chance to develop iron overload and its related disease, in the first-
degree family member screened. Whenever this risk is elevated, referral should take place to a
physician familiar with HH either to confirm or to exclude the suspicion and diagnose alternative
pathology causing the aberrant findings.
FURTHER CONTEXTUAL FACTORS
Little is known about the psychosocial impact of family screening for HH. The genetic cascade
screening program for familial hypercholesterolemia turned to be highly acceptable to screenees,
although there were some reports on social pressure [17]. For HH screening in the general
population it appeared that after screening the quality of life and the psychosocial well-being of
individuals with a diagnosis of HH without end organ damage was comparable to their unaffected
siblings after screening [18]. Similarly, an Australian study on screening for HFE-gene mutations by
cheek-brush, found no increase in general anxiety and no significant mental or physical health
changes as a result of testing, regardless of genetic test results [19]. Nevertheless, it would be wise
to investigate the social and ethical implications for HH related family screening, for instance in the
HEFAS families already screened. Also a kind of monitoring system to detect psychological and/or
societal utterances in an early phase is proposed.
To be conclusive, the plea of the Netherlands Board of Health Insurances (College voor
Zorgverzekeringen, CVZ) to implement a program for family screening on HH, as posed in March
2003, is underlined by the outcomes of this thesis.
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One of the first clinicians who described the clinical syndrome with portal cirrhosis, diabetes mellitus
and bronze skin pigmentation was Trousseau in 1865. In 1889, Von Recklinghausen named the
syndrome by its current name: hemochromatosis. Hereafter Sheldon concluded in 1935 that: ”The
view advanced as the most reasonable explanation of hemochromatosis that it should be classed as
an inborn error of metabolism, which has an overwhelming incidence in males, and which at times
actually has a familial incidence. It concerns the inner metabolism of probably all the cells of the
body.” It lasted until 1996 before a genetic basis for the clinical symptoms was established by the
discovery of a homozygous C282Y mutation in the HFE-gene by Feder. Quickly afterwards it became
clear that the HFE-gene mutation was probably one of the most common mutations in the North
European population leading to inherited metabolic abnormalities. However, despite the rapid
scientific progress in the last decades, the exact pathological mechanism for the iron overload
disorder is still unknown, but more and more evidence points to a pivotal role for hepcidin
deregulation as the main cause of the unbalanced iron metabolism. Formerly, the life-expectance of
the hereditary hemochromatosis (HH) patients was quantified as poor. The introduction of
phlebotomy treatment, to remove the iron overload from the body, attenuated disease symptoms and
brought life expectancy back to the level of healthy persons, when treatment was started before
irreversible damage had occurred.
The aim of this thesis was to investigate the potential pathophysiological mechanisms and to reveal
an optimal early management strategy for HH. In CHAPTER 2 the changing aspects of HFE-gene
related HH are discussed. First seen as a highly frequent HFE-gene related autosomal recessive
disease, with a presumed high morbidity and mortality rate, it became a disease characterized by a
highly frequent potentially pathological HFE-gene mutation, with various penetrance regarding iron
overload and an even lesser penetrance regarding organ dysfunction leading to organ failure and
death. This changing view is also reflected in the strategy recommended for the early detection of the
HFE-gene related HH. Earlier, population screening seemed to be the most accurate way to prevent
instances of disease and death. At the start of the thesis however, family screening has been
advocated. It offers the best opportunity for finding C282Y homozygous individuals (25% of the
siblings of an diagnosed proband). It also increases the chance to discover family members with the
same genetic and environmental influences as the proband, which likewise may engrave their
phenotypic expression of HH. But, for an optimal screening strategy, profound background
information on the relevance of the health problem involved, and on the clinical penetrance of the
mutation screened for is desired. Wilson and Jungner, and later Whitby provided us with criteria
useful to determine, if any type of screening should be started.
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Before pathological non-transferrin-bound iron (NTBI) related mechanisms of iron overload induced
diseases were studied, we examined the standardization of the NTBI measurements in CHAPTER 3.
The presence of NTBI is thought to be a pathological condition that may enable iron to catalyze
redox reactions and contribute to iron accumulation in organs. The exact structure of NTBI is,
however, mainly unknown. This led to the development of several diverse quantification methods for
NTBI that had never been compared before. The in this thesis performed first comparison of the
various methods showed considerable variation in their results. There was a wide spread in mean
serum NTBI measured by the collaborating laboratories regarding the between sample and within
sample variation. The results obtained with methods based on chelators correlated significantly.
However, the NTBI values obtained by the various described methods related differently with the
levels of serum transferrin. Therefore, before NTBI can be introduced into clinical practice or can be
used for screening purposes, more robust quantification methods should be developed and additional
information is needed on its structure and relevance.
In CHAPTER 4 the role of the body iron in atherosclerotic mechanisms was assessed through
determination of the relationship between levels of serum iron parameters, including NTBI, and
plasma markers of inflammation and oxidized LDL in patients screened for HH. It appeared that the
plasma level of soluble intercellular adhesion molecule-1 (sICAM-1) was positively related to ferritin
and to NTBI and negatively to total iron-binding capacity (TIBC). Next, statistically significant higher
levels of sICAM-1 were found in subjects in the highest quartile of NTBI compared with the lowest
quartile of NTBI. The white blood cell count was positively related to ferritin, whereas high sensitivity
C-reactive protein, interleukin 6, interleukin 8, oxidized LDL, oxidized LDL/apolipoprotein B and IgG
and IgM antibodies to oxidized LDL were not related to any of the markers of iron status. Thus, we
concluded that an excess body iron, reflected by elevated serum ferritin and NTBI and decreased
TIBC, is associated with increased plasma level of sICAM-1 but not with markers of in vivo LDL
oxidation. Enhanced recruitment of inflammatory cells to the extravascular compartment by increased
endothelial expression of sICAM-1 may contribute to the suggested increased risk on cardiovascular
disease at excess body iron.
After the above-mentioned two studies on NTBI measurement methods and the potential
pathophysiological mechanism of NTBI, now in this thesis a transition is made to applied medical
research, i.e. the early management of HH through early detection. In CHAPTER 5 the impact of the
introduction of a guideline on the targeted detection of HH is discussed. As HH can present itself with
a broad spectrum of complaints and organ dysfunction, it is often difficult for a physician to recognize
the disease before irreversible damage has occurred. A multidisciplinary guideline was implemented
Summary
160
in an outpatient department (OPD) at a university hospital, containing recommendations to screen for
HH when a patient presented with symptoms or signs possibly related to HH. Retrospectively the
diagnostic procedures for patients visiting the OPD in a certain period before and after the
introduction of the guideline were compared. Data showed that the number of detected HH patients
did not significantly increase, at comparable cost per case detected, with the drawback of many false
positive HH diagnoses. A better guideline implementation strategy should increase the awareness of
clinicians for HH and guarantee the improvement of the physicians’ interpretation of the results
obtained.
In CHAPTER 6 the relevance of the health problems in families with HH was studied. Clinically
diagnosed probands with HFE-gene related HH and their first-degree family members (derived from
the HEmochromatosis FAmily Study, HEFAS) were compared with an age and gender matched
normal population (sampled from the Nijmegen Biomedical Study, NBS) regarding their body mass
index (BMI), general health, medication intake, morbidity and mortality. It was shown that the
hemochromatosis related diseases were significantly more present in the HH families compared to
the normal population. This in contrast to the mortality figures, which turned out to be equal in both
populations. These findings justified further research of the value of family screening into the early
detection of HH. Furthermore they challenged us to search for environmental and genetic factors that
increase the risk for iron overload.
Next, determinants of phenotypic expression of iron overload in Dutch families with HFE-gene related
HH were studied in CHAPTER 7. The iron parameters of the first-degree family members of the HEFAS
study were related to various possible iron accumulation co-determining factors. Multivariate regression
analyses revealed that the amount of accumulated iron was strongly determined by C282Y
homozygosity, compound heterozygosity, severity of iron accumulation in the proband and age at testing
for serum ferritin. Of the environmental factors supplemental iron intake worsened iron accumulation,
while a low BMI (<20 kg/m2) showed a protective effect. Furthermore, a model was developed that is
able to predict which first-degree family members are at high risk for developing iron overload and
should be followed up with proper treatment.
In CHAPTER 8 the penetrance of the disease within the HEFAS C282Y homozygous siblings was
quantified. The penetrance was clearly higher in the homozygous siblings than in the non-
homozygous siblings for joint pain, liver diseases, rheumatism and hemochromatosis related
diseases, defined as diabetes mellitus, liver disease, rheumatism, fatigue and cardiovascular disease.
Predictive for the penetrance were genotype, age and gender, whereas serum ferritin levels were
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only correlated with disease at older age, i.e. above the age of 55 years. We could not prove the
additive value of life-style factors in the development of HH related diseases, although the R-square
statistic of only 20% for the total comparison of disease for homozygous siblings vs. non-
homozygous siblings, could indicate the existence of not yet identified co-expressing genes or
environmental influences.
In CHAPTER 9 a viewpoint is given on the realization of the early management of HH through family
screening. Based on the HEFAS outcomes there is indeed a health problem within HFE-gene related
families; i.e. there is increased iron overload, already manifestating in increased morbidity.
Furthermore, a suitable screening test for detecting the disease is available and effective. One should
look now for additional factors that may help to successfully implement family screening. Cost-
effectiveness analysis should be initiated and a strategy plan for the organization of a screening
facility should be set up. In tandem to these logistic activities ethical and social implications of HH
related family screening should be checked against the criteria developed by the Netherlands Health
Council Committee “Screening inheritable and congenital disorders”, before finally introducing HH
related family screening in the Netherlands.
Summary
162
SAMENVATTING
Samenvatting
164
Een van de eerste medici die het klinische syndroom beschreef van levercirrhose, diabetes mellitus
en gebronsde huid was Trousseau in 1865. Von Recklinghausen noemde dit ziektebeeld in 1889
voor het eerste bij zijn huidige naam: hemochromatose. In 1935 schreef Sheldon: “De meeste
waarschijnlijke verklaring voor het ontstaan van hemochromatose is een metabole ziekte, met een
hoge incidentie bij mannen en een regelmatig familiair voorkomen. Het betreft een ziekte die
waarschijnlijk op alle lichaamscellen van invloed is.” Het duurde uiteindelijk tot 1996 voordat Feder de
genetische basis van de klinische symptomen beschreef met de ontdekking van de homozygote
C282Y mutatie in het HFE-gen. Vlot hierna werd duidelijk dat de C282Y-gen mutatie binnen de
Noord-Europeese populatie waarschijnlijk een van de meest voorkomende mutaties was
verantwoordelijk voor een metabole ziekte. Het exacte pathologische mechanisme van het ontstaan
van ijzerstapeling is echter, ondanks de snelle wetenschappelijke vooruitgang de afgelopen decennia,
nog steeds niet opgehelderd. Er bestaan wel steeds meer aanwijzingen voor een sleutelrol voor het
eiwit hepcidine bij het ontstaan van deze ijzerstapelingsziekte. In vroegere tijden was de
levensverwachting van patiënten met hereditaire hemochromatose (HH) slecht. Maar met de
introductie van aderlatingen om op deze manier ijzer uit het lichaam te onttrekken, namen de
ziektesymptomen af en werd de levensverwachting van de HH-patiënten teruggebracht naar het
niveau van de gezonde bevolking, mits de behandeling met flebotomieën werd gestart voordat
irreversibele lichaamsschade was ontstaan.
Het doel van dit proefschrift was onderzoek te verrichten naar de mogelijke pathofysiologische rol
van het niet-transferrine gebonden ijzer (non-transferrin-bound iron = NTBI) en te komen tot een
optimale strategie waarmee HH in een vroeg stadium kan worden opgespoord en behandeld. In
HOOFDSTUK 2 worden de veranderde inzichten van het HFE-gen gerelateerde ziektebeeld besproken.
Hoewel HH eerder gezien werd als een veel voorkomende autosomaal recessieve aandoening met
een hoge morbiditeit en hoge mortaliteit, wordt de ziekte tegenwoordig meer gekarakteriseerd door
de aanwezigheid van de frequent voorkomende homozygote C282Y-mutatie met een zeer
wisselende penetrantie, die uiteindelijk in een gedeelte van de gemuteerde populatie leidt tot
ijzerstapeling, orgaanfalen en overlijden. Deze veranderde kijk op de aandoening komt ook tot uiting
in de strategie die wordt voorgesteld om de HFE-gen gerelateerde HH vroegtijdig te ontdekken.
Voorheen werd bevolkingsonderzoek als de meest adequate vorm van screening genoemd ter
preventie van ziekte en overlijden, maar op dit moment gaat de voorkeur uit naar familie-screening.
Deze vorm van screening geeft de meest optimale mogelijkheden om C282Y-homozygoten te vinden,
omdat immers 25% van de broers en zussen van een proband homozygoot zal zijn. Daarnaast
verhoogt familie-screening de kans op het vinden van familieleden die dezelfde genetische en
omgevingsinvloeden hebben ondervonden als de proband, leidend tot de ziekte verschijnselen die bij
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HH passen. Echter voor een optimale screeningsstrategie is gedegen achtergrondinformatie nodig
over de relevantie van het gezondheidsprobleem in de doelpopulatie en de klinische penetrantie van
de ziekte waarop men wil screenen. Eind jaren zestig hebben Wilson en Junger, en begin jaren
zeventig ook Whitby, een aantal criteria beschreven die behulpzaam zijn bij de beslissing of, en zo
ja, welke vorm van screening geïmplementeerd zou moeten worden.
Voordat we de pathologische mechanismen waarmee NTBI ziekteverschijnselen kan uitlokken
hebben bestudeerd, hebben we de standaardisatie van de NTBI-meetmethoden onderzocht en
beschreven in HOOFDSTUK 3. De aanwezigheid van NTBI wordt gezien als een potentieel
pathologische omstandigheid, waarbij het ijzer in het lichaam gebruikt kan worden om redox-reacties
te versnellen, hetgeen kan zorgen voor orgaanschade. De structuur waarin NTBI in het bloed
aanwezig is, is onvoldoende bekend. Mede hierdoor zijn er in het verleden diverse meetmethoden
ontworpen ter kwantificatie van het NTBI. In dit proefschrift zijn voor het eerst verschillende van deze
meetmethoden met elkaar vergeleken, waarbij bleek dat de methoden een aanzienlijke variatie
vertoonden in hun uitkomsten. Er was een grote spreiding in de gemiddelde serum NTBI-waarde,
zowel voor de waarden van de diverse monsters gemeten door de verschillende laboratoria, als voor
de waarden van een specifiek monster gemeten per laboratorium. De resultaten verkregen door
middel van chelatiemeetmethoden correleerden significant, maar de diverse NTBI-spiegels gemeten
door de verschillende methoden toonden allen een andere relatie tot de gemiddelde serum
transferrinewaarde. Concluderend; er dienen beter uitgewerkte kwantificatiemethoden voor het meten
van NTBI te worden ontworpen, voordat het gebruik van NTBI kan worden toegepast in de kliniek.
Daarnaast dient er meer bekendheid te komen over de precieze samenstelling van het NTBI in het
bloed.
In HOOFDSTUK 4 wordt het mechanisme onderzocht waarmee ijzer in het lichaam kan bijdragen aan
de ontwikkeling van atherosclerose. Bij patiënten, die voor HH werden gescreend, is gekeken naar
de relatie tussen de verschillende hoeveelheden plasma ijzerparameters, waaronder NTBI, en de
plasmamarkers voor inflammatie en geoxideerd LDL (low density lipoprotein). Het bleek dat de
plasmaspiegel van het oplosbare intracellulaire adhesiemolecuul-1 (soluble intercellular adhesion
molecule-1 = sICAM-1) positief is gecorreleerd met ferritine en NTBI en negatief gecorreleerd met
de totale ijzerbindingscapaciteit (TIJBC). Daarnaast worden significant hogere hoeveelheden sICAM-1
gevonden bij individuen binnen het hoogst kwartiel van NTBI-spiegels, vergeleken met individuen in
het laagste kwartiel van de gemeten NTBI. De hoeveelheid witte bloedcellen is positief gecorreleerd
met ferritine, terwijl het hoog sensitieve C-reactieve proteïne (C-reactive protein = CRP) , interleukine
6, interleukine 8, geoxideerd LDL, geoxideerd LDL/apolipoproteïne B en IgG en IgM antilichamen
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tegen LDL niet gerelateerd zijn met een van de ijzerparameters. Concluderend; een overmaat aan
lichaamsijzer, weergeven door een verhoogd serum ferritine en NTBI en een verlaagde TIJBC, is
geassocieerd met een verhoogde plasma hoeveelheid van sICAM-1, maar niet met markers van in
vivo LDL-oxidatie. Mogelijk dat de verhoogde gang van ontstekingscellen naar het extravasculaire
compartiment, door de verhoogde endotheliale expressie van sICAM-1, bijdraagt aan het
veronderstelde toegenomen risico op cardiovasculaire ziekten bij een overmaat aan lichaamsijzer.
Na de beschrijving van de meetmethoden voor NTBI en het mogelijke pathofysiologische
mechanisme waarmee NTBI zijn invloed uitoefent op het cardiovasculair lijden, wordt in het
proefschrift een overstap gemaakt naar toegepast medisch-wetenschappelijk onderzoek en wel de
aanpak rondom de vroege detectie van HH. In HOOFDSTUK 5 wordt de uitwerking beschreven van de
invoering van een protocol voor klinisch geïndiceerd onderzoek naar HH. Omdat HH zich als
ziektebeeld kan uiten met een breed spectrum aan klachten en orgaanfalen, is het voor de arts vaak
moeilijk om de aandoening te herkennen voordat er irreversibele schade is ontstaan. Daarom werd
een multidisciplinair protocol ontworpen met daarin richtlijnen voor screening op HH wanneer zich
een patiënt aanbood met klachten of symptomen passende bij HH. Dit protocol werd ingevoerd op de
poli van een academisch ziekenhuis. Retrospectief werden de diagnostische procedures die de
patiënten hadden ondergaan voor de invoering van het protocol, vergeleken met de procedures die
de patiënten ondergingen na de invoering van het protocol. De aantallen gediagnosticeerde patiënten
namen, niet significant, toe, tegen een vergelijkbare hoeveelheid gemaakte kosten, met als negatief
bijeffect een stijging van de frequentie foutpositieve diagnoses. Een betere implementatie van het
protocol zou de bekendheid van de artsen met HH moeten vergroten en de interpretatie van de
gevonden resultaten tijdens het screenen van de patiënten op HH verbeteren.
In HOOFDSTUK 6 wordt de relevantie van het met ijzerstapeling gerelateerde gezondheidsprobleem
bestudeerd in families met HH. Klinisch gediagnosticeerde probandi met HFE-gen gerelateerde HH
en al hun eerstegraads familieleden (allen voortkomend uit de HEmochromatose FAmilie Studie =
HEFAS) werden vergeleken met voor leeftijd en geslacht gematchte personen uit de algemene
bevolking (genomen uit de Nijmegen Biomedische Studie = NBS). De vergelijking betrof body mass
index (BMI), algehele gezondheid, medicatiegebruik, ziekten en doodsoorzaken. Aangetoond kon
worden dat de hemochromatose-gerelateerde ziekten significant vaker voorkwamen in de HH-families
vergeleken met de algehele bevolking. Dit was in tegenstelling tot de mortaliteitscijfers die voor beide
populaties vergelijkbaar waren. Deze bevindingen rechtvaardigden verder onderzoek naar de waarde
van familiescreening om HH vroeg te detecteren. Daarnaast daagden deze uitkomsten ons uit verder
te zoeken naar omgevings- en genetische factoren die een verhoogd risico geven op ijzerstapeling.
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Vervolgens worden in HOOFDSTUK 7 factoren beschreven die van invloed zijn op de fenotypische
expressie van ijzerstapeling in Nederlandse families met HH. De ijzerparameters van de
eerstegraads familieleden uit de HEFAS-studie werden gecorreleerd met verscheidene mogelijk
ijzerstapelingsbepalende factoren. Multivariate regressie-analyse liet zien dat de hoeveelheid
gestapeld ijzer voornamelijk wordt bepaald door C282Y-homozygotie, compound heterozygotie, ernst
van ijzerstapeling bij de probandus en de leeftijd waarop het serum ferritine bepaald werd. Van de
omgevingsinvloeden blijkt de inname van ijzertabletten de ijzerstapeling te verergeren, terwijl een
lage BMI (<20 kg/m2) een beschermend effect heeft. Daarnaast werd een model ontworpen,
waarmee voorspeld kan worden welke eerstegraads familieleden een verhoogd risico hebben op
ijzerstapeling en derhalve dienen te worden gevolgd en zonodig behandeld.
In HOOFDSTUK 8 wordt de morbiditeit bij de C282Y-homozygote broers en zussen gekwantificeerd. Er
is duidelijk meer morbiditeit bij de homozygote broers en zussen vergeleken met de niet-homozygote
broers en zussen qua gewrichtsklachten, leverziekten, reumatische klachten, vermoeidheid en
hartvaatziekten. Voorspellend voor een hogere penetrantie zijn genotype, leeftijd en geslacht. De
serum ferritinespiegels zijn alleen voorspellend bij een oudere leeftijd, zoals boven de 55 jaar. We
konden geen leefstijlverschillen aantonen die bijdroegen aan de ontwikkeling van HH-gerelateerde
ziekte. De R2 van de totale vergelijking tussen de twee (homozygote en niet-homozygote) groepen
bedroeg echter maar 20%, wat kan duiden op de aanwezigheid van nog niet-geïdentificeerde co-
factoren.
In HOOFDSTUK 9 wordt een perspectief gegeven voor de realisatie van de vroege diagnostiek van HH.
Gebaseerd op de uitkomsten van de HEFAS-studie blijkt er een groot gezondheidsprobleem te
bestaan in families met HFE-gen gerelateerde HH; er is een verhoogde ijzerstapeling en een
verhoogde ziektelast. Daarnaast bestaat er een adequate en effectieve screeningstest om de ziekte
te ontdekken. Derhalve dient er van nu af aan ook gekeken te worden naar factoren die noodzakelijk
zijn voor een succesvolle implementatie van familiescreening. Kosteneffectiviteitsanalyses dienen te
worden opgezet en er moet een strategisch plan komen voor de organisatie van de familiescreening.
Tegelijkertijd met deze logistieke activiteiten dienen de ethische en sociale implicaties van deze
familiescreening te worden beschouwd tegen de al ontwikkelde criteria voor screening door de
Commissie “Screening erfelijke en aangeboren aandoeningen” van de Gezondheidsraad, voordat
uiteindelijk HH-gerelateerde familiescreening in Nederland kan worden geïntroduceerd.
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Graag wil ik iedereen bedanken die een bijdrage heeft geleverd aan het tot stand komen van dit
proefschrift. Zonder hun bijdrage was het nooit zover gekomen. In de eerste plaats wil ik me daarbij
richten tot alle Nederlandse ‘hemochromatose’ families die vrijwillig aan deze studie hebben
meegewerkt. Dankzij hun doorzettingsvermogen de uitgebreide vragenlijst in te vullen en hun
bereidwilligheid aanvullend onderzoek te ondergaan, hebben wij een grote hoeveelheid aan kostbare
gegevens kunnen vergaren voor dit onderzoek.
Een aantal mensen wil ik in het bijzonder bedanken.
Dr. R.A. de Vries, beste Richard, jij zette mij op het pad van de hemochromatose patiënten. Jouw
interesse voor dit ziektebeeld heeft motiverend gewerkt. Mede door jouw inbreng zijn de contacten
gelegd die ten grondslag liggen aan dit proefschrift.
Dr. D.W. Swinkels, beste Dorine, jouw enthousiasme voor alles wat je aanpakt werkte aanstekelijk.
Ook voor dit proefschrift heb je vele ideeën gehad wat uiteindelijk heeft mogen leiden tot het hier
gepresenteerde resultaat. Je hebt grote zorgen gehad over het verkrijgen van alle gegevens, maar
uiteindelijk zijn we daar met hulp van velen toch zeker in geslaagd.
Prof.dr. A.L.M. Verbeek, beste André, vanaf het begin bij het onderzoek betrokken, maar vooral de
laatste maanden voor mij een steunpunt geweest. Jouw doortastende en aansprekende werkwijze
heeft de afronding van dit proefschrift in een versnelling gebracht. De rust en het vertrouwen die je
inbracht hebben goed gedaan.
Dr. J.C.M. Hendriks, beste Jan, jij bent onmisbaar geweest voor het uitwerken van alle berekeningen
in dit onderzoek. Ik ben je erkentelijk voor de wijze statistische lessen die ik van je mocht ontvangen.
Prof.dr. A.F.H. Stalenhoef, beste Anton, mede dankzij jouw inbreng konden we starten met de
Nijmeegse hemochromatose poli. Dank dat je mijn promotor wilde zijn.
Prof.dr. J.J.M., beste Jo, dank voor de inbreng van alle jouw bekende hemochromatose patiënten. Zij
vormden mede de grondslag van dit onderzoek. Ook dank voor de commentaren die je door de jaren
heen gegeven hebt op de aangeleverde ideeën en stukken. Je gespecialiseerde, kritische kijk op de
onderwerpen hebben meer dan eens verhelderend gewerkt en geholpen de uiteindelijke resultaten te
verbeteren.
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Beste Cees en Herman, ook jullie ben ik veel dank verschuldigd voor de schat aan patiënten die
jullie kenden en die een basis waren voor onze HEFAS families. Het was altijd weer een uitdaging
om tijdens een bezoek aan jullie in een zo kort mogelijke tijd zoveel mogelijk gegevens te
bemachtigen. Cees, jouw kennis over de jou bekende families verraden een grote betrokkenheid bij
jouw 'hemochromatose' patiënten. Herman, jouw enthousiasme om samen de vele gegevens in te
voeren heb ik zeker kunnen waarderen. Ik zal de treinreisjes nog missen!
Beste Lammy, dank voor je inzet voor het voortbestaan van de hemochromatose poli en de steun bij
het opzetten van de geprotocolleerde zorg rondom de flebotomieën. Jouw inbreng was waardevol
voor de uiteindelijke uitvoering.
Beste Sonja en Erny, zonder jullie als datamanagers was het verzamelen van de data vele malen
moeilijker geweest. Sonja, het was soms saai ‘kantoorwerk’, maar je hebt vele dingen toch maar
mooi geregeld gekregen. Erny, jouw vrolijkheid, jouw hulpvaardigheid en zorg voor de deelnemers én
de onderzoekers heeft velen goed gedaan. De cake kunnen we ons nog zeker herinneren!
Bedankt alle studenten en medewerkers die hebben geholpen met het invoeren van de verkregen
gegevens. Anke, Mirrin, Marja, Rein, Roel, Moniek, Karlijn en Joris, bedankt voor de dag-, avond- en
weekenduurtjes die jullie achter de computer hebben gezeten. Ondanks het feit dat sommige
stambomen een ‘eindeloos’ gepuzzel opleverden, telefoonlijstjes soms slecht bijgewerkt bleken te
zijn, ondanks moeilijk ontcijferbare handschriften of koppige computers, heeft jullie enthousiasme
zeker geholpen dit proefschrift tot een goed einde te brengen.
Beste Angela en Femke, jullie zorg voor de hemochromatose patiënten en hun te screenen
familieleden deed zeker goed.
Marieke en Inger jullie hebben als eerste mogen proeven van de resultaten van de database. Jullie
opzetjes voor verdere uitwerking zijn waardevol gebleken.
Siem, ik vermoed dat we je af en toe voor blok hebben gezet met de werkzaamheden die we voor je
bedacht hadden. Desondanks heb je altijd prima werk afgeleverd, met zorg en vlot uitgevoerd.
Onmisbaar ben je geweest bij het verwerken van de grote hoeveelheid monsters. Dank hiervoor.
Beste (oud-) AKC medewerkers die van tijd tot tijd hand en spandiensten hebben verricht voor ons
onderzoek. Jullie hulp is zeer gewaardeerd. Erwin Wiegerinck; dank voor de hulp bij de DNA-
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analyses. Felix, Gerald, Emiel, Emile en Alex dank voor jullie ICT-zorgen. Uiteindelijk is het jullie
iedere keer weer gelukt alle gevraagde programma’s en koppelingen naar behoren te laten
functioneren.
Berry, Heidi en Till het was een eer met jullie te mogen samenwerken. De uitwisseling van gegevens
heeft mooie resultaten mogelijk gemaakt.
Wim, al hebben we niet veel direct contact gehad, toch wil ik je bedanken voor de berekeningen en
herberekeningen en herberekeningen die je voor ons hebt uitgevoerd.
Femmie, je bent van grote hulp geweest bij het opzetten van de vragenlijsten. Zonder jou was het
ontwerpen van de vragenlijsten en van de "voor-meerdere-personen-toegankelijke" database een
stuk moeizamer verlopen.
Beste Annelies, Marja en Dion, ik wil jullie bedanken voor de gezellige uurtje en jullie belangstelling
voor die arts die er ineens bij kwam zitten. Jullie hebben geduldig mijn onderzoeksfrustraties
aanhoord en deelden met mij mijn enthousiasme. Ik dank jullie voor de relativering, afleiding,
betrokkenheid en zorgen.
Beste Chantal en Erwin, jullie hebben van dichtbij alle ups-en downs van mijn onderzoek mogen
meemaken. Bedankt voor jullie luisterend oor en medeleven. Het deed goed om op zijn tijd tijdens de
lunches stoom te kunnen afblazen en eens andere, zeker ook belangrijke, zaken te kunnen
bespreken.
Lieve pap en mam, ik dank jullie voor alles wat jullie gedaan hebben om het voor mij mogelijk te
maken mijn weg in het leven te vinden. Dank voor de steun, het vertrouwen, de extra oppasuurtjes,
het luisterend oor, de wijze raad en de warme belangstelling.
Lieve Arno, het is er dan toch van gekomen, de vele uurtjes achter de computer worden afgesloten
met dit boekje. Dank voor je liefde, je geduld en je onvoorwaardelijke steun. Lieve Mark, jouw
enthousiasme, gezelligheid en spontaniteit zijn een goede tegenhanger geweest voor het soms taaie
promovendus bestaan.
Lieve Paul, ook jij bracht een nieuw zonnetje mee met je vrolijke lach en brabbelende geluidjes.
Arno, Mark en Paul, jullie weten niet half hoe waardevol jullie voor me zijn. Ik ben dankbaar voor de
rijkdom van onze liefde. Er is weer plaats voor een nieuw doel in onze gezamenlijk reis.
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Esther Jacobs werd geboren op 17 maart 1971 te Groesbeek. De lagere school (het Vossenhol) en
de middelbare school (Nijmeegse Scholen Gemeenschap) werden doorlopen en in 1989 afgesloten
met een atheneum B diploma. In datzelfde jaar startte zij met de studie Geneeskunde aan de
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gemaakt met het in dit proefschrift beschreven onderzoek op de afdeling Klinische Chemie o.l.v. dr.
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Geneeskunde van het UMC St Radboud. Tevens bestonden haar werkzaamheden uit het starten van
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internist-hematoloog in het Elkerliek Ziekenhuis in Helmond. De schrijfster van dit proefschrift is
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179
De HEFAS studie heeft plaatsgevonden in samenwerking met de onderstaande klinieken
Atrium Medisch Centrum, Heerlen/Brunssum
Rijnstate Ziekenhuis, Arnhem
Universitair Medisch Centrum Groningen
Universitair Medisch Centrum St Radboud
Universitair Medisch Centrum Utrecht
